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1 
 
Summary 
Microbial secondary metabolites are a rich source of bioactive compounds which act on 
novel therapeutic targets. The availability of whole genome sequences revealed that, 
thus far, the expanse of the secondary metabolite biosynthetic potential of bacteria has 
been grossly underestimated. In this work, the biosynthetic potential of the 
myxobacterial species Myxococcus xanthus was investigated.   
Examination of the M. xanthus DK1622 genome revealed 18 biosynthetic gene clusters, 
only 5 of which have been previously assigned to compound classes. In the present work 
the application of a comprehensive secondary metabolite profiling approach in 
combination with molecular biological methods facilitated the association of 3 novel M. 
xanthus DK1622 compounds to their corresponding biosynthetic pathways.  Complete 
structure elucidation was carried out for one selected candidate and revealed an unusual 
peptide, named myxoprincomide-c506. A biosynthetic model for myxoprincomide was 
proposed based on the giant multidomain NRPS/PKS enzyme Mxp from M. xanthus 
DK1622. Further investigations established myxoprincomide-c506 as the founding 
member of an amazingly diverse metabolite family, and 15 additional myxoprincomide 
variants were identified. Their formation comprises both rare biosynthetic building 
blocks and intriguing deviations from textbook biosynthetic logic.  
Furthermore, retrobiosynthetic analysis and genome mining of the M. xanthus DK897 
genome led to the first identification of an althiomycin biosynthetic pathway encoded by 
the alm gene cluster. Following confirmation by targeted gene inactivation coupled to 
metabolite profiling of the mutants, a biosynthetic model for althiomycin assembly by a 
hybrid NRPS/PKS system was proposed. 
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Zusammenfassung 
Sekundärmetabolite mikrobiellen Ursprungs sind eine ergiebige Quelle bioaktiver 
Verbindungen, die neuartige therapeutische Angriffspunkte enthüllen. Die 
Verfügbarkeit kompletter Genomsequenzen hat offenbart, dass das Potential von 
Bakterien zur Biosynthese von Sekundärmetaboliten bis dato bei weitem unterschätzt 
worden ist. In dieser Arbeit ist das biosynthetische Potential der myxobakteriellen 
Gattung Myxococcus xanthus eingehend untersucht worden.  
Die Auswertung des Genoms von M. xanthus DK1622 lässt 18 Biosynthesegencluster 
erkennen, aber nur fünf dieser Gencluster konnten bisher Verbindungsklassen 
zugeordnet werden. Die Anwendung eines umfassenden Ansatzes zur Analyse von 
Sekundärstoffprofilen in Kombination mit molekularbiologischen Methoden, 
ermöglichte in dieser Arbeit die Zuordnung von drei neuen Verbindungen von M. 
xanthus DK1622 zu den entsprechenden Biosynthesewegen. Die Verbindung 
Myxoprincomid-c506 wurde für eine komplette Strukturaufklärung ausgewählt und 
wird hier als neuartiges Peptid mit mehreren seltenen Strukturmotiven beschrieben. Ein 
Modell der Myxoprincomid-Biosynthese in M. xanthus DK1622 wurde basierend auf 
dem 1.6 MDa großen NRPS/PKS Multidomänenenzym Mxp aufgestellt.  Es konnten 
außerdem 15 weitere Myxoprincomid-Derivate identifiziert werden. Die 
außergewöhnliche strukturelle Diversität dieser neuen Substanzfamilie beruht dabei auf 
seltenen Biosynthese-Bausteine und ungewöhnlichen Biosyntheseschritten.  
Außerdem führten retrobiosynthetische Überlegungen und die Analyse des Genoms von 
M. xanthus DK897 zur Identifizierung des Althiomycin Biosyntheseweges, der vom alm 
Gencluster kodiert wird. Nach gezielter Inaktivierung des Genclusters und Analyse der 
Mutanten bezüglich ihrer Althiomycinproduktion, konnte ein Modell für die 
NRPS/PKS-basierte Biosynthese von Althiomycin aufgestellt werden. 
        1 Introduction  
 
3 
 
1 Introduction 
1.1 Continuing relevance of natural product discovery 
Since the ancient times, the use and efficacy of natural products (NPs) for human 
therapeutics has been unrivaled.[1] Nevertheless, for the past three decades, the 
pharmaceutical industry deemed natural products-based drug discovery as a conquered 
horizon and instead refocused its drug discovery programs in combinatorial chemistry 
and high throughput screening.[2;3] Without discounting the successes of synthetic drugs, 
natural products made a more significant impact in therapeutics during this period.  
From 1981-2006, the majority of the new chemical entities (NCEs) approved for drug use 
are natural products, their derivatives, and NP-inspired synthetic structures obtained 
from plant, fungal, and microbial sources.[4]   
Most notable is the high percentage of antibacterial and anticancer agents among the 
microbial derived bioactive secondary metabolites (SMs), some of which are even 
promising drug leads. [5;6]  Majority of these bioactive compounds fall under 2 natural 
product classes: nonribosomal peptides (NRPs), and polyketides (PKs).  NRPs and PKs 
offer multifaceted binding properties due to their similarity to the binding surface of the 
drug target (NRPs) and their structural diversity and complex stereochemistry (PKs).[7]   
NRPs and PKs are products of mechanistically-cognate thiotemplated modular 
megasynthases.  The rapid progress in sequencing technologies and the tools for 
annotation of bacterial genomes hastened the process of the exploration of these 
biosynthetic pathways.  With these advances it became obvious that the breadth and 
depth of bacterial biosynthetic potential was severely underestimated, not just in terms 
of numbers but concerning the structural diversity they can provide.[8] 
In times of increasing numbers of multidrug-resistant pathogens as well as increasing 
incidences of cancer, due to a higher life expectancy in the industrialized countries, there 
is a need to reevaluate and restrategize the methods by which these diseases can be 
treated.  The new strategies entail the identification of new targets for which new 
chemotypes are required.[7] The source is boundless; it is a matter of access.   
One of the initial challenges for drug development from NRPs and PKs is the 
identification of these bioactive compounds from the complex matrices of microbial 
culture broths.  The next challenge is to obtain sufficient amounts for preclinical 
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development and clinical studies, which even after large scale fermentation of the 
producer, is an arduous task.[7]  New techniques, from improved molecular biology to 
sophisticated analytics, aim to address this multifaceted problem.   
 
1.2 Biosynthetic logic of nonribosomal peptide synthetases and 
polyketide synthases 
Nonribosomal peptide synthetases (NRPSs) are large multifunctional enzymes that 
assemble peptidic natural products.  Building block monomers are not only limited to 
the 20 proteinogenic amino acids but can include nonproteinogenic, hydroxylated, N-
methylated, and D-amino acids.[9]   
NRPSs are subdivided into modules which are responsible for the incorporation of one 
amino acid into the final product.  These modules are comprised of catalytically 
independent domains, distinguishable by highly conserved core motifs at the protein 
level.  Each domain carries out the successive reactions necessary for peptide 
elongation.[10]  The minimum set of domains for an elongation cycle consists of an 
adenylation (A) domain, a peptidyl carrier protein (PCP), and a condensation (C) 
domain. (Fig. 1.1)  
The A domain plays a central role in determining the primary sequence of the 
nonribosomal peptide by selecting and activating the substrate as an aminoacyl 
adenylate.  The 8-10 amino acids most accessible on the protein surface to the amino acid 
monomer, referred to as the specificity conferring code, dictates the cognate amino acid 
to be incorporated into the nascent chain.[11;12] NRPS annotation tools such as PKS/NRPS 
Analysis and NRPSPredictor2 (and its predecessor NRPSPredictor) use this 
nonribosomal code to provide in silico substrate predictions for the A domains.[13-15]     
The activated aminoacyl substrate is transferred and covalently bound to the thiol group 
of the 4’-phosphopantetheinyl (Ppant) arm of the PCP.  The PCP enables the transport of 
the activated amino acids between the catalytic centers of the NRPS.  The PCP is 
posttranslational modified to its holo form via the transfer of the Ppant cofactor to the 
catalytic serine residue of the apo-PCP, a reaction that is catalyzed by a dedicated 4’- 
phosphopantetheinyl transferase.[16;17]  
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Elongation is accomplished by the C domain wherein the free amino group of the 
downstream monomer attacks the carbonyl-thioester of the upstream substrate to form a 
peptide bond.  Alternatively, the dual process of condensation and cyclization to form 
oxazoline and thiazoline moieties from serine, threonine, and cysteine residues can be 
carried out by heterocyclization (HC) domains in a mechanism that is yet to be 
elucidated.[18] Formation of an oxazole or thiazole requires an oxidation domain typically 
embedded in an A domain.  Formation of thiazoles as a post translational modification is 
demonstrated in ribosomally synthesized peptides as an ATP-dependent 
cyclodehydration reaction.[19]       
 
Figure 1.1: NRPS elongation cycle.  A) Amino acid recognition, activation and loading.  B) 
Peptide bond formation and elongation.  
 
The structural diversity of NRPs can be further expanded by modifications of the 
elongating peptide carried out by methyltransferases (MT), oxidation (Ox), and 
epimerization (E) domains.  Release of the final product is performed by the terminal 
thioesterase (TE) domain either by hydrolysis or by macrocyclization.[20]   
Microbial polyketides are derived from acyl-CoA precursors (e.g. malonyl-CoA or 
methylmalonyl-CoA) that undergo sequential decarboxylative condensations assembled 
by modular polyketide synthases (PKSs) in a manner similar to fatty acid biosynthesis.[21]  
One elongation cycle requires an acyl transferase (AT) domain to select the starter or 
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extender units and loads them onto the Ppant arm of the acyl carrier protein (ACP).  
These ACP-tethered acyl moieties undergo C-C bond formation via a decarboxylative 
Claisen-type condensation accomplished by the ketosynthase (KS) domain.[22] (Fig. 1.2) 
Akin to NRPS A domains, substrates for AT domains can be predicted in silico by 
sequence analysis.[23-26]  Auxiliary domains like β-ketoacyl reductase (KR), β-hydroxyacyl 
dehydratase (DH), and enoyl reductase (ER) carry out the reductive processing at the β-
carbonyl centers. The polyketide skeleton is released by TE domains as linear structures 
or as macrolides.  Post assembly modifications such as methylations, hydroxylations, 
and glycosylation can be crucial for the full biological activity to the final product.[27]   
 
Figure 1.2: PKS elongation cycle. A) Selection and loading of an an activated extender unit.  B) 
Elongation of the polyketide chain by a Claisen-type condensation of the extender unit  
 
To date, PKS systems have been categorized into three types based on their products and 
assembly mechanisms.  Type I PKSs are giant multifunctional enzymes which generate 
macrolides, polyethers, and polyenes either in a linear or iterative manner akin to the 
mechanism presented in Figure 1.2.[22]  Type II PKS systems use multienzyme complexes 
composed of a set of discrete KSα/KSβ/ACP proteins which act iteratively to catalyze the 
formation of poly-β-keto intermediates and subsequent cyclization results in aromatic 
moieties.[28]  The chalcone synthase-like Type III PKSs are composed of homodimeric KS 
domains with a single active site that performs the iterative loading and decarboxylative 
condensation of free acyl-CoA thioesters.[29]   
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The structural diversity of PKS- and NRPS-based scaffolds can be further expanded by 
the combination of these two compatible megaenzymes into hybrid NRPS/PKS systems 
(heretofore referred to as hybrid systems).  Extension steps require catalytic leniency 
where the KS and C domains are able to perform the condensation between acyl and 
amino acid substrates at the hybrid interface.[22]   
 
1.3 Pathway to product: biology meets natural product chemistry 
The classical strategy to microbial natural product discovery is bioassay-guided serial 
fractionation of extracts.  Although this is a successful approach in discovering bioactive 
compounds, the rate of rediscovery of known compounds is nowadays quite high.[30]  
Dereplication, the rapid identification of known compounds, remains a constant 
analytical challenge.[31;32]  Fortunately, during the past two decades, biological tools were 
developed to complement analytical chemistry in natural products discovery.  To 
provide a small glimpse into the available tools, a few of the available technologies are 
highlighted in this section. 
1.3.1 The role of genome mining in natural product discovery 
The discovery of the three genes encoding the biosynthetic pathway for the PK-derived 
antibiotic erythromycin (6-deoxyerythronolide B synthase or DEBS) from 
Saccharopolyspora erythraea over 20 years ago was a milestone in the understanding of 
assembly line enzymology.  Parallel discoveries revealed that NRPs are constructed via 
an analogous modular mechanism.[8] 
The genes encoding these assembly lines are typically clustered in a locus in the 
prokaryotic genome.  The role of molecular biology in NP discovery has since expanded, 
providing a new gateway with genome mining for PKS and NRPS pathways serving as 
the central tool.[33-37] Genome annotation also revealed that the number of encoded 
biosynthetic pathways is significantly greater than the number of known compounds 
from producer strains. [8;30] (Fig. 1.3) 
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Figure 1.3:  Genetic capacity for PK, NRP, or hybrid PK/NRP biosynthesis of selected fully 
sequenced prokaryotic secondary metabolite producers.  Identified PKS and/or NRPS 
biosynthetic gene clusters are shown in black bars.  Known PK, NRP, or hybrid PK/NRPS 
compounds from the sequenced strains at the time of genome sequencing are in grey.[35]   
 
In an ideal setting in silico prediction of the associated product could be performed if the 
biosynthetic pathway follows the colinearity rule where the number and type of 
monomers as well as the expected modifications can be inferred from the domains and 
tailoring domains identified.[30]  For the most part this is not the case and several 
methods have been devised to improve the correlation between pathways and products.  
1.3.1.1 Genomisotopic approach 
The genomisotopic approach combines genome sequence analysis and feeding of 
isotope-labeled precursors followed by NMR-guided fractionation to determine the 
products of orphan biosynthetic gene clusters.  The strategy led to the correlation of the 
antibiotic orfamide A to its biosynthetic gene cluster ofa in Pseudomonas fluorescens Pf-
5.[38]  The method relies heavily on in silico A domain prediction of cognate amino acids 
to select the isotope labeled substrates.  This dependence highlights one of the method’s 
limitations: not all A domain substrates can be predicted in silico.  In addition, it is also 
likely that a labeled amino acid serves as a precursor for several orphan pathways and 
therefore direct association of gene to product could be hampered.  Last but not least it is 
strictly restricted to NRPS pathways. 
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1.3.1.2 Targeted mutagenesis followed by metabolite profiling (TM-MP) 
Targeted gene inactivation followed by comparative metabolite profiling is one of the 
“classical” methods in correlating secondary metabolites to their gene clusters and vice 
versa.  The method is particularly applicable to biosynthetic pathways which deviate 
from the colinearity rule or whose domains could not be fully characterized.  A gene 
cluster is inactivated by insertional or deletion mutagenesis and the phenotype is 
characterized by comparing the metabolite profiles of the wildype and recombinant 
strains by high performance liquid chromatography – mass spectrometry (HPLC-MS).[30]  
The sequence information of the cluster does not necessarily have to come from whole 
genome sequences.  For example, early discovered myxobacterial biosynthetic pathways 
were based on sequences obtained from cosmid libraries or recovered vectors post 
transposon mutagenesis.[39-42]  
One of the very first examples of novel secondary metabolites discovered by 
wildtype/mutant comparative metabolite profiling is the discovery of myxochromide S 
from Stigmatella aurantiaca DW4/3-1.[43]  The biosynthetic pathway was identified from a 
cosmid library but the corresponding product was unknown.  With the sequence 
information at hand, targeted gene inactivation was carried out and identification of 
myxochromides S1-3 was achieved by liquid chromatography-diode array detection-mass 
spectrometry (LC-DAD-MS) analysis of the wildtype and mutant strain extracts. As 
myxochromides S1-3 represent major metabolites in the wildtype, the absence of their 
corresponding peaks in the chromatogram of the mutant strain was easy to detect.  
This strategy can lead to rapid gene to compound correlation if the microorganism of 
interest is amenable to mutagenesis and the analytical method used is capable of 
detecting the phenotype.  
1.3.1.3 Heterologous expression of biosynthetic gene clusters 
Successful discovery of natural products by heterologous expression was achieved from 
relatively small gene clusters (e.g. the sesquiterpene avermitilol from Streptomyces 
avermitilis and the ribosomally-derived depsipeptide microviridins from Microcystis 
species).[44;45] PKS and NRPS gene clusters are by no means small.   
Although still limited by size constraints, heterologous expression of entire PKS / NRPS 
biosynthetic pathways has been effective using Red/ET recombineering.  Examples 
include the heterologous expression of the myxochromide S and myxothiazol 
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biosynthetic gene clusters from Stigmatella aurantiaca DW 4/3-1 into Pseudomonas putida 
and Myxoccocus xanthus DZF1 respectively, which resulted in high level production of 
the corresponding products.[46;47]   
The discovery of novel PKS / NRPS derived SMs by heterologous expression has only 
been recently achieved by heterologously expressing biosynthetic pathways from 
Photorhabdus luminiscens.  Using a full length RecE/RecT based direct DNA cloning 
strategy, 10 megasynthetase gene clusters were heterologously expressed in E. coli, 2 of 
which produced the novel compounds luminmycin A and luminmide A/B.[48]  
1.3.1.4 Activation of biosynthetic pathways 
Modification of cultivation conditions allows access to secondary metabolites whose 
biosynthetic pathways are not expressed under standard fermentation conditions.  For 
example, in the OSMAC (One Strain MAny Compounds) approach factors such as the 
media, aeration, temperature, and even the shape of the culture flask are varied to obtain 
a broader secondary metabolite spectrum.[49]  Additional biosynthesis inducers include 
external stressors (e.g. enzyme inhibitors), mimicry of the natural substrate, interspecies 
crosstalk by co-culturing, and manipulation of regulators to switch on the biosynthetic 
pathways.[50] 
The discovery of the prenylated quinoline-2-one alkaloids aspoquinolones from 
Aspergillus nidulans was facilitated by a combination of genome mining,  growth in 
different culture conditions, and analytical techniques.[51] (Three genes encoding proteins 
with high sequence similarity to anthranylate synthase (AS) were detected.  Anthranilate 
synthase catalyzes the conversion of chorismate to anthranilic acid, a precursor in the 
biosynthesis of quinazoline, quinolone, and acridine alkaloids.  The presence of multiple 
AS-encoding genes led to the assumption that some of them were involved in secondary 
metabolite biosynthesis but their putative products were unknown.  This prompted a 
HPLC--UV-MS screen of 40 A. nidulans HKI 0410 extracts grown under 40 different 
culture conditions.  One growth condition (solid state fermentation on rice medium) 
revealed two unknown compounds which, after isolation and structural elucidation, 
were determined to be novel prenylated quinolone alkaloids named aspoquinolone A 
and B.  Two additional structural variants (aspoquinolone C and D) were identified after 
large-scale fermentation.  
        1 Introduction  
 
11 
 
Activation of a silent PKS gene cluster by regulatory cross talk led to the discovery of the 
novel secondary metabolite asperfuranone.[52]  The production of asperfuranone was 
previously not detected under standard and modified media conditions.  The activation 
of the cluster was serendipitously observed when the regulatory gene scpR for a different 
cryptic NRPS gene cluster was being investigated and two novel compounds, not related 
to the NRPS being investigated but appear to correlate with the gene product of the PKS 
gene cluster, were identified.[53]  
1.3.2 Genome sequence independent approaches 
The challenge of biosynthetic pathway discovery is not only addressed by genome 
dependent methods, as “protein-“and “transcript-first” strategies are being developed.  
The main advantage of these two approaches is that gene clusters which are actively 
transcribed and expressed under standard cultivation conditions are detected.  It is 
necessary to point out however that detection of expressed pathways or transcribed 
genes does not necessarily equate to detection and identification of novel compounds.   
1.3.2.1 Proteomics-based approaches 
The method called PrISM (Proteomic Investigation of Secondary Metabolism) takes 
advantage of the facile release of the Ppant cofactor from carrier proteins (CPs) by 
tandem MS to identify sequences attributed to NRPS and PKS systems.[54]  Proteomes 
were separated by SDS-PAGE and protein bands with MW > 150 kDa were excised for in 
gel tryptic digest and analyzed by LC-MS/MS.  MSn experiments identified peptides 
with Ppant elimination ions and provided sufficient information for de novo sequencing.  
PCR amplification using degenerate primers can afford the rest of the sequence 
information.  Functional analysis of the gene cluster and tandem MS data were used to 
identify the products of the detected pathways.  The method was successful in 
identifying novel secondary metabolites (koranimine and a new family of 
lipoheptapeptides) from Bacillus species. [55]  An improved PrISM approach which 
eliminated Coomassie detection and included OMSSA (Open Mass Spectrometry Search 
Algorithm) database search and improved de novo sequencing facilitated the identification 
of the biosynthetic gene clusters for the siderophore foroxymithine and the patented 
antibiotic S 213 L in actinomycetes.[56]  
An alternative proteomics-based approach called orthogonal active site identification 
system (OASIS) takes advantage of activity based proteome profiling (ABPP) to identify 
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PKSs and NRPSs.[57]  Small molecule “warheads” utilize the endogenous catalytic 
domains and react irreversibly by covalent interaction with the active site residue.[58]  
CPs are labeled by azido-CoA precursors while TEs are targeted by fluorophosphonate 
probes.  The labeled proteins undergo avidin enrichment and on bead tryptic digest and 
probe bearing peptides are identified by multidimensional protein identification 
technology (MudPIT) LC-MS/MS.  A recent update of the OASIS technology combines 
ABPP approach by labeling solely the TE domains and detecting the PPant ejection ion 
from tandem MS analysis, similar to the PrISM method, in identifying fragments from 
the terminal ends of PKSs and NRPSs.[58]  
PrISM and OASIS have a common limitation: both can detect expressed PKSs and 
NRPSs but a significant amount of additional work is still required to determine the 
associated products of these modular synthases.  The PrISM method claims 
simultaneous identification of biosynthetic pathways and products. However, a close 
inspection of their methodology shows that the process, although shown to be 
successful, is not straightforward, requiring reverse translation and sequence analysis 
prior to product identification.  OASIS has not at all made significant advances in this 
regard and has stopped at CP or TE detection.  The OASIS method also suffers from the 
promiscuity of the small molecule probes, reacting with other proteins aside from the 
PKS or NRPS targets (i.e. FP-probes for TE react readily with other serine hydrolases).   
1.3.2.2 Transcriptomics-based strategy 
A recent study demonstrated the use of the messenger RNA (mRNA) transcript for 
biosynthetic pathway identification.  The screening strategy utilized the conditional 
transcriptome, a collection of cDNA based on total RNA isolated at a particular time 
point during cultivation.  PCR amplification using degenerate primers was performed 
on the selectively-enriched transcript of NRPS / PKS genes.  The sequence of six 
amplicons could not be correlated to any known biosynthetic gene clusters.  Targeted 
inactivation based on these sequences resulted in the same phenotype: loss of production 
of mycotrienin (MYC) related compounds.  Using the PCR sequences as probes, the myc 
gene cluster was obtained and annotated.  Deletion mutants spanning mycA1-mycD2 
confirmed the association of the myc cluster to the MYC products.[59]   
The main advantage of this approach is that it requires no a priori knowledge of the 
genome sequence and could readily be applied to any secondary metabolite producing 
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strain.  The method could easily be extended to examine the conditional transcriptome 
and secondary metabolite production at different time points during cultivation. 
Nevertheless, there is detection bias for the enriched NRPS and PKS genes transcribed 
and there is a risk to overlook pathways with a lower rate of transcription.   
1.3.3 Section summary 
Natural products biology has come a long way since the discovery of the DEBS pathway.  
Individually, the available tools have their advantages and drawbacks.  (Fig. 1.4)  
But combined, these methods contributed significantly to the immense progress in 
natural product discovery. A few methods mentioned in this section were instrumental 
in the advances in myxobacterial secondary metabolite research.   
 
Figure 1.4: Summary of the biological approaches to natural product discovery mentioned in this 
review with their advantages (+) and drawbacks (-).  Common to all methods is the tremendous 
task of discovering their corresponding products whether if the starting data comes from the 
genome, the proteome, or the transcriptome.   
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1.4 Myxobacteria – proficient producers of secondary metabolites 
Myxobacteria are Gram-negative δ-proteobacteria which move by gliding or creeping 
over surfaces forming swarms that spread into unoccupied areas. Soil and dung provide 
an optimal habitat for bacteriolytic and proteolytic species while cellulose degraders 
thrive on bark and decaying plant material.[60] Myxobacterial species have also been 
isolated from marine environments (i.e. members of the genus Haliangium) as well as 
from a variety of terrestrial biomes[61-64]  When myxobacteria experience starvation 
conditions, the swarms begin to form aggregates and pile up to produce fruiting bodies 
whose morphologies ranges from simple knobs (e.g. genus Myxococcus) up to 
sophisticated tree-like formations (e.g. genus Chondromyces) (Fig. 1.5).  Encased in these 
fruiting bodies are dessicant-resistant myxospores which guarantee the survival of the 
colony until nutrient levels return to normal.[65]   
 
Figure 1.5: Fruiting bodies of Myxococcus xanthus (A) and Chondromyces apiculatus (B).  Photos  
courtesy of Ronald Garcia.  
 
 
Aside from their remarkable social development, myxobacteria are known for their 
exceptional ability to produce novel secondary metabolites.[66] Majority of these 
compounds are not only distinct from those produced by other microbial sources, but 
appear to be diversified within myxobacterial genera as well.  (Fig. 1.6)  
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Figure 1.6: Distribution of 85 compound families (Appendix I) among myxobacterial genera. The 
y-axis counts the number of individual compound families produced by species from one or more 
genera (x-axis).  Thirty of the compound families are uniquely produced by members of a single 
genus while 4 compound families are common to 10 myxobacterial genera. Data based on 
Myxobase (stand: 5. January 2012) 
 
Secondary metabolites produced by the genera Sorangium, Myxococcus, Cystobacter, and 
Stigmatella dominate the myxobacterial compound spectrum admittedly because these 
genera were predominantly cultivated in the past.  However the contributions of the 
other genera are steadily expanding.  (Fig. 1.7) 
In terms of numbers of compounds discovered, myxobacteria lag behind the more 
intensively studied secondary metabolite producers like actinomycetes, fungi, and 
bacilli.[67].  The research pace is challenged by the slow growth of myxobacterial strains 
(4-14 hours doubling time) and the tedious process of re-culturing to obtain a 
homogeneous suspension. These two issues impact large scale fermentation which is 
necessary to obtain sufficient amount of pure compound for structure elucidation.[68]  
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Figure 1.7: Percent of genera in myxobacterial secondary metabolite producers.  Redundancy due 
to structural variants has been reduced by summarizing the derivatives into one compound 
family.  Data was based on Myxobase (stand: 5. January 2012) 
 
Myxobacteria are microbial predators which prey on other bacteria and yeast and use 
them as secondary substrates.[65;67]  Majority of bioactive myxobacterial natural products 
act against yeast/fungi (~54%) and bacteria (~29%), a finding that might be interpreted 
as a consequence of the competitive pressures of their natural habitat.[69] A recent study 
revealed that myxobacteria proactively use secondary metabolites as predatory 
weapons.[70]  
The primary mode of action for antifungal activity is the inhibition of electron flow 
within the mitochondrial respiratory chain by specifically targeting NADH 
dehydrogenase (complex I) and/or cytochrome bc1 (complex III), a mechanism quite 
common to myxobacterial antifungal compounds but rarely observed with fungicides 
from other bacterial sources.[71] Other targets include interruption of DNA replication 
and transcription (leupyrrins), inhibition of translation (gephyronic acid), and disruption 
of the cell membrane (ambruticin).[72-74]  The success story of soraphen, a polyketide 
which uniquely targets fungal acetyl-CoA carboxylase that was investigated as 
fungicidal agent in agriculture, was slashed by observed side effects like teratogenic and 
allergenic activity on test animals halting any further development.[66]   
Sorangium, 17.87 
Myxococcus, 
11.34 
Cystobacter, 
10.65 
unclassified,  
10.65 
Stigmatella, 8.93 
Hyalangium, 7.56 
Polyangium, 7.22 
Corallococcus, 6.87 
Archangium, 3.78 
Chondromyces, 
3.44 
Melittangium, 3.09 
Angiococcus, 2.41 
Nannocystis, 2.06 
Haploangium, 1.37 
Pyxodicoccus, 1.37 
Atactangium, 1.03 
Kofleria, 0.34 
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The antibacterial modes of action of myxobacterial natural products are just as diverse as 
the fungicidal ones.  Thuggacins target bacterial electron transport and has been shown 
to be active against Mycobacterium tuberculosis.[75]  Corallopyronin, myxopyronin, and 
ripostatin all interact with the switch region of bacterial RNA polymerase thereby 
interfering with the initiation of mRNA synthesis.[76]  Protein synthesis is inhibited by 
althiomycin at the peptidyl transfer stage[77]  whereas the potent antibiotic myxovalargin 
disrupts the binding of the aminoacyl-tRNA to the A site of the ribosome.   In addition, 
myxovalargin has at higher concentration and prolonged incubation a secondary effect 
of damaging the cell membrane.[78]  
Ten percent of myxobacterial secondary metabolites are cytotoxic to mammalian cells 
therefore making them important drug leads for cancer therapy.[68]  The eukaryotic 
cytoskeleton is the main target by interference with the polymerization of actin 
(chondramides, chivosazols and rhizopodin) [79-81] and tubulin (disorazols, tubulysins, 
and epothilone) [82;83] as the most observed modes of action.   At the forefront of 
myxobacterial chemotherapeutic agents is epothilone which is active against multidrug 
resistant cancer cell lines.   Epothilone has a similar mode of action as paclitaxel, one of 
the most important anticancer to date and can therefore be used for the treatment of 
paclitaxel-resistant tumors.[84;85]  Unlike the disorazols and tubulysins which promote 
tubulin disassembly, epothilone’s mode of action is the stabilization of tubulin 
polymerization.  The semi-synthetic analogue ixabepilone (Ixempra®) has already been 
approved by the US Food and Drug Administration (FDA) for the treatment of breast 
cancer.[86]   
Similar to what is observed from actinomycetes, availability of genome sequence 
information revealed that the biosynthetic potential of myxobacteria to produce 
secondary metabolites is much higher than previously anticipated, with the number of 
putative products significantly higher than that what has been detected so far from 
sequenced strains.[35]  To date, there are 6 published myxobacterial genomes (Table 1.1). 
The genomes are GC-rich and, with the exception of the genome size of Anaeromyxobacter 
dehalogenans, the largest among bacteria.[67]   
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Table 1.1: Selected features of myxobacterial genome  
Strain 
Genome 
Size 
(Mbp) 
GC 
content  
Total 
number 
of ORFs 
Number 
of  ORFs 
with 
assigned 
functions Ref. 
Sorangium cellulosum So ce56 13.0 71.4% 9367 4895 [87] 
Stigmatella aurantiaca DW4/3-1 10.2 67.5% 8586 4271 [88] 
Myxococcus xanthus DK1622 9.1 68.9% 7388 3608 [89] 
Anaeromyxobacter dehalogenans 2CP-C 5.0 74.9% 4287 3051 [90] 
Myxococcus fulvus HW-1 9.0 70.6% 7285 2630 [91] 
Haliangium ochraceum SMP-2T 9.5 69.5% 6898 4284 [92] 
 
Annotation of the genomes revealed that the strains Sorangium cellulosum So ce56, 
Stigmatella aurantiaca DW4/3-1, and Myxococcus xanthus DK1622 harbor multiple 
biosynthetic gene clusters encoding PKS, NRPS, and hybrid PKS/NRPS systems for 
which only a handful have been correlated to their secondary metabolite counterparts 
(Fig. 1.3). [35]  Myxobacterial natural product discovery by genome mining is not 
straightforward.  In terms of secondary metabolism, myxobacteria are biosynthetic 
nonconformists, breaking the rules of textbook assembly logic.[93]  For example, in the 
biosynthesis of myxochromide S, module skipping and iterative PKS modules were 
identified.[43]  The DH domain of AufD and KR domain of AufC of the aurafuron 
biosynthetic pathway are left unused during biosynthesis although the catalytic 
functions are theoretically intact.[94]  The recent completion of the aurachin biosynthetic 
pathway showed that the essential catalytic functions are not encoded by genes in just 
one locus but are actually spread over three distinct loci in the genome. [95] 
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Figure 1.8: Bioactive myxobacterial natural products with A) antifungal, B) antibacterial, and C) 
cytotoxic activity.  Biological targets are in parenthesis.  
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To further complicate matters, development of tools to genetically manipulate 
myxobacteria is a tedious process.  Myxobacteria harbor an inherent resistance to 
commonly used antibiotics which limits the selection markers that can be used.  Certain 
isolates initially grow as clumps or flakes and require a series of re-culturing before they 
grow homogeneously.  Generally, genetic tools have to be tailor-made for each strain as 
protocols established for one strain often are not adaptable to another one, even in cases 
where the strains are closely phylogenetically related.[68;96]   
In spite of what might seem to be a arduous task, by 2009, 25 complete biosynthetic gene 
clusters have been identified and published from myxobacteria.  Since then 8 more have 
been discovered and characterized, two of which will be presented in this work.  
 
1.5 The biosynthetic potential of Myxococcus xanthus 
Myxococcus xanthus is a myxobacterial species of the suborder Cystobacterineae that 
subsist on the dung pellets of herbivores.[61] M. xanthus DK1622 is the central and best 
studied object of myxobacterial research as it is an excellent model system for 
investigating gliding motility, intercellular interaction, and multicellular organizations in 
microbial communities.[97;98] DK1622 has one of the largest microbial genomes with a size 
of about 9.14 Mbp.[89]  This is partially ascribed to the large number of genes required to 
carry out its complex life cycle and signaling mechanisms.[99]  
Prior to genome sequencing, M. xanthus DK1622 was not known to produce any 
secondary metabolites.  Upon closer examination of the genome sequence, it turned out 
that 8.5% of its genome is dedicated to biosynthetic gene clusters (18 in total) encoding 
PKS, NRPS, and NRPS/PKS hybrid systems.  Since then, five NRPS/PKS-derived 
natural product families from DK1622 have been identified: the myxalamids (mxa), 
myxochelins (mchA), myxochromides (mxc), myxovirescins (ta), and DKxanthenes (dkx).  
(Figure 1.9)  
        1 Introduction  
 
21 
 
 
Figure 1.9: Representative structures of the M. xanthus DK1622 compound families 
 
The mxa, mxc, and mchA gene clusters were easily dereplicated as their biosynthetic 
pathways have been previously identified and characterized from S. aurantiaca strains.[88]  
The myxovirescin ta gene cluster was identified by BLAST sequence analysis of a 
PKS/NRPS sequence fragment obtained from M. xanthus ER-1.[100]  Due to the 
yellow/tan phase variance exhibited by the strain DK1622, the gene cluster associated 
with the yellow pigment DKxanthene was initially identified by transposon mutagenesis 
in the stably yellow strain DK1050.  The sequence fragments obtained after vector 
recovery were used to identify the dkx locus in DK1622.[101]   
To determine the associated products of the remaining 13 unassigned biosynthetic 
pathways, each of the gene clusters was targeted by TM-MP.  The manual comparison of 
wildtype and mutant profiles of the LC-MS data yielded no result.   
 The question reamained: is it possible to detect new compounds from M. xanthus?  A 
metabolomics-guided analysis of extracts from 98 M. xanthus isolates suggested the 
inherent potential.  By using advanced analytics (fast separation UPLC, electrospray 
ionization (ESI) and high resolution time-of-flight mass spectrometry) coupled to 
multivariate statistics by principal component analysis, 37 nonubiquitous compounds 
were identified.[102]   
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1.6 Principal Component Analysis 
Deciphering the differences among complex LC-MS data sets is not always easily 
accomplished particularly if the distinction of interest is subtle and is buried underneath 
the rich information.  The task then requires statistical tools like principal component 
analysis to dig deep into the data to expose the differences.   
Principal component analysis (PCA) is an established multivariate data mining tool 
which summarizes observations represented by inter-correlated quantitative dependent 
variables. Important information is highlighted and compressed into a new set of 
orthogonal variables called principal components.  The similarities, trends, and outliers 
are then pictorially represented by two dimensional maps called scores and loadings 
plots.[103]  
 
Figure 1.10: Scores and loadings plot. The scores plot reflects the clustering of similar samples 
whereas the loadings plot provides the clustering of observations which underpin the grouping 
pattern of the samples.  
 
PCA is a widely used unsupervised algorithm in systems biology and metabolomics to 
analyze complex NMR, GC-MS, CE-MS, and HPLC-MS data sets.[104]  When analyzing 
metabolomic HPLC-MS data with PCA, the data set has to be reduced to discrete 
metabolites represented by mass-to-charge and retention time (m/z-RT) pairs and 
described quantitatively by the intensity.[105] The dimensionality can be further reduced 
if related signals (i.e. related by isotope pattern and charge states) are compiled into one 
discrete entity referred to as molecular feature (formerly termed compound bucket) 
represented by one m/z-RT pair and described by a representative peak intensity, for 
example the intensity of the monoisotopic peak (Figure 1.11).[106]  
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Figure 1.11: The finding molecular feature (FMF) algorithm identifies isotope peaks and charge 
states from a common parent ion in subsequent spectra and combines this information into one 
compound, thereby removing redundant information from a dataset.[106]  
 
Determining the phenotype of the targeted mutagenesis on the 13 unassigned 
biosynthetic pathways of M. xanthus is a well suited problem that can be addressed by 
PCA as the difference between wildtype and mutant strains could ultimately be a single, 
low intensity peak in an information-rich LC-MS data set.   
 
1.7 Outline of the study 
The main topic of this work is to associate biosynthetic pathways identified in 
Myxococcus xanthus to their corresponding secondary metabolite counterparts.  These 
biosynthetic pathways are PKSs, NRPSs, and hybrid synthetases encoded in distinct 
genetic loci in the M. xanthus genome.  
The first part delves into the identification of the associated products of the 13 
unassigned pathways in M. xanthus DK1622.  Evaluation at the transcriptomic and 
proteomic levels asserts that the remaining 13 unassigned biosynthetic gene clusters are 
active under standard conditions for the cultivation of DK1622.[107;108]  It is presumed that 
the low abundance of the corresponding compounds in general may complicate their 
detection, thereby impeding the identification of new structures.  By coupling gene 
inactivation studies with extensive ultra-high-performance liquid chromatography-high 
resolution mass spectrometry (UHPLC-HRMS) and downstream comprehensive 
comparison of secondary metabolomes by PCA and hypothesis driven statistics, three 
novel M. xanthus compound classes were simultaneously correlated to their biosynthetic 
pathways.  In the context of pathways to products, the comprehensive secondary 
metabolome approach is an extension of the TM-MP method with the refinement that 
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statistics is capable of finding the subtle differences between wildtype and mutant 
metabolite profiles.  After optimization of production, myxoprincomide-c506 was fully 
characterized by NMR and tandem MS experiments.  Myxoprincomide, a linear peptide 
bearing unusual structural features, is produced by the NRPS/PKS hybrid system 
encoded by mxp (MXAN_3779) biosynthetic machinery.   
The second part expounds on the Group I myxoprincomide compound class.  Large 
scale cultivation for the isolation of myxoprincomide-c506 unearthed multiple 
derivatives ranging from shorter products to larger myxoprincomide variants.  
Concurrently, a heterofunctional homolog of the mxp gene was identified in a related 
strain M. xanthus DK897, yielding a different set of myxoprincomide structures (Group 
II).  Supported by feeding studies, spectroscopic and spectrometric data, the structures of 
the Group I myxoprincomide family and a biosynthetic hypothesis are presented.   
The third section deals with the identification and characterization of the althiomycin 
biosynthetic gene cluster in M. xanthus DK897.  Althiomycin, (Fig. 1.8 B) a heavily 
modified pentapeptide (MF: C18H17N5O6S2, MW : 439 g/mol), was first isolated in 1957 
from Streptomyces althioticus.[109]  It is a broad spectrum antibiotic that inhibits prokaryotic 
protein synthesis at the peptidyltransfer stage but exhibits no such effects in mammalian 
cells.[77] SAR studies revealed that the configuration of the oxime group, the 
configuration at C4 of the thiazoline ring, the methoxypyrrolinone and, to a lesser extent, 
the hydroxymethyl group are relevant for activity.[110;111]]  A previous screening of 
myxobacteria for novel antibiotics revealed that members of the genera Cystobacter and 
Myxococcus produce althiomycin.[112]  Although there are other examples described (e.g. 
saframycin), it is rather unusual to find a myxobacterial secondary metabolite to be also 
produced by a streptomycete.[113]  Through genome mining, targeted gene inactivation, 
and heterologous expression, the biosynthetic pathway was identified and a model for 
the assembly of althiomycin was proposed.  
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1.9 Appendix I – List of myxobacterial compound families 
Ajudazol Cittilin Icumazole Nannochelin Spirangien 
Althiomycin Corallopyronins Indolylacetaldoxim  Noricumazole Stigmatellin  
Ambruticin Crocacin Jerangolid Pellasoren Sulasoren 
Angiolam Crocapeptin Kulkenon PentacaronsÃ¤ure Tartrolon 
Antalam Cruentaren Leupyrrin Phenalamide Terrestribisamid 
Antalid Cyrmenin Maltepolide Phenoxan Thiangazole 
Apicularen Dawenol Maracen Pyrrolnitrin Thuggacin 
Archazolid Disorazole Maracin Pyrronazol Tichunal 
Argyrin DKxanthene Marinoquinolines Ratjadon Tubulysin 
Aurachin Elansolide Melithiazol Rhizopodin Tuscolid 
Aurafuron Eliamid Myxalamid Ripostatin Tuscoron 
Carolacton Epothilone Myxochelin Roimatacen Varnalamide 
Cerebrosid Etnangien Myxochromide Saframycin WAP 
Chivosazole Gephyronic acid Myxoprincomide Socein  
Chlorotonil Germacran Myxopyronins Soracumen  
Chlorsoraphene Haprolid Myxothiazole Sorangicin  
Chondramide Holmenon Myxovalargins Sorangiolid  
Chondrochloren Hymeron Myxovirescin Soraphen  
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2 Materials and Methods 
2.1 Chemicals 
All chemicals used in this work were obtained in analytical grade from the 
corresponding manufacturer.  
Table 2.1: Chemicals used and their sources 
Chemical Manufacturer 
Acetonitrile 
Trifluoroacetic acid 
Ethanol 
Tris base 
XAD-16 resin 
Bromophenol blue 
Nicotinamide 
p-Aminobenzoic acid  
MnCl2 • 4H2O 
DMSO 
Sigma Aldrich 
Ethyl Acetate 
Methanol 
2-Propanol 
Fischer Scientific 
Formic Acid 
KOH 
HCl 
Amino acid standards 
Xylene cyanol 
FE(III)-EDTA 
EDTA 
Fluka 
Starch 
HEPES 
Kanamycin sulfate 
Roti®-Phenol/Chloroform/Isoamyl alcohol 
Potassium acetate 
Vitamin B12 
Ampicillin 
Carl Roth 
n-Butanol 
NaCl 
VWR 
        2 Materials and Methods 
 
33 
 
KH2PO4 
n-Heptane 
Glacial acetic acid 
Glycerin 
ZnCl2 
Na2B4O7 • 10H2O 
(NH4)6Mo7O24 • 4H2O 
ZChL 
K2HPO4 Grüssing 
MOPS 
SDS 
MP Biomedicals 
Biotin 
CaCl2• 2H2O 
MgSO4 • 7H2O 
NaOH 
Pyridoxal-HCl 
FeCl3 • 6H2O 
Merck 
ZeocinTM (100 mg/ml) Invitrogen 
Sephadex LH-20 Amerscham Biosciences 
5-bromo-4-chloro-3-indolyl-beta-D-galacto-
pyranoside (X-gal) 
dATPs 
dCTPs 
dGTPs 
dTTPs 
Fermentas 
Bacto Agar 
Casitone 
Tryptone 
Yeast Extract 
Baker’s Yeast 
Becton Dickinson and Co., USA 
Casein Peptone Type S Marcor 
Agarose Biozym 
5-fluoro-DL-tryptophan  Argos Organics 
Isotopically-labeled substrates 
L-alanine-2-d 
L-leucine-5,5,5-d3 
L-leucine-2,3,3,4,5,5,5,5’,5’,5’-d10 
L-glutamic-2,3,3,4,4-d5 acid 
L-serine- 2,3,3-d3 
 
Isotec 
Deutero 
Campro Scientific 
Isotec 
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L-serine-13C3,15N 
L-cysteine-13C3,15N 
L-valine-d8 
L-threonine - 13C4; 15N 
L-phenylalanine-13C6 
L-histidine-13C6 
L-methionine-(methyl-d3), 
L-methionine-(methyl-13C) 
sodium 1-13C-acetate 
sodium 2-13C-acetate 
1,2-13C2-acetate 
CIL 
Isotec 
Isotec 
Deutero 
Isotec 
euriso-top 
CIL 
Campro Scientific 
CIL 
CIL 
CIL 
CIL 
Nα-(5-Fluoro-2,4-dinitrophenyl)-L-
leucinamide (L-FDLA) 
Nα-(5-Fluoro-2,4-dinitrophenyl)-D-
leucinamide (D-FDLA) 
TCI 
 
2.2 Enzymes, kits, and markers 
All enzymes, kits, and markers used in this work are listed in Table 2.2 and were used 
according to the manufacturers’ protocols. 
 
Table 2.2: Enzymes, kits and markers and their manufacturers 
Enzyme Manufacturer 
Taq polymerase 
Restriction endonucleases 
T4 DNA ligase 
Shrimp Alkaline Phosphatase 
GeneRulerTM  1 kb Plus DNA ladder 
GeneRulerTM 100bp Plus DNA ladder 
GeneJET™ Plasmid Miniprep Kit 
Fermentas 
Phusion DNA polymerase Finnzymes 
TOPO TA Cloning ® Kit Invitrogen 
NucleoSpin® Gel and PCR Clean-up Macherey & Nagel 
Puregene Core Kit A 
RNAse A 
Qiagen 
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2.3 Buffers and stock solutions 
Table 2.3: Buffers and solutions for molecular biology  
Buffers Components  Amount 
Resuspension buffer (P1) Tris-HCl pH 8.0 
EDTA 
RNAse A 
H2O 
0.61 g 
0.29 g 
10 mg 
to 100 mL 
Lysis buffer (P2) NaOH 
SDS 
H2O 
0.80 g 
1 g 
to 100 mL 
Neutralization buffer (P3) 3 M CH3COOK  
H2O 
glacial CH3COOH 
29.4 g 
to 100 mL 
to pH 5.5 
DNA loading dye Glycerin (87%) 
Bromphenol blue 
Xylene cyanol 
H2O 
3 mL 
25 mg 
25 mg 
to 10 mL 
TAE Buffer (1x) Tris base 
Acetic acid 
0.5 M EDTA 
H2O 
2.42 g 
572 µL 
1 mL  
to 500 mL 
0.5 M EDTA pH 8.0 EDTA 
NaOH 
H2O 
18.61 g 
2g 
to 100 mL 
50 % (v/v) Glycerol Glycerol 
H2O 
50 mL 
50 mL 
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Table 2.4: Buffers and solutions for media preparation.  The following buffers were sterilized by 
autoclaving prior to use.  
Buffers Components  Amount 
1 M Tris-HCl pH 8.0 Tris base 
HCl 
H2O 
12.11 g 
to pH 8.0 
to 100 mL 
0.8 M MgSO4 MgSO4 • 7H2O, 
H2O 
19.68 g 
to 100 mL 
1 M K2HPO4 pH 7.6  1 M K2HPO4 
1 M KH2PO4 
86.6 ml 
13.4 ml 
1 M KH2PO4 KH2PO4 
H2O 
13.61 g 
to 100 mL 
1 M K2HPO4 K2HPO4 
H2O 
17.42 g 
to 100 mL 
Fe(III)-EDTA (80 mg mL-1) Fe(III)-EDTA 
H2O 
8 g 
to 100 mL 
1 M MOPS pH 7.6 MOPS 
NaOH  
H2O 
20.93 
to pH 7.6 
to 100 mL 
Vitamin solution Biotin 
Sodium panthonenate 
Nicotinamide 
Pyridoxal-HCl 
p-Aminobenzoic acid 
Vitamin B12 
dd H2O 
Methanol 
4 mg 
68 mg 
68 mg 
68 mg 
14 mg 
15 mg 
3 mL 
7 mL 
Trace element solution ZnCl2 
FeCl3 • 6H2O 
CuCl2 • 2H2O 
MnCl2 • 4H2O 
Na2B4O7 • 10H2O 
(NH4)6Mo7O24 • 4H2O 
dd H2O 
40 mg 
200 mg 
10 mg 
10 mg 
10 mg 
10 mg 
to 1 L 
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2.4 Media 
The following media were used in this work.  For standard agar plate preparation, 15 g 
of agar were added per liter of liquid medium.  For soft agar preparation, one liter of 
liquid medium was supplemented with 7.5 g agar.   
2.4.1 LB Medium for E. coli cultivation 
Table 2.5: Components of LB medium 
Component Amount 
Tryptone 10 g 
Yeast Extract 5 g 
NaCl 5 g 
H2O to 1 L 
 
2.4.2 Media for M. xanthus cultivation 
The following media were used for the cultivation of M. xanthus during the course of this 
study.  For large scale cultivation, the medium was supplemented with Fe(III)-EDTA to a 
final concentration of 80 µg mL-1 to reduce the production of myxochelin.   
Table 2.6: Media used for the cultivation of M. xanthus 
Medium Components Amount Final pH 
CTT Casitone 
1 M Tris-HCl pH 8.0 
0.8 M MgSO4 
1M K2HPO4 (pH 7.6) 
H2O 
10 g 
10 mL 
10 mL 
1 mL 
to 1 L 
7.6 
TS Tryptone 
MgSO4 • 7H2O 
Starch 
HEPES 
H2O 
10 g 
2 g 
4 g 
1.19 g 
to 1 L 
7.2 
PS Peptone Marcor S 
MgSO4 • 7H2O 
Starch 
HEPES 
H2O 
10 g 
2 g 
4 g 
1.19 g 
to 1 L 
7.0 
VY/2 Baker’s yeast 5 g 7.0 
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HEPES 
CaCl2• 2H2O 
H2O 
1.19 
0.5 
to 1 L 
CYE Casitone 
Yeast extract 
1 M MOPS, pH 7.6 
MgSO4 • 7H2O 
H2O 
10 g 
5 g 
10 mL 
1 g 
to 1 L 
7.6 
MD1 Casitone 
CaCl2• 2H2O 
MgSO4 • 7H2O  
H2O 
3 g 
0.7 g 
2 g 
to 1 L 
7.6 
TPM Tris-HCl pH 8.0 
MgSO4 
K2HPO4 (pH 7.6) 
H2O 
10 mM 
0.8 mM 
1 mM 
to 1 L 
7.6 
MC7 (50x) MOPS 
CaCl2 
H2O 
10.5 g 
0.735 g 
to 100 mL 
7.0 
 
2.5 Antibiotics 
Table 2.7: Antibiotics used in this work 
Antibiotic Stock solution Final Concentration 
Kanamycin 50 mg mL-1 50 µg mL-1 
ZeocinTM 100 mg mL-1 20 µg mL-1 
Ampicillin 100 mg mL-1 100 µg mL-1 
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2.6 Instruments  
Table 2.8: Instruments used in this work 
Instrument Manufacturer 
Agarose gel electrophoresis 
Electrophoresis chamber SUB-CELL® 
GT  
Electrophoresis chamber MINI-SUB-
CELL® GT  
 
Biorad 
Biorad 
Centrifuges 
Cool centrifuge 5805R  
Cool centrifuge 
Tabletop centrifuge 5415D  
Tabletop centrifuge CT15E 
Tabletop centrifuge CT15RE 
Centrifuge Avanti JE 
 
Eppendorf 
Eppendorf 
Eppendorf 
Hitachi Koki 
Hitachi Koki 
Beckmann Coulter 
Electroporator 
Gene pulser XCell  
Electroporation cuvette 0.1 cm  
 
Biorad 
Biorad 
HPLC-DAD (semi-preparative) 
Agilent 1260 Infinity HPLC system 
 
Agilent 
HPLC-MS-DAD (analytical) 
Agilent 1100 series HPLC system  
Bruker HCTplus  
Dionex Ultimate 3000 RSLC 
LTQ-Orbitrap 
 
Agilent 
Bruker 
Dionex 
Thermo Finnigan 
Image documentation 
N-1000 Darkroom  
Camera biovision  
 
Peqlab 
Peqlab 
Incubators 
Incubators  
Multitron orbital shakers  
 
Binder 
Infors 
Laminar flow 
HeraeusLaminAir®  
Hera Safe 
 
Kendro 
Kendro 
NMR 
Bruker Avance 500  
Bruker Avance 700  
 
Bruker 
Bruker 
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PCR 
Mastercycler Gradient  
 
Eppendorf 
pH-measurements 
pH-Meter 766 Calimatic 
 
Knick 
Photometer 
BioPhotometer 
NanoVue Plus 
 
Eppendorf 
GE Healthcare Life Sciences 
Thermomixer 
Thermomixer compact  
Thermomixer comfort  
 
Eppendorf 
Eppendorf 
Sterilisation 
Systec VX-150  
 
Systec 
Ultrasonic bath 
Sonarex  
Vibra-CellTM 
 
Bandelin 
Sonics 
Water processing 
Milli-Q water purification system  
PURELAB ultra  
 
Millipore 
ELGA 
Fermenter 
Labfors 3 
Biostat B Plus 
 
Infors HT  
Sartorius  
 
2.7 Bacterial strains, oligonucleotides, and plasmids 
2.7.1 Bacterial strains 
Table 2.9: Bacterial strains used in this work 
Strain Characteristics References 
E. coli DH10B F-mcrAΔ(mrr-hdsRMS-mcrBC) 
Ø80dlacZΔM15ΔlacX74 deoR 
recA1 endA1 araD 139Δ 
(ara,leu) 7696 galU galK rpsL 
nupG 
[1] 
M. xanthus DK1622 Wildtype [2] 
M. xanthus DK897 Wildtype [2] 
M. xanthus A2 Wildtype [3] 
M. xanthus CSH6 Wildtype [4] 
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2.7.2 Oligonucleotides 
2.7.2.1 General primers used in this work 
Table 2.10: General primers used in genotypic verification of mutants 
Primer Label Sequence (5’  3’)  Purification 
TOPO in  CCTCTAGATGCATGCTCGAGC DST 
TOPO out TTGGTACCGAGCTCGGATCC DST 
zeorev AGTCCTGCTCCTCGGCCAC DST 
 
2.7.2.1 Primers used for the althiomycin project  
Table 2.11: Primers used in the althiomycin project 
Primer Label Sequence (5’  3’) Purification 
Alt1A1for CAAGGCAGGTATCTGACCAG DST 
Alt1A1rev GAGCTCTGGCGTATGTCATC DST 
AltTE.1f TGGAATGGAGATCTCCTGACACG DST 
AltTE.1r CCTATCACATGGCCGGCATC DST 
AltMT.1f CCGGTAGAGCGACACCAGG DST 
AltMT.1r CGAGCTGCTCCATCAACTGAAG DST 
almD.1f GTTCTCCCAGGTGTACTTCATCAG DST 
almD.1r CAGGAAGCCCATCGACTTC DST 
Alt2Elfor GTGATACGGAACTCAGTCTTG DST 
Alt2Elrev GAGAAATCTGGTACGAGGTGC DST 
Alt1A1ctrl3 GAGGACCTGGGAGCGAACTC DST 
Alt1A1ctrl4 GACCTTGCCGTTTTGATTCA DST 
AltTE.2f CATGGTGTTCATGCTGAGGTG DST 
AltTE.2r CCGAACCACTCGTTCTGGTG DST 
AltMT.3f CAGGAAGCTCATGAGCAGGTAG DST 
AltMT.3r CGCTACCTCAACATCGAATCC DST 
almD.2f GGAAGGTCCGGTGTGATGTC DST 
almD.2r AGGCCAGCATCAGTCGAAG DST 
Alt2EL.2f GGAATGGATTGAGCACGTTG DST 
Alt2EL.2r GCACGCACGACTTCCAGG DST 
almC.7f CTTGCGAGCAACAACGATG DST 
almC.7r CCCAGTTCAACGACCCTGTC DST 
almC.8f GGGACCCTCATATGACCCAGATCCTTTCGCATC DST 
almC.8r GGAAGGAATTCTTACTTGCGAGCAACAACGATG DST 
almD.4f CCGCGGAATTCTCAAACCTGCCAACCGATG DST 
2 Materials and Methods 
 
42 
 
almD.4r AGGAGCACCATATGAAGGAACCCGCATGTAC DST 
AltDRTNde.1f  ATGAGCAACATATGCTGCTCCGCGGCAAG DST 
AltDRTEco.2r GGCTGGAATTCTCAGTTGGCGGTGTTCGCG DST 
 
2.7.2.2 Primers used for the inactivation of M. xanthus DK1622 biosynthetic gene 
clusters 
Table 2.12 : Primer list for the amplification of the ~600 bp fragment of the target gene (NRPS- / 
PKS- encoding genes 
Target Gene Primer 
Label 
Sequence (5’-3’) Purification 
MXAN_1291 4445.1f CGCTTCGACCTCAGGGACGGCGT DST 
 4445.1r GGGTCCTCAGGACGATGGTGTTGAC DST 
MXAN_1600 1600.1f GATTGCGCAGCCAGTCCTC DST 
 1600.1r GACAACGTCCTCATCACCACTG DST 
MXAN_1601 1601.1f GCTCCATGAGGCGTGTCACG DST 
 1601.1r GGGGAAGAGGTGGTGCGTGAG DST 
MXAN_1602 1602.1f GAGGACTCCGCTCACTGCTGG DST 
 1602.1r CAGGTCGAGCACGTAGCGCTC DST 
MXAN_1603 4131.1f ACCATCCCCTCGCCCATCGCCA DST 
 4131.1r ACGCCGCTGGACGCCTTGCTTC DST 
MXAN_1607 4125.1f CGCGAATGAACCGGAGCTGATGG DST 
 4125.1r CGGTGCTGTAGCGGGCGAACAG DST 
MXAN_2796 2966.1f AGGGCCGCATCCTCAAGCAGC DST 
 2966.1r AGGCGACGGAGGAAGAACGAC DST 
MXAN_2798 2964.1f TTCAAGGGGCCCGTCGGCGTGT DST 
 2964.1r CGGTGATTTCAATCGGGTCGCCCAC DST 
MXAN_3619 2165.1f GCTGGGGGCGTTGAAGCTGGCT DST 
 2165.1r GTTCGACGCGGCCTTCTTCGG DST 
MXAN_3620 2163.1f CTGCTGTTCAATCTGCTCTCCCGGG DST 
 2163.1r AGCCACGCTTGTCCGTCCCCGCT DST 
MXAN_3631 2152.1f ACCTCGACCGGATCTCCCAGC DST 
 2152.1r CTGGATACGGAGTCGCGCTCG DST 
MXAN_3630 3630.1f CTGCACTTCGATGGGGTCTC DST 
 3630.1r CCTACCTGCTGCTCAACCTCATG DST 
MXAN_3634 2149.1f GGTCTGGCGGAGACGCACGAGGT DST 
 2149.1r GCCGCGTGGCGCTGAACGATT DST 
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MXAN_3635 2148.1f CGCAGCAGCGCGTGTTCCTCCAGT DST 
 2148.1r GGCCTCCACGTAGCTGATGTCGTCA DST 
MXAN_3636 2147.1f GCTGGAAACACCGTTCGACCTGTCC DST 
 2147.1r ATGCGCGTTCGCGAAGGCCTCCT DST 
MXAN_3779 2004.1f GAAGCGCAGTGGATGGACCCG DST 
 2001.1r GGGTCTCCACGTAGCCGATGT DST 
MXAN_4001 1781.1f GCGCGAGGCGGAGTGGATGGAT DST 
 1781.1r TAGCCGATGTCGCCCGCGTCCA DST 
MXAN_4402 1380.1f CAACGCCTGCTCCTGGAAGTCG DST 
 1380.1r ACGGAGGGCTTGCTGGATGAC DST 
MXAN_4414 1367.1f TCCACCTGTGGACCCGCTTGG DST 
 1367.1r GCGGGGAAAGGGATGTCCTGATG DST 
MXAN_4532 1249.1f AGCGTGACGCGCGGCTGAATCAGT DST 
 1249.1r CGTGCTGGCGAAGAACCCCAC DST 
MXAN_4592 1189.1f TGGACATCGGCCAGGGGTGTC DST 
 1189.1r GAGGATCGAGCGCGCGGTTTC DST 
MXAN_4601 1180.1f CTCCCGTTCGAGCTCCAGCAGGG DST 
 1180.1r CTCGAGCGCCTCATGGACGGT DST 
 
Table 2.13:  Control primer list for the genotypic verification of the proper integration of the 
knockout construct (successful disruption of NRPS- / PKS- encoding genes) 
Target Gene Primer 
Label 
Sequence (5’-3’) Purification 
 MXAN_1291 4445.2f CACGAAGCCCTGAGGACACGCT DST 
 4445.2r ACCTCGCCCAGGAGCTGGAGCT DST 
MXAN_1600 1600.2f CCAGGAAAGCAGAGAGCGTG DST 
 1600.2r TGCGCACCTTCTTCATGGAG DST 
MXAN_1601 1601.2f CCGAATACGCACGAGAGGTC DST 
 1601.2r GCAGCAGCAGTTGGTGCAC DST 
MXAN_1602 1602.2f CGCACAGTCACTCCACTTCTG DST 
 1602.2r GGGAGTTGTCCGCGTAGAAG DST 
MXAN_1603 4131.2f TGGTCCAAGGGCATCCAGCTCA DST 
 4131.2r ACTCGTCGAGGAGTTCCTGCGT DST 
MXAN_1607 4125.2f TGGGTGTGCTTCATGCCGCGCA DST 
 4125.2r GCGGTTGGTGTGGGCTTCCAGC DST 
MXAN_2796 2966.2f CTGAACCGGGAGCCTCAGCACG DST 
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 2966.2r AGGTTGGAGAGCTGCGCGGAGC DST 
MXAN_2798 2964.2f CTTGCGGATTCGCCAGACATCG DST 
 2964.2r TCTGCGTCTGCGTGCGGAAGGC DST 
MXAN_3619 2165.2f AGGGACTGGTGGCGAAGTCAAT DST 
 2165.2r GGAGCTGGAGCCTTCCGTCATG DST 
MXAN_3620 2163.2f TCTTCCTGGAGTGTGCCTGGTCG DST 
 2163.2r CTTCGCGGACAGCACCAGGAGC DST 
MXAN_3630 3630.2f CCCAGGTTGGGCTTGATG DST 
 3630.2r GGTGCTGAAGGATCCGCAC DST 
MXAN_3631 2152.2f TTCCAGCAGTGCGTGGGCGTTGG DST 
 2152.2r GAGCCGTGCTGGACCAGGTGGA DST 
MXAN_3634 2149.2f ATCGACGTGGGCGGCGAGGAGCG DST 
 2149.2r GGCGGCAGCGAAACATCACCC DST 
MXAN_3635 2148.2f GACCACGGCTTCTTCGACATCC DST 
 2148.2r CGAGCGGACAACGTCACCACGT DST 
MXAN_3636 2147.2f CCTGGACGAGGCCGTGCTGGAGCG DST 
 2147.2r AGCATCGCCAGCGTCGCCACGGG DST 
MXAN_3779 2004.2f CGGCTTCTTCGACCTGTCGCTGC DST 
 2001.2r CGCCAATGCCGAAGGAGCTGAC DST 
MXAN_4001 1781.2f AAGGTGGAGACCGCTTCGACGC DST 
 1781.2r CGATTCCGAACGAGCTGACGCC DST 
MXAN_4402 1380.2f CCTCGAAGACGTCGGCGCGTTC DST 
 1380.2r AGGCTCGCTCAGGATGACGTGG DST 
MXAN_4414 1367.2f ATGAGGCGTGGCTTCGGGAACG DST 
 1367.2r GCGCAGATGCCCGAGCATTCTG DST 
MXAN_4532 1249.2f AGGGTCAGCCGCGCCAGCTCCT DST 
 1249.2r CCCTCAGCAACGCCTCCAGGTG DST 
MXAN_4592 1189.2f GTTCTCGAAGACGAGCAGGCTC DST 
 1189.2r CATGCAGGAGGGAATGCTGTTC DST 
MXAN_4601 1180.3f CTCCGGCTGTACCGACGAAGCGAGA DST 
 1180.3r TCGACGAGGAGGCTGAACGGCATGG DST 
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Table 2.14: Primer list for the amplification of the ~600 bp fragment of the target gene (additional 
genes) 
Target Gene Primer 
Label 
Sequence (5’-3’) Purification 
MXAN_4698 4698.1f GCGACAGCTCCTTGATGATG DST 
 4698.1r CGTACTACCTGTCCCTCATCGAC DST 
MXAN_4699 4699.1f CATGTAGCCCATGATGTCGTG DST 
 4699.1r CGCAGTACTGTGGTCACTGCAC DST 
MXAN_6263 6263.1f GCATGGTGGACCTGCTGAG DST 
 6263.1r GGACCATCTCGTTGGGATGAG DST 
MXAN_4531 4531.1f GGAGCAGTTCATCGAGCGTG DST 
 4531.1r GGTGGCACAGGTACACGGTG DST 
MXAN_1289 1289.1f CCATGCTGGTTGACAACCCTC DST 
 1289.1r GTCGAAGAGGCGGCGATG DST 
MXAN_3880 3880.1f CGGCTCCATCCTGCTCTACTC DST 
 3880.1r GTGATGCCAATCAGGAAGCTC DST 
MXAN_3778 3778.1f GCACTCGCCTCCGAGCTCTAC DST 
 3778.1r GTTGAGGATGCGCTCGATGTAC DST 
MXAN_3780 3780.4f CTGTCGAACCTGCTGCTCAC DST 
 3780.4f ATTGGTGGCCTGACGCAG DST 
MXAN_3781 3781.1f CGGAGGACATCTCCCTCATC DST 
 3781.1r GAAGTGGAAGCCGAGCCAG DST 
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Table 2.15: Control primer list for the genotypic verification of the proper integration of the 
knockout construct (additional genes) 
Target Gene Primer 
Label 
Sequence (5’-3’) Purification  
MXAN_4698 4698.2f CCGTACTCGACGGCGTAATC DST 
 4698.2r AGGAGACGTCCGCACTGTTC DST 
MXAN_4699 4699.2f GACGAAGGGCACGTCACAG DST 
 4699.2r TCTTCACGAGCAGGACATGTG DST 
MXAN_6263 6263.2f ACGACACCTGGACGAACTGAC DST 
 6263.2r GTCGTTGATGGTGCGGATG DST 
MXAN_4531 4531.2f GCTTTCCCCAGGCGAAGT DST 
 4531.2r CGTTTCGTTCAGCGCCTG DST 
MXAN_1289 1289.2f GGAACATGCACCTGCCATC DST 
 1289.2r CCGCGTAGTGGTCAGGGAG DST 
MXAN_3880 3880.2f GACGCCTGTCGGTGATGTT DST 
 3880.2r CGGTGGACACCGACATCTC DST 
MXAN_3778 3778.2f CGGCTGTCGTTCACTACGTC DST 
 3778.2r GCCCAGGTCATAGACGAGCAC DST 
MXAN_3780 3780.2f GTGAGAAGGTCGTCGACCTGTC DST 
 3780.2f GCTGGTCGTCCAGGTGATG DST 
MXAN_3781 3781.2f GCGTCTTCGCCTATGCCAC DST 
 3781.2r TGCAGCTCGTGTGAGCTGTC DST 
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2.7.3 Plasmids  
2.7.3.1 General plasmids 
Table 2.16: General plasmids used in this work 
Plasmids Relevant Characteristics  Reference 
pCR®2.1-TOPO®  
pCR®II-TOPO® 
Cloning vector; lacZα, 
T7 promoter, f1 origin, KmR, 
bla, pUC origin 
Invitrogen 
pJET1.2 Cloning vector; eco47IR, 
PlacUV5 promoter, T7 promoter, 
bla, pMB1 replicon,  
Fermentas 
pCKT7A1 Cloning vector; 
T7A1 promoter, f1, origin, bla, 
Sh ble, KmR, pUC origin 
unpublished 
pCKT7A1_attb Cloning vector; 
T7A1 promoter, integrase 
encoding gene, xis, attb site, 
bla, Sh ble, KmR, pUC origin 
[5] 
pDKzeo1 Cloning vector; 
T7A1 promoter, xis, integrase 
encoding gene, attb site, Sh 
ble, pUC origin 
[6] 
pSBTn5-kan Cloning vector; Tn5 promoter, 
T7 promoter, f1 origin, KmR, 
bla, pUC origin 
unpublished 
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2.7.3.2 Plasmids used for the althiomycin project 
Table 2.17: Plasmids used in the althiomycin project 
Plasmids Target / Relevant characteristics 
pAlt1A1 almA / pCR-TOPO-based 
pAltTE almB / pCR-TOPO-based 
pAltMT almC / pCR-TOPO-based 
pTOPO-almD almD / pCR-TOPO-based 
pAlt2EL almF / pCR-TOPO-based 
pCKT7A1 attb AltDRT Native almE cloned into pCKT7A1 attb for heterologous 
expression in M. xanthus DK1622 
pDKzeo1-almC Native almC cloned into pDKzeo1 for complementation of 
knockout mutant AltMT.1 
pDKzeo1-almD Native almD cloned into pDKzeo1 for complementation of 
knockout mutant almD.1 
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2.7.3.2 Plasmids used for the inactivation of M. xanthus DK1622 biosynthetic gene 
clusters 
All plasmids are pCR-TOPO-based.   
Table 2.18: Plasmids used for the targeted gene inactivation of DK1622 biosynthetic gene clusters 
Plasmids Target  
pTOPO-1180.3 MXAN_4601 
pTOPO-1189.1 MXAN_4592 
pTOPO-1249.1 MXAN_4532 
pTOPO-1367.1 MXAN_4414 
pTOPO-1380.1 MXAN_4402 
pTOPO-1781.1 MXAN_4001 
pTOPO-2004.1 MXAN_3779 
pTOPO-2147.1 MXAN_3636 
pTOPO-2148.1 MXAN_3635 
pTOPO-2149.1 MXAN_3634 
pTOPO-3630.1 MXAN_3630 
pTOPO-2152.1 MXAN_3631 
pTOPO-2163.1 MXAN_3620 
pTOPO-2165.1 MXAN_3619 
pTOPO-2964.1 MXAN_2798 
pTOPO-2966.1 MXAN_2796 
pTOPO-4125.1 MXAN_1607 
pTOPO-4131.1 MXAN_1603 
pTOPO-1602.1 MXAN_1602 
pTOPO-1601.1 MXAN_1601 
pTOPO-1600.1 MXAN_1600 
pTOPO-1608.1 MXAN_1608 
pTOPO-4445.1 MXAN_4445 
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2.7.3.3 Plasmids used for the myxoprincomide project 
Table 2.19: Plasmids used for the myxoprincomide project 
Plasmids Target / Relevant characteristics 
pCKT7A1-A2.c506 First 650 bp of the MXAN_3779 A2 homolog cloned into 
pCKT7A1, KmR 
pTOPOTn5MXAN3779 First 650 bp of MXAN_3779 from DK1622 was placed 
downstream the Tn5 promoter by assembly PCR and the final 
product was cloned into pCRII-TOPO 
pTOPO-3778.1 MXAN_3778 / pCR-TOPO based 
pTOPO-3780.4 MXAN_3780 / pCR-TOPO based 
pTOPO-3781.1 MXAN_3781 / pCR-TOPO based 
pTOPO-4699.1 MXAN_4699 / pCR-TOPO based 
pTOPO-4698.1 MXAN_4698 / pCR-TOPO based 
 
2.8 Myxococcus xanthus  
2.8.1 Mutants of M. xanthus DK1622 
2.8.1.1 Targeted gene inactivation of unassigned biosynthetic gene clusters  
Table 2.20: Mutants generated from the targeted gene inactivation of unassigned biosynthetic 
gene clusters 
Strain Targeted gene / Relevant Characteristics 
1180.1 MXAN_4601 / KmR 
1189.1 MXAN_4592 / KmR 
1249.1 MXAN_4532 / KmR 
1367.1 MXAN_4414 / KmR 
1380.1 MXAN_4402 / KmR 
1781.1 MXAN_4001 / KmR 
2004.1 MXAN_3779 / KmR 
2147.1 MXAN_3636 / KmR 
2148.1 MXAN_3635 / KmR 
2149.1 MXAN_3634 / KmR 
3630.1 MXAN_3630 / KmR 
2152.1 MXAN_3631 / KmR 
2163.1 MXAN_3620 / KmR 
2165.1 MXAN_3619 / KmR 
2964.1 MXAN_2798 / KmR 
        2 Materials and Methods 
 
51 
 
2966.1 MXAN_2796 / KmR 
4125.1 MXAN_1607 / KmR 
4131.1 MXAN_1603 / KmR 
1602.1 MXAN_1602 / KmR 
1601.1 MXAN_1601 / KmR 
1600.1 MXAN_1600 / KmR 
1608.1 MXAN_1608 / KmR 
4445.1 MXAN_4445 / KmR 
 
2.8.1.2 Myxoprincomide-related mutants 
Table 2.21: Mutants generated for the optimized production and biosynthetic studies of 
myxoprincomide 
Strain Relevant characteristics 
Tn53779 Optimized DK1622 myxoprincomide producer / created using 
pTOPO-Tn53779 plasmid, / KmR 
4699.1 Knockout mutant of MXAN_3779 
4699.3 Complementation mutant of 4699.1 / KmR , Sh ble 
3778.1 Knockout mutant of MXAN_3778 / KmR 
3780.4 Knockout mutant of MXAN_3780 / KmR 
3781.1 Knockout mutant of MXAN_3781 / KmR 
 
2.8.1.3 Althiomycin  
Table 2.22: Mutant of DK1622 generated for the althiomycin project 
Strain Relevant characteristics 
attb_almE Integration of almE at the attB site for heterologous expression, 
KmR , Sh ble 
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2.8.2 Mutants of M. xanthus DK897 
Table 2.23: Mutants of M. xanthus DK897 generated in this work 
Strain Relevant characteristics 
DK897::Alt1A1 almA knockout mutant,  KmR 
DK897::Alt2TE almB knockout mutant,  KmR 
DK897::AltMT almC knockout mutant,  KmR 
DK897::almD almD knockout mutant,  KmR 
DK897::Alt2EL almF knockout mutant,  KmR 
Tn5stopalmC almC knockout mutant with Tn5 promoter insertion, KmR 
Tn5stopalmD almDknockout mutant with Tn5 promoter insertion, KmR 
Tn5stopalmC::attb_almC Complementation mutant of Tn5stopalmC / KmR , Sh ble 
Tn5stopalmD::attb_almD Complementation mutant of Tn5stopalmD / KmR , Sh ble 
 
2.8.3 Mutants of M. xanthus A2 
Table 2.24 : Mutants of M. xanthus A2 generated in this work 
Strain Relevant characteristics 
A2.c506 Optimized A2 myxoprincomide producer / created using 
pCKT7A1-A2.c506, / KmR 
 
2.9 Cultivation and conservation of strains  
2.9.1 Cultivation of E. coli  
Single colonies of E. coli strains were picked, inoculated into LB medium (1.5 mL), and 
cultivated in 2 mL Eppendorf tubes overnight (37 oC, 950 rpm).  Stock cultures were 
prepared by mixing liquid culture (0.75 mL) with 50% v/v glycerol (0.75 ml) and stored 
at -80 oC.  Strains were revived by inoculating fresh LB medium with a few cells from the 
stock culture using an inoculating loop.  Media were supplemented with the respective 
antibiotic where appropriate.  
 2.9.2 Cultivation of M. xanthus 
M. xanthus strains were grown and maintained in CTT medium.  To exclude the 
cultivation of tan-variants, M. xanthus DK1622 cells were first streaked on CTT agar 
plates and observed for yellow colored swarms  Once growth was observed, typically 
after 2 days, yellow M. xanthus cells were scraped from the plate and inoculated into 
CTT medium (50 mL).  For storage at -80 oC, liquid culture (0.75 mL) was mixed with 
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50% v/v glycerol (0.75 mL).  Cells were revived by streaking a small amount of the 
frozen culture on CTT agar plates using an inoculating loop.  M. xanthus mutant strains 
were similarly grown in CTT and CTT agar plate with the appropriate antibiotic.   
 
2.10 Isolation of prokaryotic DNA 
2.10.1 Isolation of genomic DNA 
Isolation of genomic DNA from M. xanthus using the Puregene Core Kit A was 
performed according to the manufacturer’s instructions.   
2.10.2 Isolation of plasmid DNA by alkaline lysis 
The cell pellet from a  1.5 ml overnight culture of E.coli was separated from the medium 
by centrifugation and resuspended in  resuspension buffer P1 (250 µL). Lysis buffer P2 
(250 µL) was added and the mixture was shaken gently and allowed to stand at room 
temperature (5 min).  The lysate was neutralized by adding neutralization buffer P3 (250 
µL) and mixed by inverting the tube several times.  The mixture was cooled in ice for 15 
minutes then centrifuged (4 oC , 13000 rpm, 15 min).  The supernatant containing the 
plasmid DNA was transferred into 1.5 mL Eppenderf tubes containing pre-cooled 
isopropanol (500 µL).  The tubes were inverted several times to precipitate the plasmid 
DNA then centrifuged (4 oC , 13000 rpm, 15 min).  The supernatant was discarded and 
the plasmid DNA pellet was washed with 70% ethanol (500 µL), air dried, and 
redissolved in sterile water (50 µL). 
2.10.3 Isolation of plasmid DNA by GeneJET™ Plasmid Miniprep Kit 
Isolation of plasmid DNA with the GeneJETTM Plasmid Miniprep kit was performed 
according to the manufacturer’s instructions. 
   
2.11 Separation and purification of DNA 
2.11.1 Separation of DNA by agarose gel electrophoresis 
Agarose gel (0.8% agarose in TAE buffer) with ethinium bromide (~0.25 μg mL-1) was 
prepared.  DNA samples were mixed with 6x DNA loading dye (1 µL dye per 10 µL 
DNA sample) and were loaded onto the gel. DNA ladders (GeneRulerTM 100 bp Plus for 
PCR samples, GeneRulerTM 1 kb DNA ladder for restriction digest DNA samples, 
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Fermentas) were used to determine the size of the DNA samples.  Electrophoresis was 
performed in 1x TAE buffer with a voltage of approximately 10 V per cm gel length until 
the xylene cyanol and bromophenol blue was visibly separated by 3-4 cm.  DNA was 
visualized under UV light (254 nm) using a gel documentation system equipped with a 
UV fluorescent table.   
2.11.1 Extraction of DNA from agarose gels 
After separation by gel electrophoresis, the desired DNA fragments were excised from 
the gel under UV light. Extraction from the gel was carried out with the NucleoSpin® 
Extract Kit, according to the manufacturer’s protocol. 
 
2.12 Polymerase chain reaction 
Polymerase chain reaction (PCR) was carried out using two different polymerases.  
Unless otherwise stated, PCR was carried out using the Taq polymerase-based protocol.  
Amplifications of gene fragments for complementation and promoter insertion were 
performed using Phusion® polymerase.   
2.12.1 Standard PCR setup 
The composition of a standard PCR setup is shown in Table 2.24.  The annealing 
temperature was adjusted depending on the primers used.   
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Table 2.25: PCR Protocols  
 Taq polymerase Phusion® polymerase 
Buffer 10x Q buffer (2.5 µL) 5x HF buffer (5 µL) 
25 mM MgCl2 0.5 µL - 
DMSO 0.75 µL 1 µL 
Primer 1 (10 pmol µL-1) 0.75 µL 0.75 µL 
Primer 2 (10 pmol µL-1) 0.75 µL 0.75 µL 
25 mM dNTPs 0.5 µL 0.5 µL 
Template 0.2 µL 0.2 µL 
Polymerase 0.2 µL 0.2 µL 
Sterile water 18.05 µL 16.9 µL 
   
Primary denaturation 
98 oC 
 3 min 
98 oC, 
2.5 min 
Denaturation 
98 oC 
10 s 
98 oC 
10 s 
Annealing 
58 oC 
15 s 
65 oC 
15 s 
Extension 
72 oC 
30s / kb  
72 oC 
15 s / kb 
Final extension 
72 oC 
8 min 
72 oC 
8 min 
Cycles 30 30 
 
2.12.2 PCR setup for genotypic verification of targeted gene inactivation 
Recombinant M. xanthus strains were verified by PCR with the use of TOPO in and 
TOPO out primers (specific for pCR®2.1-TOPO® and pCR®II-TOPO®) and control 
primers specific for each inactivated gene. (Fig. 2.1).   
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Figure 2.1 : Scheme of the genotypic verification of M. xanthus recombinant strains.  Backbone 
primer I and backbone primer II could either be TOPO in or TOPO out primers depending on 
how the target gene fragment was cloned into the TOPO-based vector.   
 
The reaction mixture is given in Table 2.25.  To reduce the number of reactions, TOPO in 
and TOPO out primers are included in all reactions but control primers I and II are 
added in separate tubes.  The PCR cycler set up is similar to that found in Table 2.24 with 
the annealing temperature set to 58 oC.   
Table 2.26 : Reaction mixture for the genotypic verification of recombinant M. xanthus strains. 
 Taq polymerase 
Buffer 10x Q buffer (2.5 µL) 
25 mM MgCl2 0.5 µL 
DMSO 0.75 µL 
TOPO in  (10 pmol µL-1) 0.75 µL 
TOPO out (10 pmol µL-1) 0.75 µL 
Control primer I or  
Control primer II 
0.75 µL 
25 mM dNTPs 0.5 µL 
Mutant genomic DNA 0.2 µL 
Taq Polymerase 0.2 µL 
Sterile water 17.3 µL 
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2.13 Enzymatic manipulation of DNA 
2.13.1 Restriction endonucleases 
Digestions of DNA by restriction endonucleases were performed at 10 µL scale.  A 
typical reaction consisted of DNA (5 µL), 10x buffer (1 µL), sterile water (3.8 µL), and the 
restriction enzyme (0.2 µL).   The restriction mixtures were incubated at 37 oC for 1-2 
hours.  For double digestion of DNA, the amounts of buffer and sterile water in the 
reaction mix were adjusted according to the manufacturer’s recommendations 
(Fermentas).   
2.13.2 Dephosphorylation 
For the dephosphorylation of digested vector DNA, shrimp alkaline phosphatase (SAP) 
(1 µL), was added to the restriction mixture.  Incubation was carried out at 37 oC for 10 
minutes.  The enzyme was inactivated by heating the reaction at 65 oC for 15 minutes.   
2.13.3 Standard ligation 
Cloning of gene fragments into vectors was carried out in a total reaction volume of 10 
µL.  Each reaction was composed of 5 µL gene fragment, 1 µL cloning vector, 1 µL 10x T4 
DNA ligase buffer, 1 µL T4 DNA ligase, and 2 µL sterile water.  The ligation mix was 
incubated at 16 oC overnight.  The reaction was heat inactivated at 65 oC for 10 minutes.  
The resulting plasmid DNA was subjected to phenol / chloroform extraction (Section 
2.13.5) prior to electroporation into E. coli DH10B.  
 
2.13.4 TOPO TA cloning 
PCR products amplified by Taq polymerase were cloned into pCR®2.1-TOPO® or 
pCR®II-TOPO® using the TOPO TA cloning kit according to the manufacturer’s 
protocols. Blunt end PCR products were incubated with Taq polymerase at 72 oC for 10 
minutes prior to TOPO TA cloning to attach a single deoxyadenosine (A) to the 3’ end of 
the PCR product.   
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2.13.5 pJET1.2 cloning 
Phusion-amplified PCR products were cloned into pJET1.2/blunt cloning vector using 
the CloneJet™ PCR cloning kit according to the manufacturer’s protocols. The constructs 
were extracted using phenol / chloroform prior to electroporation into E. coli DH10B.   
2.13.6 Phenol / chloroform extraction of ligation products 
The ligation products obtained from pJET cloning and standard ligations were extracted 
using phenol / chloroform prior to electroporation into E. coli DH10B.  Nuclease-free 
water (80 µL) was added to 20 µL of ligation reaction mixture.  A solution of phenol / 
chloroform / isoamyl alcohol (100 µL) was added and mixed by vortexing.  The mixture 
was centrifuged and the aqueous layer was transferred into a new Eppendorf tube (1.5 
mL) which contained 100% isopropanol (700 µL) to precipitate the plasmid DNA.  The 
plasmid DNA was obtained as a small pellets by centrifugation.  The isopropanol phase 
was removed and the DNA was washed with 70% ethanol (700 µL).  The supernatant 
was removed and the DNA was dissolved in nuclease-free water (10 µL).  One microliter 
was used to transform E. coli DH10B.   
 
2.14 Transformation of bacteria 
2.14.1 Electroporation of E. coli 
Electrocompetent E. coli DH10B stocks were prepared by growing the strain in LB 
medium until OD600= 0.6-0.8 per ml.  Cells were separated from the medium and washed 
first with 200 ml then with 20 mL of cold 10% glycerol.  Finally the cells were 
resuspended in cold 10% glycerol (2.5 mL).  The resuspended cells were distributed into 
50 µL aliquots which were flash frozen in liquid nitrogen and then stored at -80 oC.  To 
transform E. coli, a 50 µL aliquot was electroporated with plasmid DNA (1 µL) in an ice 
cold 0.1 cm cuvette (1250 V, 200 Ω, 25 mF).  To transfer the cells, LB medium (1 mL) was 
pipetted up and down the cuvette.  The cells were allowed to recover in 2 mL Eppendorf 
tubes (37 oC, 950 rpm, 1 h) prior to plating on LB agar plates supplemented with the 
appropriate antibiotic for selection of positive transformants.  For E. coli transformed 
with a TOPO-based plasmid, the plates were infused with X-gal solution (40 µL, 40 mg 
mL-1) prior to plating.   
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2.14.2 Electroporation of M. xanthus strains 
The M. xanthus strain was grown in CTT medium (50 mL) to a cell density of 1.5 x 108 
cells per mL (OD600= 0.5 per mL).  The cells were separated from the medium by 
centrifugation at room temperature and washed with sterile water (2x, once with 20 mL 
followed by a second washing step with 1 mL).  Cells were resuspended in sterile water 
(500 µL).  The plasmid DNA (1 µg) was mixed with a 50 µL aliquot of the competent M. 
xanthus cells and electroporated (650 V, 400 Ω, 25 mF) at room temperature. The cells 
were allowed to grow in antibiotic-free CTT medium (1 mL) in 2mL Eppendorf tubes (30 
oC, 1050 rpm, 4-6 hours).  After recovery, the cells were mixed with CTT soft agar 
equilibrated to 42 °C (5 mL) by vortexing and poured onto a CTT agar plate which was 
supplemented with the appropriate antibiotic.  Plates were incubated at 30 oC and 
transformants could typically be observed 5-7 days after electroporation. Clones were 
picked and restreaked onto fresh CTT selection plates.   
 
2.15 Genetic manipulation of M. xanthus 
2.15.1 Targeted gene inactivation 
Mutant strains were constructed by amplifying an internal 600 bp fragment of each 
NRPS or PKS encoding gene using Taq polymerase. The PCR product was cloned into 
pCR®2.1-TOPO® or pCR®II-TOPO®.  The plasmid was electroporated into M. xanthus 
DK1622 (650 V / 400 Ω/ 25 µF).  Transformants were selected on CTT agar plates 
supplemented with kanamycin (50 µg ml-1).  Proper integration of the construct into the 
target gene was genotypically verified using the protocol outlined in Section 2.12.2.  
2.15.2 Complementation of inactivated genes in M. xanthus  
The respective native gene was amplified by Phusion polymerase using primers 
containing an NdeI restriction site in the forward primer and and EcoRI restriction site in 
the reverse primer.  The PCR product was digested using the aforementioned restriction 
endonucleases and cloned into pDKzeo1.  The resulting construct was electroporated 
into the corresponding knockout mutant M. xanthus strain and plated on a CTT agar 
plate supplemented with kanamycin (50 µg mL-1) and zeocin (20 µg mL-1).  Genotypic 
verification by PCR was performed in a first step to verify the original inactivation by  
use of the control primers and in a second step the integration of the copy intended for 
complementation was verified using zeorev primer and a primer internal of the 
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respective gene.  The phenotype was determined by growing the wildtype, the knockout 
mutant, and the complementation mutant in production cultures from which extracts 
were prepared that were analyzed by HPLC-HRMS.   
2.15.3 Tn5 promoter insertion by single crossover homologous recombination 
A ~600 bp internal fragment of the target gene was amplified using Phusion polymerase.  
The forward primer contained an in-frame substitution of a codon with a stop codon.  
The Tn5 promoter region was amplified separately.  The final products were assembled 
by PCR using Taq polymerase and cloned into pCR2.1-TOPO.  Alternatively, the ~600 bp 
internal fragment was amplified using primers with NdeI and EcoRI restriction sites.  The 
PCR product was digested with NdeI and EcoRI and cloned into pSBTn5.  Final 
constructs were transformed into M. xanthus.   
2.15.4 Heterologous expression of almE in M. xanthus DK1622 
The gene almE was amplified using AltDRTNde.1f and AltDRTEco.2r  primers.  The PCR 
product was digested with NdeI and EcoRI restriction enzymes and cloned into pCK-
T7A1 attb.[5]  The plasmid was electroporated into M. xanthus  DK1622 and the 
transformants were plated on CTT agar plates supplemented with zeocin (20 µg mL-1).  
Mutants were verified by PCR using primers binding to almE. The phenotype was 
determined by disc assays against wildtype and the DK1622 mutant harboring the almE 
gene to display different althiomycinrelated growth inhibition zones.   
 
2.16 Analysis of secondary metabolite production of M. xanthus 
strains  
2.16.1 Preparation of production cultures 
Wildtype and recombinant M. xanthus strains were grown in CTT medium (50 mL) 
supplemented with Amberlite XAD-16 resin (2%, Sigma–Aldrich) and the appropriate 
antibiotic (for mutant strains). Cultures were grown in Erlenmeyer flasks (250 mL) at 
30 oC for 96 h at 200 rpm. Cell and XAD resin pellets were harvested by centrifugation 
(20 min, 5000 rpm, 20 oC). Pellets were extracted with methanol (2 x 30 mL). Extracts 
were dried in vacuo and resuspended in distilled methanol (1 mL).  
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2.16.2 LC-HRMS analysis 
LC-HRMS was carried out with a Dionex Ultimate 3000 RS LC coupled to a LTQ 
Orbitrap (Thermo Scientific) equipped with a TriVersa NanoMate (Advion) ion source.  
Separation was performed on an RP-18 column (50 x 2.1 mm, particle size 1.7 mm, 
Waters Acquity BEH) with a mobile-phase system consisting of water and acetonitrile 
(each containing 0.1% formic acid) using a gradient from 5 – 95% of the organic phase in 
12 minutes. Data sets were acquired in positive electrospray (ESI) mode with a scan 
range from 200–2000 m/z. 
 
2.17 Sequence analysis of the Myxococcus xanthus PKS / NRPS 
biosynthetic gene clusters 
Routine DNA and protein  in silico sequence analysis tasks were carried out using the 
Geneious v5 Software.[7] 
2.17.1 Annotation of the M. xanthus DK1622 biosynthetic gene clusters 
The complete genome sequence of M. xanthus DK1622 is publicly available (Genbank 
accession no. NC_008095). Sequences of the unassigned biosynthetic gene clusters were 
extracted and initial annotation of the catalytic domains was performed using the 
PKS/NRPS analysis software (http://nrps.igs.umaryland.edu/nrps/index.html).[8]  
Additional prediction of A domain substrates was done using the NRPSpredictor2 
software.[9] 
2.17.2 Annotation of the althiomycin biosynthetic gene cluster from M. xanthus DK897 
Open reading frames were assigned using FramePlot web software 
(http://nocardia.nih.go.jp/fp4/).  Annotation of the NRPS and PKS catalytic domains 
and the prediction of A domain substrates were performed using the same protocol 
outlined in Section 2.16.1.  The gene cluster was deposited in the EMBL/Genbank 
database with the accession number FR831800.   
2.17.3 Domain alignment and phylogenetic analysis 
All sequence alignments were performed by ClustalW.[10]  Phylogenetic trees were 
generated using the Mr. Bayes plugin of the Geneious software suite. The Bayesian 
estimation for the phylogenetic analysis of TE domains used the same parameters used 
by Buntin, et al.[11]     
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2.18 Comprehensive analysis of M. xanthus DK1622 secondary 
metabolome  
2.18.1 Preparation of M. xanthus sample sets 
M. xanthus wild-type and mutant strains were grown in replicates (n=4) in 50-mL scale  
cultures and the corresponding extracts were prepared as described in Section 2.15.1.   
2.18.2 Liquid chromatography – high resolution mass spectrometry (LC-HR-MS) 
LC-HR-MS method development was carried out using an UltiMate 3000™ rapid 
separation liquid chromatography system (Dionex RSLC) coupled to an UHR-TOF mass 
spectrometer (Bruker Daltonik maXis) operating in positive ESI mode. LC-nanoESI 
measurements were performed using an Accela UPLC system coupled to an LTQ 
Orbitrap mass spectrometer (Thermo Scientific) equipped with a TriVersa NanoMate 
nanoESI source (Advion).  Separation was performed on an RP-18 column (50 mm x 2.1 
mm, particle size 1.7 µm; BEH, Waters) using a mobile phase system consisting of water 
and acetonitrile (each containing 0.1% formic acid). The following gradient was applied 
for separation with a flow rate of 400 μL/min using (A) Water + 0.1% formic acid (B) 
Acetonitrile + 0.1% formic acid as mobile phase: 0 min 1% B; 1 min 1% B; 10 min 99% B; 
12 min 99% B; 12.5 min 1% B; 14 min 1% B. Data sets were acquired with a scan range 
from 200-2000 m/z. Targeted verification was performed by creating individual extracted 
ion chromatograms of the candidate m/z values generated by PCA and t-test models.   
2.18.3 Statistical treatment of data 
PCA and t-test evaluation were both performed using the ProfileAnalysis v. 2.0 software 
(Bruker Daltonik GmbH) using the find molecular features (FMF) tool. For each sample 
set four replicates (n=4) were used. The LC-MS data were processed from 2 to 11 
minutes and mass ranges of 200 – 1000 m/z and 1000 -2000 m/z.  The bucketing 
parameters for the FMF approach were Δm/z = 30 mDa and ΔRT = 30 s. Compound 
detection was performed using the following parameters : S/N = 5; Correlation 
coefficient threshold = 0.7; Minimum compound length = 10 spectra; Smoothing width = 
2.  To improve visualization of clusters in the scores and loadings plot, the bucket table 
was subjected to pretreatment by log transformation and pareto scaling.[12]  Pairwise 
comparison of wild-type and mutant strain sample sets were performed for both the 
PCA and t-test evaluation. 
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2.19 Yield optimization and large scale fermentation of 
myxoprincomide 
2.19.1 Determination of the best producer 
To determine the best producer for myxoprincomide, five myxoprincomide-producing 
M. xanthus strains (A23, A2, A5, A85, Mxx17) were selected and grown quantitatively 
against DK1622 at 15-ml scale (14.4 mL CTT, 0.3 mL XAD-16, 0.3 mL inoculum) in 
replicates.  All 5 strains were grown to an OD600 / ml= 0.5 prior to inoculation to ensure 
an equal starting point. The XAD and cell pellet were extracted with methanol (30 mL) 
and concentrated to final volume of 300 µL.  The corresponding extracts were analyzed 
by HPLC-MS (Section 2.18.3). 
2.19.2 Media optimization 
M. xanthus DK1622 and A2 were grown in 15-ml scale production cultures in 4 different 
media: CTT, CYE, MD1, and TS.  After extraction, the samples were analyzed by HPLC-
MS (Section 2.18.3) 
To significantly reduce the production of myxochelin, which coelutes with 
myxoprincomide, TS medium was supplemented with Fe(III)-EDTA (80 µg mL-1).   
Further comparison of myxoprincomide production was conducted between TS and 
VY/2 medium.  Similar to previous experiments, the cultures were grown at 15-mL scale 
and the extracts were prepared.  The extracts were analyzed by LC-HR-MS (Section 
2.17.2).  Peak integration of myxoprincomide ( [M+2H]2+ = 506.2717 m/z) was performed 
using the Xcalibur QualBrowser software.   
2.19.3 Quantitative analysis of M. xanthus extracts 
Extracts were analyzed by HPLC-MS on an Agilent 1100 series solvent delivery system 
coupled to Bruker HCTplus ion trap mass spectrometer. Chromatographic separation of 
a 5 µL sample was carried out on a Luna C18(2) column  (100 x  2 mm, 2.5-μm particle 
size; Phenomenex) equipped with a precolumn C18 (8 × 3 mm, 5 μm). The mobile-phase 
gradient was composed of solvent A [water + 0.1% formic acid] and solvent B 
[acetonitrile + 0.1% formic acid] linear from 5% B at 1 min to 95% B at 12 min at a flow 
rate of 400 µL min-1.  Quantitation was carried out in manual MS2 mode. Ions of m/z 
[M+2H]2+ = 506.3 were collected and subjected to fragmentation. The intensities of the 
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characteristic fragment ions m/z = 797.5 and m/z = 497.4 were summed up, and peak 
integration was carried out utilizing the Bruker DataAnalysis software package. 
2.19.4 Strain optimization 
M. xanthus A2 was engineered to produce higher myxoprincomide titers by promoter 
insertion directly before the gene MXAN3779.  A copy of the first 650 bp of MXAN_3779 
was linked to the T7A1 promoter sequence by cloning the fragment into the plasmid 
pCKT7A1.  Single crossover recombination in M. xanthus A2 resulted in two copies of 
the 650 bp MXAN_3779 fragment.  The first copy of MXAN_3779 is truncated whereas 
the second copy  represent the in-frame and  full-length gene under control of the T7A1 
promoter. The first 650 bp of MXAN 3779 were amplified with Phusion polymerase 
using primers with NdeI (MXAN3779_startNdeI – 5’- 
CGCTCATATGCACGAGACTCCGCGAAC) and EcoRI (MXAN3779_Eco – 5’- 
ATGGAATTCTACGGCGGCAGCCAGATGAC) restriction sites designed using the 
available M. xanthus DK1622 genome sequence.  The PCR product was cloned into the 
pCKT7A1 vector and sequenced.  The plasmid was electroporated into M. xanthus A2 
(650 V / 400 Ω/ 25 µF).  Transformants (A2.c506) were verified by PCR amplification 
using a forward primer specific for pCKT7A1(5’- CACGTGCTGATCAGATCCATTAC) 
and a reverse primer specific for MXAN 3779 (5’- GGAGGATGCCTCCGATGAG) and 
grown quantitatively against M. xanthus A2 wild type with a starting OD600 / mL= 0.25.   
2.19.3.2 Optimization of the introduction of XAD-16 resin   
Four pairs of 15 ml production cultures of the optimized strain A2.c506 were prepared 
using TS medium supplemented with Fe(III)-EDTA and kanamycin.  XAD-16 resin (300 
µL) was added at different time points during cultivation: Sample set A: start of 
cultivation, sample set B: after 24 hours, sample set C: after 48 hours, and sample set D: 
after 72 hours.  Sample sets A to C were harvested 72 hours after inoculation.  Sample set 
D was allowed to grow for an additional 72 hours (death phase).  The extracts were 
prepared as previously described and the samples were analyzed by HPLC-MS (Section 
2.18.3) 
2.19.4 Large scale fermentation 
To obtain sufficient amount of myxoprincomide, the optimized strain M. xanthus A2.c506 
was grown in PS medium (300-L) and VY/2 (fed-batch 9-L) 
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2.19.4.1 300-L PS medium 
The optimized myxoprincomide producer strain M. xanthus A2.c506 was grown at 300-L  
scale in PS  medium (10 g Casein Peptone Type S (Marcor) 2 g MgSO4 80 μg/ml Fe(III) 
EDTA and 4 g starch per liter pH 7.0)   for 72 hours before the addition of 2% XAD-16 
resin.  Fermentation was carried out at 250 rpm,. 30 oC, and pH was maintained at 7.0.   
After XAD introduction, the cultivation was allowed to proceed for an additional 72 
hours before harvesting.  The cells and XAD-16 resin were separated from the medium 
and amounted to 6.6 kg.   
2.19.4.2 9-L fed-batch VY/2 fermentation 
Six liters of VY/2 medium (without HEPES) supplemented with kanamycin (50 µg mL-1),  
vitamin solution (100 µL per liter medium) and trace elements (2 mL per liter medium) 
were inoculated with 500 mL of M. xanthus A2.c506 grown in VY/2 + Kan50.  
Fermentation was run at 250 rpm, 30 oC, pH 7.0 and the pO2 was maintained by flow.  
The feed solution 10x VY/2 (50 g Baker’s yeast, 0.5 g CaCl2, H2O to 1 L) and XAD-16 
were added once the logarithmic phase had started. The feeding rate was manually 
adjusted to maintain a linear oxygen consumption curve.  Cultivation was terminated at 
the onset of the stationary phase.  
 
2.20 Purification of myxoprincomide from the optimized producer 
strain M. xanthus A2.c506   
2.20.1 Isolation of myxoprincomide-c506 from 300-L PS medium fermentation of M. 
xanthus A2.c506 
The cells and XAD-16 resin from the 300-L scale fermentation were extracted with 
methanol. Before concentration, the methanol extract was defatted with n-heptane.  The 
methanol phase was dried in vacuo. The dried residue (~30g) was washed with ethyl 
acetate.  The excess ethyl acetate was removed and the remaining residue was 
partitioned between water and n-butanol (1:1).  The water phase was lyophilized at -
80oC.  2.5 g of the dried residue was immersed in 10 ml of methanol.  The mixture was 
centrifuged and the supernatant was fractionated on a Sephadex LH-20 column using 
methanol as the eluent.  Aliquots from fractions were obtained and analyzed by 
HPLC-MS.  Fractions containingmyxoprincomide were pooled, dried in vacuo, and re-
dissolved in double distilled water (500 µl).  The myxoprincomide-containing fraction 
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was purified by reverse-phase HPLC (Jupitor 4u Proteo 90A, 250 x 10 mm, 4 micron, 
DAD at 220 nm and 280 nm) using a H2O-acetonitrile containing 0.05% trifluoroacetic 
acid.  Elution was carried out as follows: 15% ACN (0 - 5 min), 15 – 20% ACN (5-10 min), 
20% ACN isocratic (10-20 min).  Myxoprincomide (1.2 mg, tR = 15.1 min) was collected 
and dried in vacuo at -80oC prior to NMR analysis. 
2.20.2 Isolation of myxoprincomide variants from 9-L fed-batch VY/2 fermentation of 
M. xanthus A2.c506 
The XAD-16 resin was separated from the culture broth and was washed with water.  
The resin was defatted with n-heptane followed by extraction with ethyl acetate until 
most of the DKxanthenes was removed from the XAD-16 beads, judged by visual 
inspection.  Final extraction was carried out with methanol until the supernatant 
remained colorless.  The methanol fraction was dried in vacuo and the dried residue was 
redissolved in 10 mL methanol.  The concentrated sample was fractionated on a 
Sephadex LH-20 column with methanol as the mobile phase.  Fractions were analyzed 
by HPLC-MS.  Fractions containing myxoprincomide variants were pooled, completely 
dried, and redissolved in double distilled water (100 µL per 10 mg dried residue).  
Purification of the myxoprincomides by reverse-phase HPLC using the exact same 
conditions detailed in Section 2.20.1.   
 
2.21 Structure elucidation of myxoprincomide 
2.21.1 NMR Analysis 
NMR spectra for the myxoprincomides were recorded on a Bruker Avance 700 
instrument at 700 MHz and 175 MHz in DMSO-d6 as a solvent and internal standard.   
2.21.2 Determination of the absolute stereochemistry of N-MeSer, Ser, Leu, OH-Val, 
Tyr, β-Lys, and Ala 
Purified myxoprincomide-c506 (0.6 mg) was hydrolyzed with 6N HCl in a sample vial 
for 16 h at 100 oC. The hydrolysates were evaporated to dryness, dissolved in H2O (100 
µl), and aliquoted to 50 µl portions. 1N NaHCO3 (20 µl) and 1% 1-fluoro-2,4-
dinitrophenyl-5-L-leucinamide (L-FDLA or D-FDLA solution in acetone, 100 µl) were 
added to each aliquot. The mixtures were incubated at 37 oC for 1h. The solutions were 
cooled to room temperature, neutralized with 2N HCl (20 µl), and evaporated to 
dryness. The residues were dissolved in acetonitrile (810 µl) and analyzed by LC-MS.   
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HPLC-DAD-MS analysis of the L/D-FDLA derivatives was performed on an HPLC-
DAD-MS system operated in switching ionization mode. Separation was achieved using 
a Luna RP-C18 column (100 mm x 2 mm, particle size 2.5 µm, Phenomenex) using a 
mobile phase system consisting of water and acetonitrile containing 0.1 % formic acid. 
Elution was performed with a linear gradient of 5 – 95% acetonitrile in 20 min at a flow 
rate of 0.4 ml / min. MS data were acquired at a scan range of 100 – 1400 m/z.  
2.21.3 Determination of the absolute stereochemistry of the 2-oxo-beta-leucine in 
myxoprincomide-c506 
The following procedure was adapted from the method described by Itagaki et al.[13] To a 
stirred solution of myxoprincomide-c506 (0.3 mg) in 5% NaOH (0.5 ml), 35% H2O2 (0.1 
ml) was added dropwise to the reaction.  The reaction was stirred at 65 oC for 40 min 
after which the reaction was hydrolyzed with 6N HCl (1.0 ml) at 100oC for 16h.  The 
reaction mixture was dried in vacuo and the hydrolysates were derivatized with FDLA as 
previously described. 
2.20.4 Tandem MS fragmentation 
MSn analyses were carried out on a LTQ Orbitrap mass spectrometer by collision 
induced dissociation (CID) at normalized collision energies of 35% at a mass resolution 
of R = 30 000.  Parent ions were isolated with a 2 m/z window.  For HPLC-MS/MS2 
analyses, full scan measurements were acquired in the Orbitrap and fragments were 
measured in the LTQ.  For direct infusion of purified compounds, full scan and fragment 
measurements were carried out in the Orbitrap.   
 
2.21 Feeding of labeled substrates 
2.21.1 CTT (20 mL) 
Shake flask production cultures (20-mL) of M. xanthus DK1622 were supplemented with 
1 mM of labelled amino acids.  The following amino acids were  used: L-alanine-2-d; L-
leucine-5,5,5-d3; L-leucine-2,3,3,4,5,5,5,5’,5’,5’-d10;  L-glutamic-2,3,3,4,4-d5 acid; L-serine- 
2,3,3-d3; L-valine-d8; L-serine- 13C3, 15N; L-threonine - 13C4; 15N; 5-fluoro-DL-tryptophan; 
L-phenylalanine-13C6; L-histidine-13C6; L-methionine(methyl-d3); sodium 1-13C-acetate; 
sodium 2-13C-acetate; & 1,2-13C2-acetate.  Cultures were grown for 96 hours at 30oC , 200 
rpm.  The cells and XAD were separated from the medium by centrifugation and were 
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extracted with 2 x 15 ml methanol.  The extracts were concentrated to a final volume of 
300  l and analyzed by HPLC-HR-MS.   
2.21.2 VY/2 (50 mL) 
Shake flask production cultures (50-mL) of the M. xanthus strain were supplemented 
with 1 mM of labelled amino acids.  The following amino acids were  used: L-alanine-2-
d; L-leucine-5,5,5-d3; L-valine-d8; L-serine- 13C3, 15N; L-phenylalanine-13C6; L-
methionine(methyl-d3); sodium 1-13C-acetate; sodium 2-13C-acetate; & 1,2-13C2-acetate.  
Cultures were grown for 96 hours at 30oC , 200 rpm.  The cells and XAD were separated 
from the medium by centrifugation and were extracted with 2 x 30 ml methanol.  The 
extracts were concentrated to a final volume of 1 mL and analyzed by HPLC-HR-MS.   
 
2.22 Isolation and structure elucidation of althiomycin 
Myxococcus xanthus DK897 was grown in a 300 L fermenter with PS medium (10 g/L 
Casein Peptone Type S (Marcor), 2 g/L MgSO4, 80 μg/ml Fe(III) EDTA , and 4 g/L 
starch) pH = 7.09). After 72 h, 2 % XAD-16 resin was added. The culture was harvested 
after a total of 144 h of cultivation, and XAD and the cells were separated from the 
liquid. The XAD cell mixture was subsequently extracted with water, a mixture of 
water/methanol 1:1, and pure methanol. The methanol fraction contained althiomycin. 
The volume of the methanol fraction was reduced and the concentrated methanol 
fraction was defatted with n-heptane. The methanol phase was dried in vacuo. The crude 
extract was dissolved in water and extracted with ethyl acetate. Major parts of 
althiomycin stayed in the ethyl acetate fraction.  This fraction was dried and applied to a 
Sephadex LH-20 column and eluted using methanol. The althiomycin containing 
fractions were pooled and concentrated.  
 
A further purification step was performed via a Waters AutoPurification System with a 
Xbridge Prep C18 OBD column (19 x 150 mm, 5 μm particle size; Waters) using buffered 
water (5 mM NH4HCO2 pH 5.8) as solvent A and methanol (containing 5 % of A) as 
solvent B. A gradient of 40 – 95% B in 6.5 min was initiated after 2 min. Detection was 
performed by a 3100 Mass Detector (Waters) and fractions containing althiomycin were 
collected on a 2767 Sample Manager (Waters), pooled, and concentrated.  
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NMR spectra for althiomycin were recorded on a Bruker Avance 500 instrument at 500 
MHz and 125 MHz in DMSO-d6 as a solvent and internal standard.   
 
2.23 Bioactivity assays 
2.23.1 Althiomycin sensitivity assay on M. xanthus DK1622 wildtype and attb_almE 
mutant strains 
Paper discs were soaked with 15 µl of purified althiomycin and dehydrated althiomycin 
with concentrations of 1 mg ml-1.  The discs were placed on top of M. xanthus DK1622 
wild-type and attb_almE lawns.  Detection of inhibition zones was performed by visual 
inspection.   
2.23.2 Activity screening for myxoprincomide 
2.23.2.1 Cell culture 
Cell lines were obtained from the American Type Culture Collection (ATCC) and the 
German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung für 
Mikroorganismen und Zellkulturen, DSMZ). All cell lines were cultured under 
conditions recommended by the respective depositor. Media were purchased from 
Sigma, fetal bovine serum (FBS Gold) from PAA, and other reagents from GIBCO 
(Invitrogen). The stable cell line CHO/NFκBp65-GFP was obtained from Affymetrix and 
grown in medium supplemented with hygromycin (100 µg mL-1). U-2 OS cells 
expressing GR-EGFP were generated by lentiviral transduction and calcium phosphate 
transfection of an expression vector encoding a fusion protein of the glucocorticoid 
receptor and EGFP. 
2.23.2.2 Cytotoxic activity  
Myxoprincomides were dissolved in 60 µl cell culture medium to a concentration of 300 
µg/ml in 96-well cell culture plates. Then, 120 µl cell suspension (5 x 104 cells/ml) of 
either HCT-116 (human colon carcinoma) or CHO-K1 (Chinese hamster ovary) cells 
were added to achieve a final drug concentration of 100 µg/ml. Viability of cells was 
assessed after 4 d treatment by tetrazolium salt reduction (MTT) and compared to the 
solvent control. 
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2.23.2.3 ROS assay 
U-2 OS cells were grown in 96-well imaging plates until they reached approximately 
80% confluency and washed with KRH buffer (Krebs-Ringer-HEPES; 119 mM NaCl, 4.7 
mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 1.2 mM KH2PO4, 10 mM HEPES, pH 7.4). Cells 
were loaded with 5 µM DCFDA  (100 µl/well) for 1 h at 37°C. After washing with KRH 
and 30 min recovery in cell culture medium, cells were stimulated 30 nM tBHP (tert-
butyl hydroperoxide) in order to artificially stimulate ROS (reactive oxygen species) 
production. In parallel, counteraction (ROS scavenging) of myxoprincomides was 
assessed at a final concentration of 100 µg/ml and compared to 50 µM Resveratrol 
(positive control; described antioxidant). DCFDA is oxidized by ROS and upon that 
shows strong fluorescence in the GFP channel. Images were recorded on an automated 
microscope (BD Pathway855) and processed in AttoVision v1.6.2. Fluorescence intensity 
was determined on a single cell basis and averaged over one well.  
2.23.2.4 NFκB inhibition 
CHO/NFκBp65-GFP cells were grown in 96-well imaging plates in F12 medium 
supplemented with 10% FBS / hygromycin (100 µg mL-1) until 80-90% confluency. 
Medium was changed to serum-free F12 and cells were incubated for 3 h at 37°C. 
Myxoprincomides were added at a final concentration of 100 µg/ml and cells were 
treated for 1 h prior to the addition of 25 ng/ml IL-1β. By this, NFκBp65 translocation 
from the cytoplasma to the nucleus can be observed and it is expected that anti-
inflammatory compounds that act via NFκB signaling are able to inhibit this stimulus-
induced translocation. After 30 min stimulation at 37°C cells were fixed with 4% PFA 
(paraformaldehyde) and nuclei were stained with Hoechst33342 (Molecular Probes). 
Images were recorded on an automated microscope (BD Pathway855) and processed in 
AttoVision v1.6.2. Hoechst images were used for segmentation on nuclei. The GFP 
fluorescence was determined in both, cytoplasmic and nuclear segments, as average 
value of cells within the field of view. After scaling, ratios of GFP fluorescence in the 
nuclei and cytoplasmic regions were calculated.  
2.23.2.5 GR translocation 
U-2 OS/NR3C1-GFP cells were cultured in 96-well imaging plates and treated with 
either 100 µg mL-1  myxoprincomides or 100 nM dexamethasone (Dex) as a positive 
control. Glucocorticoid receptor ligands like Dex lead to a translocation of GR from the 
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cytoplasma to the nucleus and by this, generally suppress immune and inflammatory 
responses. After 3 h treatment at 37°C cells were fixed with 4% PFA (paraformaldehyde) 
and nuclei were stained with Hoechst33342 (Molecular Probes). Images were recorded 
on an automated microscope (BD Pathway855) and processed in AttoVision v1.6.2. 
Hoechst images were used for segmentation on nuclei. The GFP fluorescence was 
determined in both, cytoplasmic and nuclear segments, as average value of cells within 
the field of view. After scaling, ratios of GFP fluorescence in the nuclei and cytoplasmic 
regions were calculated.  
2.23.2.6 Bacterial cultures 
All microorganisms were handled under standard conditions recommended by the 
depositor. Overnight cultures of bacteria were prepared in EBS medium (0.5% peptone 
casein, 0.5% proteose peptone, 0.1% peptone meat, 0.1% yeast extract; pH 7.0) and of 
yeast and fungi in Myc medium (1% phytone peptone, 1% glucose, 50 mM HEPES, pH 
7.0) by inoculation either from cryocultures or of single colonies on agar plates. The next 
day, OD600 was measured on a photometer. 
Table 2.27: List of strains used for the bioactivity assays 
Strain Source (Strain collection) Temperature [°C] 
Candida albicans HZI / DSMZ (DSM 1368) 30 
Mucor hiemalis HZI  30 
Pichia anomala HZI / DSMZ (DSM 70263) 30 
Chromobacterium violaceum HZI  30 
Pseudomonas syringae HIPS  30 
Pseudomonas aeruginosa HZI 30 
Escherichia coli TolC HZI / Ciba-Geigy AG, 
Basel 
37 
Bacillus subtilis HIPS 30 
Mycobacterium smegmatis mc2 155 ATCC (700084) 37 
Staphylococcus aureus MRS3 HZI 30 
Mycobacterium diernhoferi HZI 30 
Micrococcus luteus HZI 30 
 
2.23.2.7 Antimicrobial testing 
Overnight cultures of microorganisms were diluted to OD600 0.01 (bacteria) or 0.05 
(yeast/fungi) in the respective medium. Inhibition experiments were performed in 96-
well plates at a final drug concentration of 200 µg/ml in a total volume of 150 µl 
suspension culture/well. After overnight treatment, growth inhibition was assessed by 
OD600 measurement on a plate reader. 
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2.23.3 Development Assay, sporulation frequency and motility rates 
The wildtype and mutant strains were grown to a cell count of 0.6 x 108 cells per mL.  
One milliliter of the cultures was centrifuged for 5 minutes at 10,000 rpm at room 
temperature.  The supernatant was discarded and the cell pellet was washed with MC7 
medium.  The cell suspension was centrifuged for 5 minutes at 10,000 rpm.  The cell 
pellet was resuspended in MC7 medium (15 µL) in order to have a final cell 
concentration of 5 x 109 cells per mL.  The cell suspension (5 µL) was spotted on TPM 
agar in triplicates.  The spots were allowed to dry.  The plates were incubated at 30 oC.  
Photographs were taken after 6h, 12h, 24h, 48, and 72h at x10 magnification through a 
dissecting microscope.  
Measurement of the sporulation frequencies and motility rates were conducted using the 
protocol described by Velicer et al. with a few modifications.[14]   
Preparation of the starvation plates for the sporulation frequency assay was identical to 
the procedure used for the development assay except that 50 µL of the cell suspension 
was spotted on the TPM agar.   
For the motility assay, 50 µL of culture was spotted on soft and hard CTT agar plates.  
Swarm perimeters were marked after 72 and 144 hours of incubation.   
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4 The molecular diversity of the myxoprincomides: 
linear peptides assembled by an aberrant NRPS/ 
PKS hybrid synthetase 
 
Myxoprincomides are linear peptides produced by Myxococcus xanthus constructed by 
the NRPS/PKS megaenzyme Mxp.  Mxp is the largest, single, continuous hybrid 
synthetase reported from myxobacteria known to date which is capable of assembling an 
entire structural backbone.   
The first reported myxoprincomide structure is that of myxoprincomide-c506 (1) from M. 
xanthus DK1622. Independent investigation of the secondary metabolome of another M. 
xanthus strain (DK897) uncovered a group of myxoprincomide analogs represented by 
myxoprincomide-c580 (2). Based on the mass spectrometric data obtained from the pilot 
study on the hidden secondary metabolome of 98 M. xanthus isolates, the production of 
these two groups of structural analogues is determined to be mutually exclusive.[1] (Fig 
4.1) Consequently, it can be surmised that the corresponding hybrid synthetases Mxp1622 
and its heterofunctional homolog Mxp897 are equally exclusory within the species.   
Group I is designated to the myxoprincomides produced by Mxp1622 which is 
represented by myxoprincomide-c506 and the myxoprincomides assembled by the 
Mxp897 pathway (myxoprincomide-c580 and structural variants) belong to the group II 
myxoprincomides.  This chapter delves into the molecular diversity of the group I 
myxoprincomides. Unlike myxoprincomide-c506 and the group II myxoprincomides, for 
which the masses were uncovered during the M. xanthus secondary metabolome pilot 
study, the group I myxoprincomide derivatives to be presented in this chapter evaded 
detection by LC-MS mainly due to their low titers under standard conditions for M. 
xanthus cultivation.  These structural variants were identified during the course of 
optimizing the isolation process for myxoprincomide-c506, an M. xanthus compound 
already considered to be produced in low abundance.   
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Figure 4.1: Tally of group I and group II myxoprincomide producers.  The data is based on the 
pilot study on the secondary metabolomes of 98 M. xanthus isolates.[1] Group I myxoprincomides 
are represented by myxoprincomide-c506 (1) and group II myxoprincomides are represented by 
myxoprincomide-c580 (2).   The image of M. xanthus was adapted from Velicer et al., 2003.[2]  
 
4.1 Optimization of myxoprincomide production and identification 
of 15 additional structural variants 
4.1.1 Optimization of myxoprincomide production 
Myxoprincomide-c506 was purified from a cultivation of the optimized strain M. xanthus 
A2.c506 in 300 L PS medium (Section 2.19.4.1).  PS medium is highly similar to TS 
medium, the medium which was previously identified as the optimal culture media for 
myxoprincomide production.  PS medium differs from TS medium in that it uses 
peptone instead of tryptone as nitrogen source.   Nevertheless, the chromatographic 
profile of the extract grown in either media are highly similar (data not shown).  
Although the isolation of myxoprincomide-c506 from the PS medium cultivation was 
successful, the process was both labor and resource intensive.  The main culprit is the 
overwhelming amount of polar media compounds which adsorb to the XAD-16 resin 
and coelute with myxoprincomide-c506.  To illustrate, from ~25 g of lyophilized 
methanol crude extract derived from 100 L of culture broth, the product yield was ~1 mg 
after five chromatographic steps.  Whereas the amount of purified compound was 
sufficient for structural elucidation by NMR, the time and resources spent in separating 
myxoprincomide-c506 from the media compounds deemed the process inefficient.  
Therefore an alternative cultivation condition was required to reduce the amount of 
interfering media compounds.   
 4 Myxoprincomides 
 
123 
 
A viable alternative was the growth of the optimized strain A2.c506 in VY/2 medium.  
VY/2 medium is a complex medium long used for myxobacteria cultivation.[3]  
Chromatographic profiles of crude extracts from the cultivation of Chondromyces strains 
in VY/2 meidum revealed that the components of this medium were observed 
minimally during sample work up. (R. Garcia & S. Hüttel, personal communication)  
Semi-quantitative analysis of myxoprincomide-c506 production in VY/2 and TS media 
revealed that myxoprincomide-c506 is produced two-fold more in VY/2 than in TS 
medium, with the added benefit of a reduced matrix effect on the chromatographic 
profile.  (Fig. 4.2) 
 
Figure 4.2: A) Comparison of the myxoprincomide-c506 production in TS and VY/2 media.  B) 
UV traces of the crude extracts obtained from the cultivation of M. xanthus A2.c506 in TS and 
VY/2 media as analyzed using the HPLC method detailed in Section 2.20.1. Marked in asterisks 
(*) are the peaks corresponding to myxoprincomide-c506.   
 
Using VY/2 as cultivation medium, a 9-L scale fed batch fermentation yielded 0.5 mg of 
purified myxoprincomide-c506 with a simplified isolation process. (Section 2.20.2) 
4.1.2 Identification of myxoprincomide variants 
The improved myxoprincomide-c506 production and sample work up facilitated the 
acquisition of MS2 data which unambiguously identified 15 additional myxoprincomide 
variants. (Table 4.1)   
The relationship to myxoprincomide-c506 was determined by two peptide sequence tags 
(PST) obtained from tandem MS analysis.  PST A consists of the product ions 187 m/z, 
215 m/z, 330 m/z, and 417 m/z which are consistent with the a2, b2, b3, and b4 fragments 
from the fragmentation of myxoprincomide-c506.  PST B includes 797 m/z, 682 m/z, and 
595 m/z which correspond to y7, y6, and y5 from myxoprincomide-c506.  (Fig. 4.3 & S4.2) 
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Figure 4.3:  Myxoprincomide-c506 with the y- and b- fragment ions marked.  The shorthand form 
and position number for each amino acid residue are listed below the structure and will be used 
accordingly in the discussion.   
 
The smallest and one of the largest myxoprincomide variants, named myxoprincomide-
c534 and myxoprincomide-c708 respectively, were isolated and structurally elucidated 
by NMR and mass spectrometry analysis.  Structures are proposed for nine structural 
variants based on de novo peptide sequencing using tandem MS data and feeding of 
labeled substrates.  Four variants (c528, c535, c555, and c584) were identified based on 
their peptide sequence tags.  However, due to their low titers at 50-ml cultivation scale, 
the volume in which the feeding of isotope-labeled amino acid substrates was carried 
out, structures could not be proposed for these derivatives.   
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Table 4.1: List of Group I myxoprincomides variants.  The variants are further subdivided to 
Group I-A (short myxoprincomides), Group I-B (large myxoprincomides with PST A), Group I-C 
(large myxoprincomides with PST B), Group I-D (large myxoprincomides with PST A but lacking 
the 417 Da fragment ion). * has identical y2-y10 product ions as myxoprincomide-c708.   
 
4.1.2.1 Group I-A: identification and characterization of myxoprincomide-c534, -c649, 
and –c651 
LC-MS/MS2 analysis of the size exclusion chromatography (SEC) fraction eluting after 
myxoprincomide-c506 revealed 3 compounds with monoisotopic masses m/z [M+H]+ = 
534.3 Da, 649.3 Da, and 651.4 Da whose MS2 fragmentation pattern include PST A.  
Group I-A 
Myxo 
ID 
Cmpd m/z[M+H]+ 
(measured) 
Predicted  
Molecular Formula  
m/z 
(calc’d) 
Δ ppm PST 
2668 c534 534.3134 C23 H44 O9 N5 534.3133 0.085 A 
2669 c649 649.3395 C27 H49 O12 N6 649.3402 -1.228 A 
2670 c651 651.3556 C27 H51 O12 N6 651.3559 -1.746 A 
Group I-B 
Myxo 
ID 
Cmpd m/z [M+2H]2+ 
 (measured) 
Predicted  
Molecular Formula 
m/z[M+2H]2+ 
(calc’d) 
Δ ppm PST 
2309 c506 506.27122+ C45H76N10O16 506.2721 -0.130 A 
2754 c513 513.2789 (2+) C46H78O16N10 513.2793 (2+) -0.905 A 
2755 c528 528.2841 (2+) C47H80O17N10 528.2846 -1.490 A 
2767 c535 535.2915 (2+) C46H80O16N13 535.2917 0.671 A 
2769 c591 591.8342 (2+) C44H74O17N10S 591.8337 0.655 A 
2738 c562 562.8124 (2+) C51H87O17N11 562.8135 -0.465 A 
2671 c708 708.3928 (2+) C66H108O20N14 708.3947 -0.363 A 
Group I-C 
Myxo 
ID 
Cmpd m/z [M+2H]2+ 
 (measured) 
Predicted  
Molecular Formula 
m/z[M+2H]2+ 
(calc’d) 
Δ ppm PST 
2739 c515 515.2494 (2+) C44H74O16N10S 515.2496 -1.222 B 
2762 c523a 523.2466(2+) C44H74O17N10S 523.2468 0.226 B 
2740 c523b 523.2632 (2+) C48H74O16N10 523.2637 -0.792 B 
2842 c717 717.3715 (2+) C65H106O20N14S 717.3708 0.812 * 
Group I-D 
Myxo 
ID 
Cmpd m/z [M+2H]2+ 
 (measured) 
Predicted  
Molecular Formula 
m/z[M+2H]2+ 
(calc’d) 
Δ ppm PST 
2770 c555 555.8055 (2+) C47H80O17N10 555.8050 1.484 A – 417 
2768 c584 584.8265 (2+) C44H74O16N10S 584.8259 0.945 A - 417 
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Reverse phase HPLC-MS analysis revealed that the retention times of these compounds 
fall within the time range when myxoprincomide-c506 elutes. (Fig. 4.4) 
 
Figure 4.4: Chromatographic profiles of myxoprincomide-c506, c534, c649, and c651 as produced 
in VY/2 medium 
Compound c534 elutes as a single peak with a monoisotopic mass of m/z [M+H]+ = 
534.3134 corresponding to a predicted molecular formula of C23H44N5O9 (Δppm = 0.085) 
as analyzed by high resolution ESI-MS.  
MS2 fragmentation of c534 revealed y ions whose neutral losses correspond to the five N-
terminal amino acid residues in myxoprincomide-c506. (Fig. S4.3) Feeding with 13C3,15N-
L-serine, d3- L-leucine, and d8-L-valine confirmed the incorporation of two serine, one 
leucine, and 2 valine residues. (Fig. S4.3)  An observed loss of a deuterium atom from 
one of the incorporated d8-L-valine residues could correspond to the displacement of the 
deuterium atom at Cβ by a –OH group to for L-β-OH-valine.  (Fig. S4.1) Growth in the 
presence of L-methionine-(methyl-13C) showed the incorporation of the labeled methyl 
group carbon attributed to the N-methylation of L-serine, possibly derived from an 
intracellular pool of (methyl-13C)-S-adenosyl-13C-methionine.   
To confirm the structure, 1.1 mg of c534 was purified and analyzed by one- and two-
dimensional (1D & 2D) NMR experiments (1H, 13C, [1H,1H]-HSQC, and [1H-13C]-HMBC) 
in DMSO-d6. (Table 4.2 and Fig. S4.14-18)  
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Table 4.2: NMR spectroscopic data for myxoprincomide-c534 (DMSO-d6).  a Recorded at 175 
MHz; referenced to residual DMSO-d6 at δ 39.51 ppm.  b Recorded at 700 MHz; referenced to 
residual DMSO-d6 at δ 2.50 ppm.  c Proton showing HMBC correlation to indicated carbon  
 
 δCa δHb (J in Hz) HMBCc 
N-MeSer 
1 166.0   
2 61.9 3.83 m 1, 3 
3 59.6 3.83, 3.68 2 
NH2+  8.43 8.04 t 2 
Nme 31.3 2.51  
OH  5.48 br s  
    
Leu 
1 171.2   
2 51.2 4.48 q 1, 3, 4, 1NmeSer 
3 40.1 1.49 t 1, 2, 4, 5, 6 
4 23.9 1.62 m 2, 3, 5, 6 
5 21.1 0.87 d (6.1) 3, 4, 6 
6 22.9 0.88 d (6.7) 3, 4, 5 
NH  8.68 d (7.7) 1NmeSer 
    
OH-Val 
1 169.4   
2 59.5 4.43 d (9.2) 1, 3, 4, 5, 1Leu 
3 71.7   
4 27.6 1.12 s 2, 3, 4 
5 24.4 1.09 s 2, 3, 5 
NH  7.95 d (8.2) 1Leu 
OH  5.01 s 2, 3, 4, 5 
    
Ser 
1 170.0   
2 54.8 4.36 m 1, 3, 1OH-Val 
3 59.4 3.68, 3.59 m 1, 2 
NH  7.95 d (8.2) 1OH-Val 
OH  4.96 br  
    
Val 
1 172.5   
2 57.2 4.12 dd  
(6.2, 6.1) 
1, 3, 4, 5, 1Ser1 
3 29.6 2.03 m 1, 2, 4, 5 
4 18.9 0.87 d (6.5) 2, 3, 4 
5 17.9 0.86 d (6.5) 2, 3, 5 
NH  7.90 d (8.3) 1Ser 
    
 
Using the NMR spectra of myxoprincomide-c506 as reference, the observed 1H and 13C 
chemical shifts from the c534 NMR spectra were compared and subsequently shown to 
be in good agreement with those of amino acids 1-5 of myxoprincomide-c506.  (Fig. 4.5) 
The only clear difference observed is C1 from L-valine which has a 13C chemical shift of δ 
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172.5 ppm in c534 but is δ 196.4 ppm in myxoprincomide-c506.  The deviation is 
expected as the L-valine C1 from c534 is part of the –COOH terminus while the same 
carbon in myxoprincomide-c506 belongs is C2 of the L-valine-derived 2-oxo-leucine 
moiety. The absolute configuration of the amino acid residues were determined by 
advanced Marfey’s method and myxoprincomide-c534 was determined to contain only 
L- amino acids as previously observed in myxoprincomide-c506.   
 
Figure 4.5: Structure of myxoprincomide-c534 (3) 
 
Compound c649 and c651 were analyzed by HR ESI-MS and were determined to have a 
monoisotopic mass of m/z [M+H]+ = 649.3396 Da (predicted formula of C27H49N6O12 
(Δppm = -1.228)) and m/z [M+H]+ = 651.3556 Da (predicted formula C27H51N6O12 (Δppm 
= -1.746)) respectively.  Compound c649 elutes as multiple peaks akin to 
myxoprincomide-c506 while compound c651 elutes slightly earlier as a single peak.  (Fig 
4.4)   
Tandem MS analysis of both c649 and c651 clearly generated PST A implying that the 
first four amino acids are comprised of N-MeSer, Leu, OH-Val, and Ser, and that the 
difference between these two compounds lie on the two C-terminal amino acid residues.  
Feeding with d8-L-valine and 13C3,15N-L-serine showed that both compounds contain two 
L-valine derived residues and three L-serine residues.  Neutral losses to form the b5 ion 
544.22 m/z from c649 and b5 ion 546.27 m/z from c651 indicate a loss of an L-serine 
residue at the C-terminus (Fig. S4.4 & S4.5) 
The subsequent neutral loss to form the b4 ion 417.15 m/z indicated that the difference 
between c649 and c651 lies between Ser2 and Ser3 of the molecules.  Using the structural 
information from the group II myxoprincomides from M. xanthus DK897 where 2-oxo 
and 2-hydroxy structural features were observed (O. Revemann, Dissertation, 
Universität des Saarlandes, 2012), we propose that c649 is the shunt product with the 2-
oxo moiety is retained and c651 contains a 2-hydroxy group in lieu of the 2-oxo 
functional group. (Fig. 4.6) 
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Figure 4.6: Proposed structure for myxoprincomide-c649 (4) and for myxoprincomide-c651 (5). 
The proposed stereochemistry is based on the absolute configuration of the representative 
structure myxoprincomide-c506. 
Myxoprincomide-c534, -c649, and c-651 were confirmed to be shunt products released 
from the Mxp1622 assembly line. The possibility that these 3 shorter myxoprincomides are 
post assembly degradation products was negated when all 3 compounds were detected 
in the crude extract of DK1622 mutant strains which could not produce the necessary β-
lysine precursor necessary for the biosynthesis of the larger myxoprincomides (e.g. 
myxoprincomide-c506).  (Section 4.2.1) 
4.1.2.2 Group I-B : Identification and characterization of c513, c562 and c708 
Compounds c513, c562 and c708 were determined to be related to myxoprincomide-c506 
after LC-MS/MS2 analysis of the SEC fraction eluting before myxoprincomide-c506.  The 
MS2 spectra of c513, c562, and c708 all reflect PST A, establishing the relationship to 
myxoprincomide-c506.   
 
Figure 4.7: Chromatographic profiles of myxoprincomide-c506, -c513, -c562, and -c708 as 
produced in VY/2 medium (A).  Magnified EIC of c513, c562, and c708 
 
Compound c513 has a monoisotopic mass of m/z [M+2H]2+ = 513.2789 Da with a 
predicted formula of C46H78O16N10 (Δppm = -0.905) which corresponds to an additional  
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methylene group (-CH2-) in comparison to  myxoprincomide-c506.  Analysis of the d8-L-
valine labeled c513 revealed the incorporation of a labeled L-β-OH-valine but not a 
labeled L-valine.  (Fig. S4.6) This implies that only OH-Val is incorporated into c513 and 
that the second valine is replaced by another amino acid which we believe to be a leucine 
as an additional L-leucine is observed in the d3-L-leucine-labeled c513.   
MS2 analysis of c513 disclosed that the neutral losses between the product ions are 
congruent with most of the monomers observed in myxoprincomide-c506 with the 
exception of y5  y4. The neutral loss between y5 and y4 from c513 contains an additional 
14 Da in comparison to the same position in myxoprincomide-c506 consistent with the 
ValLeu hypothesis.  The proposed structure is presented in Figure 4.8.  
 
 
Figure 4.8: Proposed structure for myxoprincomide-c513 (6).  The proposed stereochemistry is 
based on the absolute configuration of the representative structure myxoprincomide-c506. 
 
Based on HR ESI-MS, compound c562 has a monoisotopic mass of m/z [M+H]+ = 
562.81352+ and a predicted formula of C51H87N11O17 (Δppm = -0.465).  The mass difference 
between c562 and myxoprincomide-c506 is 113.08 Da implying an incorporation of an 
additional L-leucine.  The incorporation of two d3-L-leucine residues in c562 confirms this 
hypothesis. (Fig. S4.7) 
Examination of the b ions from the isotope-labeled c562 enabled the determination of the 
position of the second L-leucine in the molecule. (Fig. 4.9) The b9 ion 1035.61 m/z indicate 
the loss of L-alanine.  This b9 ion is observed to contain two d3-L-leucine residues.   
The b8 ion reflected a mass difference from b9 consistent with a L-leucine residue.  The b8 
ion from the d3-L-leucine labeled c562 appears to contain only one d3-L-leucine thereby 
confirming that L-leucine was indeed the amino acid lost from b9 to b8.  The subsequent 
b7, b6, and b5 ions were consistent with the loss of a L-β-lysine, L-tyrosine, and L-serine 
respectively. 
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Figure 4.9: Observed b8, y9 and b9 product ions of the unlabeled (A) and d3-L-leucine-labeled 
myxoprincomide-c562. 
 
Given the tandem MS data from unlabeled and isotope-labeled c562, a structure for 
myxoprincomide-c562 is proposed. (Fig. 4.10) 
 
 
Figure 4.10: Proposed structure for myxoprincomide-c562 (7).  The proposed stereochemistry is 
based on the absolute configuration of the representative structure myxoprincomide-c506. 
 
Determination of c708 as a myxoprincomide variant via the identification of PST A 
initially led us to believe that we obtained the intact myxoprincomide with a 
hypothetical acyl starter unit preceding the N-MeSer residue.  However, 13C-acetate 
labeled c708 only indicated the incorporation of one C2 carbon from acetate, similar to 
myxoprincomide-c506, eliminating the possibility of an acetate-derived acyl starter 
chain.  Analysis of the c708 containing isotope labeled amino acids revealed that c708 
contains extra leucine and phenylalanine-derived residues in comparison to 
myxoprincomide-c506.   Assuming that L-tyrosine is the additional phenylalanine 
derived residue, the only unaccounted mass difference is 128 Da which could 
correspond to a lysine or a β-lysine.  Fragment ions a2 and b2 - b8 from c708 and 
myxoprincomide-c506are identical, denoting that this portion of the two compounds is 
putatively identical.  (Fig. S4.8) Subsequent neutral loses from b9 to b11 appear to 
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correspond to tyrosine, lysine/ β-lysine, and leucine.  The difference between M+H+ and 
b11 is equivalent to a loss of alanine.   
1D and 2D NMR experiments were carried out on 0.5 mg of pure c708. (Fig. S4.19-24)  
The NMR spectra were recorded in the same solvent and instrument as that used for the 
structural elucidation of myxoprincomide-c506 to facilitate comparison.  Examination of 
the –NH region of the 1H spectra indicated 3 NH groups (δ 8.16 ppm, δ 7.59 ppm, δ 7.98 
ppm) not identified in myxoprincomide-c506.  The proton with a chemical shift of δ 8.16 
ppm was determined to belong to a tyrosine residue as determined by [1H, 13C]-HSQC 
and [1H, 13C]-HMBC.  Using TOCSY couplings of the -NH protons with chemical shifts δ 
7.59 ppm, δ 7.98 ppm were determined to belong to β-lysine and leucine respectively.  
Assignment of the rest of the c708 signals was facilitated by their identity to those 
observed in the NMR spectra of myxoprincomide-c506. (Table 4.3)   
Table 4.3: NMR spectroscopic data for myxoprincomide-c708 (DMSO-d6).  a Recorded at 175 
MHz; referenced to residual DMSO-d6 at δ 39.51 ppm.  b Recorded at 700 MHz; referenced to 
residual DMSO-d6 at δ 2.50 ppm.  c Proton showing HMBC correlation to indicated carbon.  d 
Proton showing ROESY correlation to indicated proton, * not assigned 
 
 δCa δHb (J in Hz) HMBCc ROESYd 
NmeSer 
1 166.2    
2 61.8 3.86 br s 1, 3 Nme, NHLeu 
3 59.4 3.83, 3.70m 2 Nme, NH2+, NHLeu 
NH2+  8.84, 8.76 br s  2, Nme 
Nme 31.1 2.52 2  
OH  5.49 br s   
     
Leu1 
1 171.6    
2 51.2 4.50 dt (8.8, 6.3) 1, 3, 1NmeSer 3, 4, 5, NH, NHOH-Val 
3 40.3 1.48 m 1, 2, 4, 5 2, 5, NH 
4 24.1 1.63 m 2, 3, 5, 6 2, NH 
5 21.1 0.87 d (6.6) 3, 6  
6 22.8 0.89 d (6.6) 3, 4, 5  
NH  8.70 d (8.3) 1NmeSer 2, 3, 4 
     
OH-Val 
1 169.2    
2 59.5 4.43 d (9.1) 1, 3, 4, 5, 1Leu 4 
3 71.9    
4 27.3 1.13 s 2, 3, 5 2, NH 
5 24.5 1.08 s 2, 3, 4  
NH  7.99 d (8.2) 1Leu1 4, 1Leu1 
OH  *   
     
Ser1 
1 170.8    
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2 55.3 4.38 m 1, 3, 1OH-Val 3, NH 
3 61.6 3.37 3.58 m 1, 2 NHOH-Val 
NH  8.00 d (8.1) 1OH-Val 2 
OH  5.20 br   
     
2-oxo-β-Leu 
1 172.1    
2 196.9    
3 57.6 5.14 dd (5.4, 5.5) 2, 4, 5, 6, 1Ser1 4, 5, 6, NH, NHSer2 
4 29.5 2.17 m 3, 4, 5 3, 5, 6 
5 19.7 0.87 d (6.6) 3, 4, 6 3, 4 
6 17.5 0.81 d (6.8) 3, 4, 5 3, 4, NH 
NH  8.05 d (8.0) 1Ser1 3, 6, 2Ser1 
     
Ser2 
1 168.8    
2 50.3 4.33 m 3, 12-oxo-β-Leu 3, NH, NHTyr 
3 61.6 3.62, 3.57 m 1, 2 1, NH 
NH  8.33 d (7.9) 12-oxo-β-Leu 2, 3, 32-oxo-β-Leu 
OH  *   
Tyr1 
1 170.5    
2 54.8 4.35 m 3 3, 2’, 6‘ NHβ-Lys1 
3 36.9 2.87 dd (14.0, 4.3) 1, 2, 1’, 2’ 2, 2’, 6‘ 
  2.68 dd (14.1, 9.0) 1, 2, 1’, 2’ 2’, 6‘ 
1’ 127.9    
2’, 6’ 130.2 6.98 d (8.6) 3, 4’ 2, 3 
3’, 5’ 114.6 6.63 d (8.4) 4’  
4’ 156.0    
NH  8.16 d (7.5) 1Ser2 2, 3, 2‘, 3‘, 2Ser2 
OH  9.16 s   
     
β-Lys1 
1 169.5    
2 40.1 2.12 br d (6.2) 1, 3 3, NH, NHTyr2 
3 45.2 3.92 m  2, 4, 5, 6, NH 
4 29.9 1.35, 1.09 m 2, 3, 6 3, NH2, NH 
5 23.4 1.35, 1.45 m 3, 6 6, NH2 
6 38.3 2.63 br 4, 5 5, NH2 
NH2  7.59 m 6 5, 6 
NH  7.80 d (8.8)  1Tyr1 2, 3, 4, 2Tyr1 
     
Tyr2 
1 170.8    
2 54.3 4.38 m 3 3, 2’, 6‘ NHβ-Lys2 
3 37.0 2.82 dd (13.5, 3.9) 1, 2, 1’, 2’ 2, 2’, 6‘ 
  2.59  1, 2, 1’, 2’ 2’, 6‘ 
1’ 128.1    
2’, 6’ 130.0 6.99 d (8.6) 3, 4’ 2, 3 
3’, 5’ 114.6 6.63 d (8.4) 4’  
4’ 156.0    
NH  8.04 d (8.4) 1β-Lys1 2, 3, 2‘, 6‘, 2β-Lys1 
OH  9.16 s   
     
β-Lys2 
1 170.0    
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2 40.1 2.20 br d (6.2) 1, 3, 4 NH, NHLeu2 
3 45.3 4.02 br  NHLeu2 
4 30.3 1.46, 1.36  m 2, 3, 6 6, NH 
5 23.6 1.46, 1.52 m 2, 6 6, NH2 
6 38.4 2.73 dd (12.0, 7.0) 4, 5 5, NH2 
NH2  7.64 m 5, 6 5, 6 
NH  7.89 d (8.3)  1Tyr2 2, 2Leu2 
 
Leu2 
1 172.1    
2 50.3 4.33 m 1 NHAla 
3 40.8 1.43 m 1 2, 5, NH, NHAla 
4 23.8 1.62 m 2, 3, 5, 6 2, NH 
5 21.8 0.84 d (6.6) 3, 4, 6 2 
6 23.5 0.87 d (6.6) 3, 5  
NH  7.98 d (8.2) 1β-Lys2 2β-Lys2 
 
Ala 
1 174.3    
2 47.1 4.13 t (7.3) 1, 3, 1Leu2 3, NH, 2Leu2 
3 16.8 1.22 d (7.3) 1, 2 2, NH 
NH  8.23 d (7.3) 2, 3, 1Leu2 3, 2Leu2 
 
Using the [1H, 13C]-HMBC connectivities, the correct sequence of the amino acids were 
determined.  Myxoprincomide-c708 is comprised of L-amino acid subunits as 
determined by advanced Marfey’s method.  The final structure is shown in Figure 4.11.   
 
 
Figure 4.11: Final structure of myxoprincomide-c708 (8) 
 
4.1.2.3 Group I-C: Identification and characterization of myxoprincomide-c515, -c523a, 
c523b 
Group I-C myxoprincomides are characterized by the PST B.  Common to all three 
compounds is the replacement of Leu at position 2, as confirmed by the lack of d3-L-
leucine incorporation (Figure S4.9-11). 
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Figure 4.12: Chromatographic profiles of myxoprincomide-c506, -c515, -c523a, and –c523b as 
produced in VY/2 medium (A).  Magnified EICs of c515, c523a, and c523b 
The incorporation of two 13C-labeled methyl groups derived from L-methionine-(13C-
methyl) could be observed in compound c515. (Fig. S4.10) One of these 13C-labeled 
methyl groups is correlated to the N-MeSer residue and is underpinned by the loss of 
one 13C-label after the neutral loss (101 Da) to form the y8 ion.  The subsequent y7 product 
ion no longer holds a 13C-methyl label indicating the position of the second 13C-labeled 
methyl containing residue.  (Fig. 4.13) 
 
 
Figure 4.13: Observed y7 and y8 product ions from the fragmentation of unlabeled (A) and L-
methionine-(13C-methyl)-labeled myxoprincomide-c515 
The fragment ion y8 (928.32 m/z) is 131.04 Da larger than the y7 ion (747.36 m/z) which 
corresponds to the residue mass for methionine.  The incorporation of an intact 
methionine accounts for the second 13C-labeled methyl group.  The replacement of Leu 
by Met, a less hydrophobic amino acid, could explain why c515 elutes slightly earlier 
than myxoprincomide-c506 under standard LC-MS analysis (Fig 4.14).  A methionine-
containing analog of myxoprincomide-c708 was also identified with a monoisotopic 
mass m/z [M+2H]2+ = 717.3715 Da (predicted formula: C65H106O20N14S, Δppm = 0.812). 
(Fig. 4.15 & S4.12) 
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Figure 4.14: Proposed structure for myxoprincomide-c515 (9).  The proposed stereochemistry is 
based on the absolute configuration of the representative structure myxoprincomide-c506. 
 
 
Figure 4.15: Proposed structure for myxoprincomide-c717 (10).  The proposed stereochemistry is 
based on the absolute configuration of myxoprincomide-c708. 
Similar to myxoprincomide-c515, analysis of the 13C-methyl labeled c523a revealed the 
incorporation of two 13C-methyl groups and their corresponding neutral losses indicate 
once again that both labeled carbon atoms are in the first two amino acid residues.  (Fig. 
4.16 and Fig. S4.10)   
 
Figure 4.16: Observed y7 and y8 product ions from the fragmentation of unlabeled (A) and L-
methionine-(13C-methyl)-labeled myxoprincomide-c523a 
The difference between y8 and y7 is 147.04 Da which corresponds to the residue mass of 
methionine sulfoxide.    The calculated monoisotopic mass (m/z [M+2H]2+ =  523.2468) for 
the proposed c523a structure (Fig. 4.17) is in very good agreement with the measured 
m/z value  (m/z [M+2H]2+ =  523.2466) 
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Figure 4.17: Proposed structure for myxoprincomide-c523a (11).  The proposed stereochemistry is 
based on the absolute configuration of the representative structure myxoprincomide-c506. 
 
Compound c523b, which has a 0.04 Da higher mass than c523a (m/z [M+2H]2+ = 523.2633 
Da, predicted formula C48H74O16N10, Δppm = -0.792 ), likely contains a phenylalanine in 
position 2.  (Fig. 4.18) We propose this based on the detection of a doubly L-
phenylalanine-13C6-ring labeled c523b and the observed y8  y7 loss of a phenylalanine 
residue (147.07 Da) from tandem MS analysis. (Fig. S4.11)   
 
 
Figure 4.18: Proposed structure for myxoprincomide-c523b.  The proposed stereochemistry is 
based on the absolute configuration of the representative structure myxoprincomide-c506. 
 
4.2 Biosynthesis of the non-proteinogenic amino acid precursors L-
β-lysine and L-β-hydroxyvaline 
Observed from the group I myxoprincomides are two non-proteinogenic amino acids: L-
β-lysine, present in the larger group I myxoprincomides (MW > 1000 Da) and L-β-OH-
valine, observed in all variants.  As genes encoding the enzymatic functions for the 
biosynthesis of thes two unusual amino acids were not observed in the vicinity of the 
mxp1622 (Fig 3.4) the enzymes responsible for the formation of L-β-lysine and L-β-OH-
valine were hypothesized to be encoded by distinct genes.   
4.2.1 Formation of β-lysine  
Beta-lysine is a non-proteinogenic amino acid found in nature as an intermediate in the 
anaerobic catabolism of L-lysine.[4]  In some  Streptomyces species, β-lysine acts as a 
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precursor to produce bioactive compounds such as tuberactinomycins (e.g. viomycin) 
streptothricins, and nourseothricin.[5;6]  The transfer of the amino group group from the 
Cα to Cβ is in these cases catalyzed by SAM-dependent 2,3-lysine aminomutases (2,3-
LAM).[4]   
The most well characterized 2,3-LAM is KamA which is involved in lysine metabolism in 
Clostridium subterminale SB4.  X-ray crystallographic studies on KamA, where the 
substrate and cofactors are bound to the active center, have shown that catalysis requires 
a CxxxCxxC binding motif  which encloses a [4Fe-4S] cluster, Lys337 for the binding of 
pyridoxal pyrophosphate, and Arg134-Asp293-Asp330 which interact with the carboxyl and 
amino groups of the lysine substrate.[7]  
Annotation of the genes upstream and downstream of mxp1622 did not reveal any 
aminomutase-encoding genes that could possibly catalyze the conversion of lysine to β-
lysine.  However, it is plausible that the 2,3-LAM encoding gene could be located 
somewhere else in the genome similar to the dispersed genetic loci of the aurachin 
biosynthetic pathway.[8] 
Based  on their sequence similarity of their gene products to the amino acid sequence of 
KamA, VioP (1,335 bp, 455 aa), a 2,3-LAM involved in the biosynthetis of viomycin,and 
SttO (CAB67710, 1,201 bp,  403 aa) of the strepthricin biosynthetic pathway, [5], 3 genes, 
namely MXAN_4699, MXAN_4698, and MXAN_6263 were identified as possible 2,3-
LAM-encoding candidates.  (Table 4.4 and Fig. S4.13)  The gene products of these 3 M. 
xanthus genes contain the required residues for 2,3-LAM activity.  (Fig. S4.13) 
Table 4.4: Percent identity / similarity of putative M. xanthus DK1622 2,3-KAM encoding genes to 
VioP (Accession no. AAP92506.1) 
 
Gene Length (bp /aa) Identity /Similarity (in %) 
MXAN_4699 1,371 / 456 61 / 74 
MXAN_4698 1,233 / 410 31 / 46 
MXAN_6263 1,329 / 443 26 / 45 
 
These three genes were individually inactivated and out of the three only the 
MXAN_4699 knockout mutant strain 4699.1 was deficient in myxoprincomide-c506 
production. Whereas a polar effect on the downstream MXAN_4698 gene (Fig. 4.19) 
could in theory contribute to the loss of β-lysine production, a synergistic relationship 
between the two proteins for the biosynthesis of the myxoprincomide β-lysine precursor 
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is unlikely as independent inactivation of MXAN_4698 did not impede 
myxoprincomide-c506 production.   
 
Figure 4.19: Gene organization of MXAN_4699 and MXAN_4698 showing the intergenic region 
with a length of 12 bp.  
 
To further confirm the role of MXAN_4699 as the 2,3-LAM involved in myxoprincomide 
biosynthesis, genetic complementation of MXAN_4699 (mutant strain 4699.3) by 
insertion of the native gene into the attb phage attachment site of the knockout strain 
4699.1 was constructed. Alternatively, the 4699.1 production culture was supplemented 
with 1 mM L-β-lysine.  Both approaches restored myxoprincomide-c506 production.  
(Fig. 4.20) 
 
Figure 4.20: Extracted ion chromatograms for myxoprincomide-c506 from the wildtype, 2,3-KAM 
knockout mutant 4699.1, the complementation mutant 4699.3, and the L-β-lysine-fed 4699.1 
mutant strain.  
 
Interestingly, the assembly of the group I-A myxoprincomides were unaffected by the 
inactivation of MXAN_4699, thereby suggesting that these intermediates are released 
from Mxp1622 and are not products of post-assembly degradation. (Fig. 4.21)  
 
Figure 4.21: Extracted ion chromatograms of the group I-A myxoprincomides from the wildtype 
and 2,3-KAM knockout mutant 4699.1.  
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4.2.2 Formation of L- β-hydroxyvaline  
One of the prominent features of the myxoprincomides is the unusual L-β-hydroxyvaline 
(OH-Val) situated consistently at position 3 of the group I myxoprincomides.  In group II 
myxoprincomides, this non-proteinogenic amino acid is even found twice, one at 
position 2 and the other position 4. (O. Revermann, Dissertation, Univerität des 
Saarlandes, 2012) Myxovalargin, a long discovered myxobacterial compound, also 
contains a OH-Val residue,[9;10] however the biosynthetic pathway is only being currently 
investigated.  (U. Scheid, personal communication) 
To our knowledge, an enzyme which catalyzes the hydroxylation of valine at Cβ is not 
yet known. The hydroxylation of Val in myxoprincomide possibly occurs as a post 
assembly or post incorporation modification by a yet to be identified oxidizing enzyme.  
We raise this possibility because the binding pocket of module 3 A domain (8 Å 
signature: LGSAFDASTLEGWLLAGGDVNGYGPTESTTFTAC / nonribosomal code: 
DALWLGGTFK) showed very high similarity to a Val-activating A domain. (Table S3.5) 
Both the 8 Å signature and the nonribosomal code lack an amino acid with a basic side 
chain (e.g. Arg or His) commonly observed in the binding pockets of hydroxyl group 
containing amino acid Ser- and Thr-activating A domains.[11]  
Similar to the aminomutase MXAN_4699, it was presumed that the necessary gene/s for 
the biosynthesis of OH-Val is found somewhere else on the genome as the genes 
surrounding mxp1622 do not appear to encode proteins for hydroxylation.  To facilitate the 
search, the amino acid for MPS1, a leucine hydroxylase which hydroxylates one of the 
Cδ of leucine as the first step of (2S-4S) methylproline biosynthesis (Y. Katsuyama, 
unpublished data) was used as tblastn search query.  The BLAST search analysis yielded 
three candidates: MXAN_1289, MXAN_4531, and MXAN_3880.  However, discrete 
targeted inactivation of all three candidate genes did not yield any myxoprincomide-
negative mutants.  
 
4.3 Tn5 promoter insertion upstream of NRPS module 1  
The N-terminus of Mxp contains a loading module comprised of an acyl-CoA ligase and 
ACP domains preceding the first NRPS module (module 1) which incorporates the N-
MeSer residue.  The C domain of module 1, in theory, is responsible for the condensation 
of an acyl moiety provided by the loading module and N-MeSer.  However, since none 
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of the identified myxoprincomides contain an acyl moiety attached to the amine group 
of N-MeSer and that the module 1 C domain lack the complete set of required C domain 
motifs for activity (core motifs C5 and C7 are missing (Fig. S3.5)), this C domain is 
postulated to be inactive.   
In order to ascertain whether the loading module is required, the Tn5 promoter sequence 
was inserted in frame upstream of the module 1 A domain gene sequence.  Three mutant 
strains were generated (Fig. 4.22): one where the Tn5 promoter is directly upstream the 
5’ end of the module 1 A domain sequence (mutant strain A1.1, Tn5 promoter inserted 
upstream base 3,382) and the other two bear the Tn5 promoter in two distinct positions 
within the coding sequence of the module 1 C domain (mutant strain C1A.1, Tn5 
promoter inserted upstream base 2,095; mutant strain C1B.1, Tn5 promoter inserted 
upstream base 2,860).   
All three mutations resulted in a loss of myxoprincomide production. (Fig. 4.22) It is 
possible that the lack of the loading module and C domain sequence in the mutant 
strains’ gene products have implications on the protein folding of the shortened Mxp1622, 
thereby resulting in a loss of biosynthetic activity.   
 
Figure 4.22: A) Extracted ion chromatograms of myxoprincomide from the wildtype and Tn5 
promoter insertion mutants A1.1, C1A.1, and C1B.1.  B) Arrows indicate the position where the 
Tn5 promoter was inserted in the mxp1622 gene.   
 
Alternatively, assuming that the module 1 C domain is active, it is possible that an 
acylated myxoprincomide is biosynthesized early during the growth phase but cleaved 
off at a later time point similar to the conversion of didemnin X and Y to didemnin B by 
Tistrella mobilis or the prodrug activation of xenocoumacin by the membrane-bound 
peptidase XcnG in Xenorhabdus nematophila.[12;13]  However, XcnG does not cleave an acyl 
group per se but an amino acid (L-glutamine) to which the N-terminal acyl group is 
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bound to. A gene encoding a peptidase that could carry out this cleavage was not 
identified from the genes surrounding mxp.  The closest candidate is the gene product of 
MXAN_3780, but inactivation of MXAN_3780 appears to have no effect on 
myxoprincomide biosynthesis. (see Section 4.4.1)  Genes encoding proteins with 
sequence similarity to XcnG (Accession no. YP_003711952, length 489 a.a.) were 
identified in the DK1622 genome (MXAN_2364: length = 469 a.a., 27% identity, 48% 
similarity; MXAN_6409: length: 524 a.a., 23% identity, 42% similarity; MXAN_7171: 
length 741 a.a., 23% identity, 42% similarity).  However, the involvement of the products 
of the aforementioned genes in myxoprincomide biosynthesis was not investigated in 
this study.   
 
4.4 Unusual features of the group I Mxp1622 assembly line  
The structural diversity of the myxoprincomides encompass displaced monomeric units 
and derivatives of various peptide lengths. (Fig. 4.23) Based on domain organization, 
Mxp1622 is predicted to assemble a lipopeptide comprised of 10 amino acid residues, an 
acyl chain at the N-terminus, and a malonate-derived C2 unit in the middle of the 
peptide.  Myxoprincomide-c506 could be presumed as the primary Mxp1622 product 
given its relatively higher abundance, leading to its early detection prior to any of the 
other myxoprincomide variants.  In itself, myxoprincomide-c506 deviates from strict 
colinearity by lacking the N-terminal acyl chain, the L-leucine residue near the C-
terminus, and a carbon from the incorporated C2 unit.   The discovery of a multitude of 
other myxoprincomide variants demonstrates the atypical nature of Mxp1622 for linear 
nonribosomal peptide biosynthesis.   
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4.4.1 Release of intermediates 
The identification of 5-er (myxoprincomide-c534) and 6-er (myxoprincomide-c649 & 
myxoprincomide-c651) shunt products highlights one of the unusual features of the 
myxoprincomide assembly. (Fig. 4.25)  
Assembly line efficiency is dependent on seamless substrate channeling within the 
modules of the enzyme.[14]   For example, the interaction of a C domain and the upstream 
and downstream PCP domains dictate the timing of the peptidyl chain growth.[15]   Any 
inter- or intramodular kinetic blocks that may delay or hamper substrate channeling 
therefore affects the overall biosynthetic turnover.   Therefore, release of shunt products 
could be viewed as an adaptive mechanism, unfavorable in terms of the overall 
biosynthetic efficiency of the full product.  However, the release of intermediates does 
expand the chemical diversity of the compound family.   
The lack of 1- to 4-er and 8-er intermediates from the crude extracts insinuates that the 
release of the intermediates is not a simply a matter of non-enzymatic hydrolysis based 
on the labile nature of the peptidyl-thioester bond. [16]  The production 5-er 
(myxoprincomide-c534) and 6-er (myxoprincomide-c649 and –c651) are pronounced in 
large scale fermentation enabling their detection, isolation, and structural elucidation 
signifying that the corresponding modules from which they are released are hotspots for 
premature hydrolysis. (Fig. 4.25)   A mass for the 7-er intermediate (m/z [M+H]+ = 
812.4040 Da, predicted formula C36H58N7O14, Δppm = 0.448) was detected from the crude 
methanol extract from the large scale cultivation of M. xanthus A2.c506. Unfortunately, 
this putative intermediate neither endured the isolation work up nor was detected from 
the crude extracts from 50-ml scale cultivation, therefore structural elucidation by NMR 
or  de novo peptide sequencing by tandem MS was not possible.  
C domains which are unable or weakly able to recognize amino acids in their acceptor 
sites are hypothesized to release the intermediate when a water molecule enters the C 
domain acceptor site and reacts with the upstream peptidyl-thioester.[15]  Expanding on 
this idea, a C domain or a KS domain, which is “waiting” on the downstream PCP 
domain to provide a substrate for the acceptor site, could also possibly facilitate a 
hydrolytic release of the intermediates.  Following this hypothesis, it is possible that the 
group I A myxoprincomides are stalled peptidyl intermediates released as a 
consequence of the pressure of the next round of assembly.  Formation of the α-keto 
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moiety could be the first rate determining step during the biosynthesis and instead of 
stalling the assembly, myxoprincomide-c534 might be released.   In the case of 
myxoprincomide-c649 and –c651, module 9 is occupied with the second round of L-
tyrosine extension required for the biosynthesis of myxoprincomide-c708. The shorter 
nascent chain is then stalled at module 8 and is released by hydrolysis.  Although there 
are type II thioesterases which act as proofreading enzymes in NRPS pathways, these 
TEIIs act on aminoacyl substrates and not on peptidyl substrates.[17]  C domain-mediated 
release of peptidyl intermediates is the current proposal for the formation of NRP shunt 
products.[16]  However, the exact mechanism is not yet fully understood. 
Hydrolytic release of upstream NRP intermediates were observed from the calcium-
dependent antibiotic biosynthetic pathways after the A domains were engineered by site 
directed mutagenesis to alter specificity.  It was proposed that the acceptor site of the C 
domain did not recognize the noncognate amino acid substrate thereby resulting in 
kinetic blockage.[16]   
The release of shunt products by hydrolysis was previously observed in two PKS 
pathways when the genes encoding the release mechanisms of bacillaene (BaeR TE 
domain) and rifamycin (amide synthase RifF) were deleted.[18;19]   The lack of an off-
loading functionality resulted in the saturation of the assembly line with tethered linear 
intermediates.  In the case of rifamycin, RifR, a type II thioesterase, was postulated to 
perform the off-loading of the intermediates from the assembly line.  The release of the 
bacillaene intermediates was hypothesized to be carried out by an acyltransferase-like 
enzyme similar to PedC of the pederin biosynthesis.[20]   
MXAN_3780, a gene which putatively encodes a patatin-like phospholipase (PLP),[21]  
was initially thought to be involved in the release of the myxoprincomide intermediates. 
The predicted lypolytic activity of MXAN_3780 is the closest biochemical functionality 
that could explain the release of shunt products.    Inactivation of this gene however did 
not abrogate group I-A myxoprincomide production.  Genes encoding PLPs are also 
found in the DKxanthene, leupyrrin, and tubulysin biosynthetic gene clusters[22-24]  
Inactivation of the PLP-encoding genes orf17 and orf18 of the tubulysin pathway led to 
the significant reduction of the production of the major tubulysins but led to the 
discovery of tubulysin-glycerol esters, deeming the PLPs responsible for the cleavage of 
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glycerol from the C-terminus of the peptide.[25] The exact role of PLPs in DKxanthene, 
leupyrrin, and now myxoprincomide biosyntheses has not been established.    
Gene disruption of MXAN_3778, which encodes a molecular chaperon DnaK, also did 
not affect the biosynthesis, not even a polar effect on the downstream mxp1622 gene whose 
start codon is 143 bp away from the stop codon of MXAN_3778.  (Fig. 4.24) 
 
Figure 4.24: Genetic environment of mxp1622 (MXAN_3779).  The predicted functions for the gene 
products are as follows: MXAN_3777 - Inosine-5‘-monophosphate dehydrogenase; MXAN_3778 - 
DnaK family protein; MXAN_3779 – hybrid PKS / NRPS; MXAN_3780 - Patatin-like 
phospholipase family protein; and MXAN_3781 - DedA family protein.  (See Table S3.4 for the 
source of homologous proteins) 
  
With the exception of the PedC-mediated release of bacillaene intermediates, most of the 
previous observations of shunt product release were results of artificial conditions 
wherein the release mechanisms or the A domains were inactivated or modified.  To our 
knowledge there has been no previous report of NRP shunt products that are released 
from the natural assembly line making myxoprincomide-c534, -c651, and c649 the first 
clear example of this phenomenon in NRP assembly.    
4.4.2 Sluggish NRPS module and NRPS module stuttering 
In the biosynthetic hypothesis of myxoprincomide-c506, we initially proposed that 
module 11 incorporates the final Ala monomer into the nascent peptide chain and is 
released by the TE domain, skipping the C-A-PCP of module 12 of Mxp1622.[26]  However 
the discovery of myxoprincomide-c562 and myxoprincomide-c708 provided evidence 
which forced us to revise our previous biosynthetic hypothesis. (Section 3.4)  In this 
revision, we propose that module 12 is active and is responsible for the Ala extension 
and that module 11 is a sluggish NRPS module which sometimes elongates the peptide 
chain with a Leu.   
We describe module 11 as a sluggish NRPS module because majority of the large 
myxoprincomides do not contain Leu in the penultimate position, thereby suggesting 
that the module is skipped.  Nevertheless, we cannot omit the possibility that the 
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module is active as all the conserved motifs required for catalysis are present in the C, A, 
and PCP domains of module 11. (Fig. S3.5) This is unlike in the skipping of the NRPS 
module 4 in the myxochromide biosynthesis where core motifs of the A4 domain 
significantly deviates from conserved A domain motifs required for activity and PCP4 
lacks the catalytic serine residue.[27]   
A possible scenario is that the activation and loading of Leu at module 11 occurs, 
resulting in myxoprincomide-c562, but the process is perhaps not efficient wherein there 
is no Leu loaded onto module 11 thereby stalling the biosynthesis at module 10.  Instead 
of releasing the stalled peptide similar to the group I-A myxoprincomides, the Mxp1622 
synthetase alternatively allows the peptidyl-thioester at module 10 to condense with the 
PCP-bound amino acids of a) module 11 resulting in module skipping forming 
myxoprincomide-c506, -c515, and the group I-C myxoprincomides, or b) module 9 
exhibiting NRPS stuttering where the nascent chain at module 10 condenses with 
another L-tyrosine bound to the PCP domain module 9.  The chain elongates further with 
a second pass through module 10 for a second L-β-lysine extension followed by the 
condensation with L-leucine and L-alanine in modules 11 and 12 resulting in 
myxoprincomide-c708.  The occurrence of NRPS isomodular stuttering, or usage of the 
same module multiple times, is known for the biosynthesis of saframycin A and 
congocidine from streptomycetes.[28;29] Iteration in NRPS where extension with 
precursors tethered to the modules upstream of the immediate elongation module, 
termed here as retromodular stuttering, has been recently reported in the biosynthesis of 
thalassospiramides from marine bacteria.[30]  Modules 2 to 4 of the NRPS assembly line 
undergo a second, and even a third, round of extension to expand the thalassospiramide 
chemical diversity.  The exact mechanism is yet to be fully understood but it is 
hypothesized that the PCP-PCP didomain in module 4 may be involved in the substrate 
shuttling in order for the iterative assembly to occur.  In the case of Mxp1622, no such PCP 
didomain is present in any of the modules.  The only “free” thiolation (ACP) domain is 
that of the loading module.  However, the involvement of the loading module ACP 
domain is speculative, as its role in myxoprincomide biosynthesis is not yet fully 
understood.     
4.4.3 Substrate promiscuity of the A domains of Mxp1622 module 2 and module 6 
The group I-C myxoprincomides are distinct from the other groups in that the amino 
acid at position 2 of the molecules deviates from the more commonly observed Leu 
4 Myxoprincomides 
 
148 
 
residue.  The incorporation of methionine (myxoprincomide-c515 and –c523a (as 
methionine sulfoxide in the latter)) or phenylalanine suggests substrate promiscuity in 
the A domain of module 2.   Coincidentally, the predicted nearest neighbor for the 
module 2 A domain based on in silico analysis is the TycB module 2 A domain of the 
tyrocidine biosynthetic pathway, which itself flexibly recognizes both phenylalanine and 
tryptophan.[31]   
The observation that Leu is the preferred substrate and that Met and Phe are alternative 
substrates suggests that the Mxp1622 module 2 A domain is amenable to amino acids with 
hydrophobic side chains.  The observation of the methionine-S-oxide containing variant 
myxoprincomide-c523a is somewhat anomalous as the sulfoxide moiety is polar. This 
residue is observed in known nonribosomal peptides from marine sponge (haligramide 
B & waiakemide) and cyanobacteria (nodulapeptin B, somamides).[32-35] It is therefore 
proposed that the formation of the sulfoxide occurs as a post-incorporation 
nonenzymatic oxidation, similar to the proposed biosynthesis of nodulapeptin C.[34]  
However, we could also not exclude the possibility that methionine sulfoxide is 
incorporated as the binding pocket represented by the 8 Å signature 
(LGTSFDVSSVEGLLMVGGETNAYGPTECSTMVTR) contains a number of amino acids 
with polar side chains that could interact with the polar sulfoxide functional group.  
Establishing the molecular recognition profile of the Mxp1622 module 2 A domain 
requires experimental proof by ATP-pyrophosphate exchange assay in vitro using 
recombinant A domain similar to that used for TycA.[36]   
The substrate plasticity of module 6 A domain is simpler in its range of substrates. 
Majority of the products observed contains the Val residue west of the α-keto moiety.  
Leucine is accepted as well (myxoprincomide-c513) but to a lesser extent.  The additional 
methylene group in Leu likely lowers the catalytic efficiency of the module 6 A domain, 
resulting in the low production rate of myxoprincomide-c513.  The same trend is 
observed in the group II myxoprincomides produced by M. xanthus DK897 where the 
intensity of the Val-containing variants is more than twice than that of the Leu-
containing group II myxoprincomides (Fig. S4.25).  (O. Revermann, Dissertation, 
Universität des Saarlandes, 2012)  
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4.4.4 Revised and extended model for the biosynthesis of myxoprincomides 
Based on the spectrum of myxoprincomides produced by M. xanthus DK1622, we revise 
the previously presented biosynthetic model to accommodate the structural features 
observed in the products.  (Fig. 4.25)  
Since none of the myxoprincomide variants identified so far contain an acyl starter unit, 
we will presume that condensation between a hypothetical acyl chain on the loading 
module and the L-serine precursor does not occur due to an inactive C domain in 
module 1.  Therefore biosynthesis is hypothesized to begin in module 1 with the 
incorporation and N-methylation of L-serine.  The substrate promiscuity of the module 2 
allows the catalytic flexibility to select, activate, and load L-leucine, L-methionine (and 
possibly L-methionine sulfoxide), or L-phenylalanine, with L-leucine as the preferred 
substrate.  Chain extension proceeds with the incorporation of L-β-OH-valine (possibly a 
L-valine first followed by a hydroxylation event) and L-serine by modules 3 and 4.  
Module 5 extends the peptide with L-valine but the module also accepts a L-leucine 
(myxoprincomide-c513) albeit at a lower catalytic efficiency. At this stage, the module 5 
PCP-tethered intermediate could either be released forming myxoprincomide-c534 or 
extension could occur with the downstream PKS module.  Similar to our previous 
biosynthetic model, we propose that the PKS module 6 elongates the nascent chain with 
a malonyl-CoA followed by an unusual oxidation of the carbon at position α to the 
thioester function presumably catalyzed by the module 7 oxidation domain.  (Fig. S3.17)  
Tautomerization possibly forms an α-keto moiety which is the preferred nucleophilic site 
of the downstream L-serine amino group.  We conclude this based on the fact that 
feeding with 13C-labeled acetate consistently maintained only the carbon at position 2 in 
all of the α-keto-containing myxoprincomides. (Table S4.1)  The L-serine extended 
peptide could either prematurely hydrolyze to release myxoprinomcide-c649 or 
myxoprincomide-c651 or chain extension proceeds with the incorporation of L-tyrosine 
and L-β-lysine by modules 9 and 10 respectively. The next elongation step has three 
possible scenarios.  The most common based on the observed product profile is the 
skipping of module 11 and the consequent elongation with an L-alanine precursor by 
module 12 followed by a TE-facilitated release.  The second possibility is that module 11 
is used and a L-leucine is incorporated before the L-alanine extension and is released as 
myxoprincomide-c562 by the TE domain.  The last route is the presumed retromodular 
stuttering wherein the module 10 PCP-bound intermediate is extended by a repeat 
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extension with L-tyrosine and L-β-lysine by modules 9 and 10 and the consequent 
incorporation of L-leucine and L-alanine by modules 11 and 12 to form myxoprincomide-
c708.  
 
4.5 Bioactivity 
Myxoprincomide-c506 and myxoprincomide-c708 underwent extensive activity 
screening spanning cytotoxicity, antibacterial, and antifungal assays. (Section 2.23.2)  
Myxoprincomide-c506 was not found to be active in any of the assays performed even 
up to a concentration of 200 µg mL-1.  On the other hand, myxoprincomide-c708 was 
observed to weakly inhibit the growth of the filamentous fungi Mucor hiemalis at 200 µg 
mL-1.  The minimum inhibitory concentration (MIC) of myxoprincomide-c708 was 
approximated to be between 50 – 100 µg mL-1.  (Fig, 4.26) 
 
Figure 4.26: Antimicrobial assay of myxoprincomide-c708 at 200 µg mL-1 (A) and determination 
of MIC against M. hiemalis (B).  
 
B) 
A) 
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To determine whether myxoprincomides are relevant for M. xanthus social development 
and motility, the DK1622 wildtype, mxp1622 knockout mutant (MXAN_3779-), and 
overproducer (Tn5_3779) strains were analyzed by fruiting body development, 
sporulation frequency, and motility assays.  Comparison of the formation of fruiting 
bodies over a course of three days did not reveal any significant difference among all 
three strains.  (Fig. 4.27) 
 
Figure 4.27: Fruiting body formation assay on MXAN_3779-, wildtype, and Tn5_3779 strains.  
Images were taken at the indicated time points above each column.  
 
Formation of spores was also not affected by the inactivation or overexpression of 
mxp1622 as viable colonies of comparable numbers were observed on agar plates after 
disruption and overlay of the formed spores.  Swarming motility was not significantly 
impeded nor enhanced in the knockout and overproducing mutant strains as swarming 
was observed at approximately the same speed within the experimental error window.  
(Table 4.5) 
Table 4.5: Average swarming speeds (mm/day) of the M. xanthus 
DK1622 wildtype, knockout mutant, and overproducer strains 
 
 CTT Agar CTT Soft Agar 
Strain Average  
mm / day 
Average  
mm / day 
DK1622 2.78 3.22 
MXAN3779- 3.08 3.42 
Tn5_3779 3.01 3.74 
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4.5 Outlook  
Majority of the myxoprincomide structures presented in this chapter were structurally 
elucidated by tandem MS and LC-MS/MS2 analysis of isotope-labeled 
myxoprincomides.   Although the interpretation is sound, the proposed structures could 
be further confirmed by purification and subsequent analysis by NMR.  Obtaining 
sufficient material for structural elucidation will be challenging but by scaling up the 
VY/2 fed batch cultivation, the availability of the myxoprincomides could be achieved.  
Moreover, increasing the number of purified variants affords more chemical entities for 
bioactivity assays and will enable to determine whether the variation in the structures 
present any evolutionary advantage for M. xanthus.   
The molecular diversity of the myxoprincomides revealed the atypical nature of Mxp1622. 
The proposed biosynthetic model provided reflects a good agreement between the 
chemical reality and the genetic evidence.  However, there are biosynthetic steps which 
still  require in vivo or in vitro analysis for support.   
An ATP-pyrophosphate exchange assay similar to that used for TycA[36] could provide 
empirical proof to establish the extent of the substrate promiscuity of Mxp1622 module 2 
A domain and additionally provide a kinetic evidence for the L-leucine incorporation 
bias.    But the most interesting segment for further investigation would be modules 9 to 
11 where retromodular stuttering and module skipping / usage occurs.   
A deeper understanding of the PKS-derived formation of the α-keto / α-hydroxy moiety 
could be achieved by in vitro analysis using synthetic intermediates and a recombinant 
partial assembly line. Given the issues of expressing partial assembly lines, an 
alternative to fully elucidate the biosynthesis would be to construct truncated assembly 
lines with promoter insertion upstream of modules 6 and 7 separately and to feed with 
activated synthetic intermediates.  The assumption mainly is that the truncated assembly 
line could still properly fold and is functional to carry out the rest of the biosynthesis.  In 
addition, point mutations in the Ox domain could lead to domain inactivity possibly 
producing myxoprincomides without the α-keto moiety.  
 Fusion of the TE domain upstream of the later modules forming a truncated Mxp1622 
could provide further insight into the release mechanism of the shunt products.  This 
technique has been shown to provide truncated intermediates from polyketide synthase 
assembly lines.[18;37;38] 
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4.7 Supplementary Information 
 
 
 Figure S4.1: Deuterium-labeled L-β-OH-valine and L-valine residues.  
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Figure S4.2: Myxoprincomide-c506 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-I) HR-ESI MS spectra of labeled compounds  
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Figure S4.3: Myxoprincomide-c534 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.4: Myxoprincomide-c649 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.5: Myxoprincomide-c651 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.6: Myxoprincomide-c513 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.7: Myxoprincomide-c562 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.8: Myxoprincomide-c708 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.9: Myxoprincomide-c515 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.10: Myxoprincomide-c523a MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.11: Myxoprincomide-c523b MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
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Figure S4.12: Myxoprincomide-c717 MS data. A) HR-ESI MS spectrum. B) MS2 analysis. C) 
Annotated product ions. D-G) HR-ESI MS spectra of labeled compounds  
 4 Myxoprincomides 
 
169 
 
Table S4.1: Result of 13C-acetate labeling of myxoprincomides.  Shown are the relative intensities 
of the isotope peaks in the control (unlabeled), 1-13C-acetate, 2-13C-acetate, and 1,2-13C-acetate 
labeled myxoprincomides. 
Myxoprincomide-c534 Relative Intensity (in %) 
Sample /  
labeled acetate 
 
534.3124 m/z 535.3160 m/z 536.3188 m/z 
Control 100.00 25.35 4.54 
1-13C-acetate 100.00 26.02 4.77 
2-13C-acetate 100.00 27.95 5.21 
1,2-13C2-acetate 100.00 26.03 4.74 
Myxoprincomide-c649 Relative Intensity (in %) 
Sample /  
labeled acetate 
 
649.3396 m/z 650.3433 m/z 651.3461 m/z 
Control 100.00 30.18 6.25 
1-13C-acetate 100.00 29.69 6.40 
2-13C-acetate 100.00 40.95 10.73 
1,2-13C2-acetate 100.00 32.20 7.50 
Myxoprincomide-c651 Relative Intensity (in %) 
Sample /  
labeled acetate 
 
651.3555 m/z 652.3590 m/z 653.3619 m/z 
Control 100.00 31.14 6.73 
1-13C-acetate 100.00 30.71 6.71 
2-13C-acetate 100.00 38.92 9.73 
1,2-13C2-acetate 100.00 32.74 7.50 
Myxoprincomide-c506 Relative Intensity (in %) 
Sample / labeled 
acetate 
506.2715 m/z 506.7729 m/z 507.2758 m/z 507.7767 m/z 
Control 100.00 53.32 17.20 3.77 
1-13C-acetate 100.00 55.07 17.75 4.06 
2-13C-acetate 100.00 98.35 45.84 15.04 
1,2-13C2-acetate 100.00 68.83 27.37 8.08 
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Table S4.1 (cont’d) 
Myxoprincomide-c515 Relative Intensity (in %) 
Sample / labeled 
acetate 
515.2759 m/z 515.7775 m/z 516.2789 m/z 516.7804 m/z 
Control 100.00 51.27 16.69 3.95 
1-13C-acetate 100.00 54.09 16.32 4.15 
2-13C-acetate 95.11 100.00 43.76 16.92 
1,2-13C2-acetate 100.00 67.73 27.40 8.01 
Myxoprincomide-
c523a 
Relative Intensity (in %) 
Sample / labeled 
acetate 
523.2468 m/z 523.7483 m/z 524.2499 m/z 524.7483 m/z 
Control 100.00 48.58 12.97 2.87 
1-13C-acetate 100.00 52.59 16.85 3.84 
2-13C-acetate 100.00 82.97 32.50 10.81 
1,2-13C2-acetate 100.00 62.08 22.99 3.62 
Myxoprincomide-
c523b 
Relative Intensity (in %) 
Sample / labeled 
acetate 
523.2633 m/z 523.7649 m/z 523.2668 m/z 523.7648 m/z 
Control 100.00 53.71 16.53 2.80 
1-13C-acetate 100.00 56.82 17.90 4.26 
2-13C-acetate 99.24 100.00 41.08 12.62 
1,2-13C2-acetate 100.00 78.14 31.29 9.83 
Myxoprincomide-c562 Relative Intensity (in %) 
Sample / labeled 
acetate 
562.8134 m/z 563.3151 m/z 563.8178 m/z 564.3188 m/z 
Control 100.00 59.43 25.07 6.47 
1-13C-acetate 100.00 62.24 21.93 7.68 
2-13C-acetate 90.47 100.00 48.84 20.10 
1,2-13C2-acetate 100.00 73.03 30.00 11.68 
 
Myxoprincomide-c708 Relative Intensity (in %) 
Sample / labeled acetate 708.3919 m/z 708.8937 m/z 709.3954 m/z 709.8969 m/z 
Control 100.00 79.68 37.38 11.13 
1-13C-acetate 100.00 80.25 37.38 13.22 
2-13C-acetate 77.16 100.00 65.30 51.20 
1,2-13C2-acetate 100.00 95.81 51.20 20.72 
Myxoprincomide-c717 Relative Intensity (in %) 
Sample / labeled acetate 717.5715 m/z 717.3726 m/z 718.3722 m/z 718.8744 m/z 
Control 100.00 71.77 32.30 13.96 
1-13C-acetate 100.00 69.86 38.51 17.59 
2-13C-acetate 92.22 100.00 62.72 28.63 
1,2-13C2-acetate 97.21 100.00 54.21 22.23 
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MXAN_4698       ------------MLPAGLPPEPTAARASLSAEGRKRLFPNATDAEWADWRWQQRHAVRGL 48 
MXAN_4699       MQTTPIRAKPEAGPAEQPFTYPHRREFIEPDWRRIPGFKDVSAADWENSVWQRKHTIKNL 60 
MXAN_6263       ------------------MSVMSNAALALSTGRRYRAYTTRHLDELTTRAGLSADERLAV 42  
KamA            ------------MINR-----------------RYELFKDVSDADWNDWRWQVRNRIETV 31  
SttO            ----------------------------------MPSW---------------ATCSTRA 11  
VioP            ---------------------------MEPDWRRLPGWHDVTAAQWHDVQWQRAHCVKNA 33  
                                                      :                         
 
MXAN_4698       EQLERYVP-----LTSNERAGVQETSALFRIGISPYYLSLIDP------------EHPFC 91 
MXAN_4699       KELKATLGALLPDDLAESMERDQRERATMSLLVPPQMLNTMN-----------LEDLWRD 109 
MXAN_6263       QAVAHVLPFRTNSYVVDELIDWAAAPADPIYRLVFPQADMLPTEDVARMVD--LLSSGAS 100 
KamA            EELKKYIP-----LTKEEEEGVAQCVKSLRMAITPYYLSLIDP------------NDPND 74  
SttO            --------------FYEDWEWDRSHYATMSVLLPPQMINTMAPEVAAARPGELTKAFYDD 57  
VioP            RQLRAVVGDGLDDKFYDDLTEDQEHMATMAMLITPQMLNTIAPETPADSDG-YHDAFYAD 92  
                                :.              :     . :                      
 
MXAN_4698       PVRMQSIPVRAEAR----IRPGELADPLGEDKTRPEECIVHKYPDRVLFLALD--TCSVY 145 
MXAN_4699       PVRRYMLPAYADRLTEWTNHPKASRDSLHEQDMWVVEGLTHRYPTKVLAEMLP--TCPQY 167 
MXAN_6263       PLELNAAANEIRARLNPHPAGQMQLNVPKLANEEPVPGLQHKYKETVLIFPKQGQTCHAY 160 
KamA            PVRKQAIPTALELN----KAAADLEDPLHEDTDSPVPGLTHRYPDRVLLLITD--MCSMY 128 
SttO            PVRRYMMPVMSDRHPQWPSHPMASRDSLHEQDMWVVEGLTHRYPTKVLAELLS--TCPQY 115 
VioP            PVRRYMVPVRSDRDLRWPSHPLSSRDSLHEAEMWVVEGLTRRYPTKVLAELVA--TCPQY 150  
                *:.    .                 :            : ::*   **        *  *   
 
MXAN_4698       CRHCTR-RRITQGGVAELSK--------EQLRRGVDYVRSHPEVRDVLISGGDPFMLSDS 196 
MXAN_4699       CGHCTR-MDLVGNDVPQVSKHKFGIGPKDRYAQMLDYLRRTPTVRDVVVSGGDIANLPIQ 226 
MXAN_6263       CTYCFRWAQFVGDADLKFAS--------REIEPLVNYIRAHPEVTNVLFTGGDPMIMTEA 212 
KamA            CRHCTR-RRFAGQSDDSMPM--------ERIDKAIDYIRNTPQVRDVLLSGGDALLVSDE 179 
SttO            CGHCTR-MDLVGNSTPQVTKSRLQLKPVDRADRILAHLRVSPGIRDVVVSGGDLANMPWP 174 
VioP            CGHCTR-MDLVGGSTPSVDKQRLTLRPADRQEAILDHLRRTPGVRDVVVSGGDVANVPWP 209  
                * :* *   :.     ..           .    : ::*  * : :*:.:***   :.     
 
MXAN_4698       RLEELLAPLSEIPHVEMIRIGTRVPVCLPMRVTD---------ALAKTLRRYAPVFVVTH 247 
MXAN_4699       QLEPFVSSLMDIPNIRDIRLASKGLMAIPQHFLQDSVLQGLDRLAKKAVERGVDLALHTH 286 
MXAN_6263       VLAKYIEPLLDIEHLEAIRIGTKALAYWPQRFVTDSDADDILRLFEKVVASGKSLAFMAH 272 
KamA            TLEYIIAKLREIPHVEIVRIGSRTPVVLPQRITP---------ELVNMLKKYHPVWLNTH 230 
SttO            RLERFLDDLLEIDSIRDIRLASKALIGLPQHWNSGPLLEGVARIARKARSRGVRIALHTH 234 
VioP            RLESFLLRLLEIDSVRDIRLASKALVGLPQHWLQPQVVSGLENVAGVAARRGVHLAVHTH 269  
                 *   :  * :*  :. :*:.::     * :                       : . :*   
 
MXAN_4698       FNHPKEVTPEAREACERLVDHGVP-VENQAVLMRQLNSDARIIKELSHLLLRSR-VRPYY 305 
MXAN_4699       VNHAQQLTPLVGKAVRKLLEMGFRDVRNQGVLLRGVNDSPQALLDLCFTLLDHAKILPYY 346 
MXAN_6263       FSHPNEMVPEIVQEAVRRIRGTGAVIRTQAPLIRTINDTPGTWESMWRTHLRHG-MVPYY 331 
KamA            FNHPNEITEESTRACQLLADAGVP-LGNQSVLLRGVNDCVHVMKELVNKLVKIR-VRPYY 288 
SttO            ANAAQQVTPAVARAAWALLDAGLHDVRNQGVLMRGVNDSAHDLLDLCFALTDHAGITPYY 294 
VioP            ANHVQSVTPLVAEGARALLDAGVRDVRNQGVLMRGVNDSTAALLDLCFALQDEAGILPYY 329  
                 .  :.:.    .            : .*. *:* :*.      .:         : ***   
 
MXAN_4698       LHQMDVAEGCEHLRTPIAKGLEIIQQLRGYTTGLAVPHLAVDLPGGGGKVTLQPDYAVEY 365 
MXAN_4699       FYMCDMIPNSEHWRLSVAQAQQLQHDIMGYMPGFATPRIVCDVPFVG---KRWVHQVAEY 403 
MXAN_6263       MFVERDTGPQDYFAVPLAEAYDIFRNAFQSVSGLARTVRGPSMSATPG--KVCVDGVAEI 389 
KamA            IYQCDLSLGLEHFRTPVSKGIEIIEGLRGHTSGYCVPTFVVDAPGGGGKTPVMPNYVISQ 348 
SttO            FYMCDMIPNAEHWRVPLHRAQLIQRQIMGYLPGFATPRIVCDVPMAG---KRWVDQTDSY 351 
VioP            FYMCDMVPGAEHWRTSLAEAQDLQHAIMGYLPGYATPRIVCDVPYVG---KRWVHQAVEY 386  
                :.        ::   .: ..  : .      .* . .    . .          . . .    
 
MXAN_4698       GAQETVFRNYKGERFTYPEPEETDCTCPYDG-VWQERAPRYGYR-----KG--------- 410 
MXAN_4699       DRERGISYWTKNYRTGIELNDADALSRKYEYFDPIDQLSEAGQAWWR---EQQKAA---- 456 
MXAN_6263       AGEKVFVLHFIQSRDPELVGRPFFAKYDEKASWLFDLKPAMGATHFPWEEPSA------- 442 
KamA            SHDKVILRNFEGVITTYSEPINYTPGCNCDVCTGKKKVHKVGVAGLLNGEGMALEPVGLE 408 
SttO            DRELGVSHWSKSYLTPLEAADRDAHDGTYHYYDPIDTLPLDGQRWWR---DIRQG----- 403 
VioP            DRERGISYWTKNYRTAIELDDPDALTRRYPFHDPLSTLPESGWRWWERQVAAREGQACA- 445  
                  :  .                             .     *         
             
MXAN_4698       --------  
MXAN_4699       --------  
MXAN_6263       --------  
KamA            RNKRHVQE 416  
SttO            --------  
VioP           -------- 
 
Figure S4.13: Alignment of MXAN_4698, MXAN_4699, and MXAN_6263 and known 2,3-lysine 
amino mutases KamA (AAD43134), SttO (CAB67710), and VioP (AAP92506.1). Highlighted are 
the conserved motifs for 2,3-LAM activity: CxxxCxxxC (yellow), Arg134-Arg293-Asp300 (turquoise), 
and Lys337 (purple).  
 
 
4 Myxoprincomides 
 
172 
 
 
 
Figure S4.14: 1H NMR spectrum of myxoprincomide-c534 in DMSO-d6 
 
Figure S4.15: COSY NMR spectrum of myxoprincomide-c534 in DMSO-d6 
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Figure S4.16: HMBC NMR spectrum of myxoprincomide-c534 in DMSO-d6 
 
 
Figure S4.17: HOHAHA spectrum of myxoprincomide-c534 in DMSO-d6 
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Figure S4.18: HSQC NMR spectrum of myxoprincomide-c534 in DMSO-d6 
 
 
Figure S4.19: 1H NMR spectrum of myxoprincomide-c708 in DMSO-d6 
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Figure S4.20: COSY NMR spectrum of myxoprincomide-c708 in DMSO-d6 
 
 
Figure S4.21: HMBC NMR spectrum of myxoprincomide-c708 in DMSO-d6 
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Figure S4.22: HOHAHA NMR spectrum of myxoprincomide-c708 in DMSO-d6 
 
Figure S4.23: HSQC NMR spectrum of myxoprincomide-c708 in DMSO-d6 
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Figure S4.24: ROESY NMR spectrum of myxoprincomide-c708 in DMSO-d6 
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6 Conclusion & Outlook 
The main achievement of this work is the association of four secondary metabolites 
produced by Myxococcus xanthus to their corresponding biosynthetic pathways.  These 
compounds include three novel compound classes from M. xanthus DK1622, including 
the myxoprincomides and the known broad spectrum antibiotic althiomycin as 
produced by M. xanthus DK897. A full de novo structural elucidation for the 
myxoprincomide compound family is reported.    Based on these findings, models for 
althiomycin and myxoprincomide biosynthesis by M. xanthus are presented.  
 
6.1 Secondary metabolome mining 
The effectivity of coupling gene-inactivation by targeted mutagenesis with 
comprehensive analysis of HPLC-high resolution MS data sets to unearth the products 
of orphan pathways was clearly shown in this work.  Three unassigned biosynthetic 
pathways from M. xanthus DK1622 were correlated to their associated products via a 
straightforward methodology, i.e. targeted gene inactivation, one cultivation condition, 
one extraction method, one separation condition, and one MS ionization mode. It is an 
extended version of the targeted mutagenesis-metabolite profiling method in that 
instead of manual inspection of HPLC-HR MS data sets, a comprehensive analysis of the 
extract profile is performed by principal component analysis following an advanced 
compound finding algorithm.  The development and application of the compound 
finding algorithm and PCA to uncover the “hidden” secondary metabolome of 
myxobacterial strains was previously done and allowed to define a panel of hypothetical 
compounds by high-resolution mass values and calculated putative molecular 
formulae.[1, 2]  However, in the present study the underlying “comprehensive 
metabolomics” analytical platform was applied to directly correlate select biosynthetic 
pathways to their corresponding products.   
Using this approach, three new secondary metabolites—c506, c844, and c329—were 
identified and correlated to their biosynthetic gene clusters in Myxococcus xanthus 
DK1622 (c506 : MXAN_3779, [M+2H]2+ 506.27 m/z), c844 : MXAN_1599 – MXAN_1608, 
[M+H]+ 844.37 m/z) and c329 : MXAN_3628 – MXAN_3633, [M+H]+ = 329.19 m/z).   
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Amongst the three compounds, further work on compound c506, termed 
myxoprincomide-c506, was carried out.  Myxoprincomide-c506 was an interesting 
compound to investigate as its biosynthetic pathway MXAN_3779 was the largest, 
continuous hybrid synthetase from DK1622 capable of assembling an entire structural 
backbone.   
Using semiquantitative M. xanthus species-wide metabolomics data, M. xanthus A2 was 
determined to be a better producer of myxoprincomide-c506.  In addition to optimizing 
cultivation conditions to generate a higher yield, M. xanthus strain A2 was genetically 
engineered to artificially overexpress its MXAN_3779 homologue by insertion of the 
T7A1 promoter upstream of the gene resulting in the optimized strain A2.c506 which can 
produce myxoprincomide-c506 at levels 30 times higher than DK1622. Large-scale 
cultivation and fractionation of A2.c506 enabled the isolation of 1.2 mg of pure 
myxoprincomide-c506 allowing for structural elucidation by extensive 2D NMR 
spectroscopy and ESI-MS/MS techniques.  
After discovery, access to the purified compound is the next challenge to be addressed 
for a complete secondary metabolite structural characterization.  The case of 
myxoprincomide-c506 is a clear example of the efforts required to obtain sufficient 
amounts of pure low abundance compounds.  On top of cultivation optimization, 
genetic manipulation by insertion of a strong constitutive promoter contributed to the 
overall product yield enhancement.   Fortuitously, the M. xanthus strains used in this 
work (DK897 and A2) were genetically-tractable and the transformation protocol for M. 
xanthus DK1622 was intraspecifically-suitable.  However, this is not necessarily the case 
for other myxobacterial strains.  The need to tailor, establish, and improve molecular 
biological tools to perform targeted mutagenesis benefits not just the correlation of 
pathways to their products but also the improvement of secondary metabolite 
production by genetic manipulation.   
Further work is required to isolate and determine the final structures of the DK1622 
compounds c844 and c329.  The same amount of effort placed into the determination of 
the final structure of myxoprincmide-c506 should be done for the structure elucidation 
of c844 and c329. Initial investigations have been done in this regard, particularly in 
determining the best native producer for each of the compounds (data not shown).  
Whereas the biosynthetic gene cluster for c329 appears to be encoded in one operon, 
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which can be easily subjected to yield optimization by insertion of a constitutive 
promoter, the biosynthetic gene cluster for c844 (MXAN_1600 – MXAN_1608) is not and 
therefore requires regulation of gene expression facilitated by, for example, enhancer 
binding proteins, to alter its production.[3]  
Although this work was successful in expanding the secondary metabolite portfolio of 
M. xanthus, further efforts are required to associate the remaining 10 unassigned 
biosynthetic pathways to their corresponding products.   For unidirectional gene 
clusters, a statistical comparison of the LC-MS profiles between an overexpression vs. 
knockout mutant is a promising strategy to extricate new compounds.  Modification of 
cultivation conditions by changing the growth medium (e.g. to VY/2) or by exposing the 
strains to environmental stress (i.e. higher or lower growth temperature or pH) could 
also impact secondary metabolite production.  As opposed to the endpoint-to-endpoint 
method used in this work, a kinetics approach where strain culture replicates are 
harvested at different time points during cultivation could provide insight into 
compounds produced early during bacterial growth but are consumed or degraded at 
later stages of the growth cycle.   
Extraction procedures could be expanded by using other solvents aside from methanol 
to extract the compounds adsorbed on the XAD-16 resin.  Whereas methanol is an 
excellent solvent, it was noticeable that the XAD-16 resin was still significantly colored 
post extraction implying that there are still a significant amount of compounds bound to 
the resin. A methanol / acetone solution could potentially extract more compounds.  
One caveat is the amount of artifacts normally observed when using acetone as an 
extraction solvent.  One could also conduct a serial extraction using hexane, ethyl 
acetate, and methanol as three separate extraction stages.   
Utilizing a buffer with a higher pH during separation and shifting to negative ionization 
mode could unearth more compounds which do not ionize well under acidic conditions.  
For the data already on hand, lowering the stringency of the molecular feature finding 
parameters could reveal more compounds. This has the risk of increasing the complexity 
of the bucket table but it does increase the chance of including the low abundance 
compounds whose mass peak clusters have a lower number of consecutive scans 
(smaller compound length).   
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6.2 The Myxoprincomides from DK1622 
In the process of optimizing the production of myxoprincomide-c506, the structural 
diversity of the myxoprincomides was revealed.  Fifteen additional myxoprincomide 
variants were identified and categorized into four different groups.  Group I-A is 
composed of myxoprincomide variants which are shorter than the representative 
structure myxoprincomide-c506.  Myxoprincomide-c506 is part of Group I-B which are 
composed of structures with L-leucine at position 2 of the structure.  Group I-C on the 
other hand are made up of myxoprincomide variants with different residues at position 
2 (i.e. methionine, methionine sulfoxide, phenylalanine).  Group I-D differentiates itself 
from the rest by lacking the 417 m/z product ion in its MS2 spectra.   
Out of the 15 additional variants observed, 11 variants were structurally elucidated by 
combining isotope-labeled substrate feeding, spectrometric, and spectroscopic analyses.  
Further efforts are required to carry out the structural elucidation of myxoprincomide-
c535, -c591,  -c555, and c-584 as their low concentration have prevented tandem MS 
analysis.   
The structural depth of the myxoprincomides further established the extent by which 
Mxp1622 biosynthetic pathway deviates from strict colinearity.  The advantage of using 
the comprehensive metabolomics approach in discovering this novel myxobacterial 
compound family is clear in that the actual product spectrum could not have been 
predicted by genome mining and sequence analysis alone.  In addition, the 
myxoprincomide structural diversity highlights the unusual features of the Mxp1622 
assembly line. Adenylation domain substrate promiscuity, formation of the α-keto 
functional group, shunt product release, an irregularly functional module (module 11), 
and retromodular stuttering are among the biosynthetic steps peculiar to Mxp1622. 
The revised and extended biosynthetic model provided in Section 4.4.4 is a sound, 
hypothetical proposal as to how the myxoprincomides are assembled.  Nevertheless, 
empirical evidence by in vivo and in vitro analysis are necessary to confirm the proposed 
biosynthetic steps.   
The extent of the substrate promiscuity of Mxp1622 module 2 A domain can readily be 
determined using the classical ATP-pyrophosphate exchange assay.[4] The same assay 
can establish the kinetic proof as to why L-leucine is the preferred substrate over 
phenylalanine and methionine. 
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The α-keto moiety observed in almost all of the myxoprincomides is a rarely observed 
functional group in secondary metabolites.[5-8] Mxp1622 is the first reported molecular 
assembly line to contain an enzymatic module which can form this unusual functional 
group. Elucidation of the mechanism of the PKS-derived formation of the α-keto moiety 
could be achieved by in vitro experiments using a recombinant partial assembly line 
(including Mxp1622 PKS module 6 and NRPS module 7) and synthetic intermediates.  The 
success of this in vitro assay is admittedly dependent on the behavior of the recombinant 
protein (i.e. proper folding, solubility) and determination of the proper assay conditions.  
Alternatively, in vivo experiments using the optimized producer strain A2.c506 and 
feeding with 18O2 during fermentation could provide insight as to the source of oxygen 
and the possible mechanism by which the oxidation occurs.[9] Also insertion of a 
promoter upstream of modules 6 and 7 separately to form a truncated assembly line and 
feeding with activated synthetic intermediates could provide further understanding 
about the assembly, assuming that the truncated assembly line is still catalytically 
functional.  The role of the Ox domain in the installation of the α-keto functional group 
could also be determined by a point mutation or an alanine scan of the Ox domain, 
providing mutants with a defective Ox domain which could generate myxoprincomide 
variants with the intact acyl extension in the middle of the peptide.  
The group I-A myxoprincomides were shown to be legitimate shunt products when 
these compounds were detected in the crude extract after the gene encoding the 2,3-
lysine aminomutase (MXAN_4699), which provides the β-lysine for module 10 of 
Mxp1622, was inactivated. Fusion of the TE domain upstream of the later modules forming 
a truncated Mxp1622 could provide further insight into the release mechanism of the 
shunt products. This method has been shown to release intermediates from polyketide 
synthase assembly lines. [10, 11] 
The discovery of the larger myxoprincomides (-c562, c708, and c717) which contain an L-
leucine residue in the penultimate position in relation to the C-terminus conceded that 
module 11 is still a functional module.  This revelation is contrary to the lack of L-leucine 
prior to L-alanine in majority of the observed myxoprincomides.  It is possible that 
module 11 of the Mxp1622 pathway is a sluggish module which impart three biosynthetic 
scenarios: 1) Module 11 is skipped to form most of the myxoprincomide structures.  2) 
module 11 works and installs L-leucine to create myxoprincomide-c562.  3) Module 11 is 
stalled and instead of skipping, the chain extension reverts back to module 9 in a 
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biosynthetic step termed here retromodular stuttering and proceeds with a L-tyrosine, L- 
β-lysine, L-Leucine, and L-alanine extension to form myxoprincomide-c708 and -c717. 
Isomodular stuttering has been previously reported for NRPS pathways (e.g. SfmC of 
the saframycin pathway is used twice to install a second 3-hydroxy-5-methyl-O-methyl-
tyrosine to complete the tetrapeptide backbone and Cgc18 A domain is used iteratively 
to load both Cgc18 _PCP in cis and Cgc19_PCP in trans) .[12, 13] However, retromodular 
stuttering in Mxp1622 during chain elongation is a rare occurrence in NRP biosynthesis 
and it is worth to explore the mechanism by which this remarkable phenomenon takes 
place. 
The release of shunt products and the occurrence of retromodular stuttering raise the 
question of the catalytic efficiency of Mxp1622.  In vivo translation of large multienzyme 
complexes and the consequent secondary metabolite biosynthesis are metabolically 
costly for the microorganism. Therefore, if there are any rate limiting steps that lower the 
catalytic efficiency of Mxp1622, it is possible that the pathway compensates by releasing 
the intermediates, skipping modules, or reusing the upstream modules.  The formation 
of the α-keto moiety possibly stalls the nascent chain at module 6.  (Fig. 4.25) Instead of 
proceeding with the PKS extension and α-keto formation, and with the pressure of the 
next round of peptide biosynthesis pushing the assembly, myxoprincomide-c543 is 
released.  For the growing peptide which actually proceeds through modules 6 to 8, the 
nascent chain could once again be stalled at module 8 while module 9 is reused for 
retromodular stuttering resulting in the release of myxoprincomide-c649 and -c651.  
Module 11 could be the next rate limiting biosynthetic step.  Although functional, it is 
possible that the module is catalytically inefficient and perhaps as not to “waste” the 
already assembled peptide chain stalled at module 10, module 11 is either skipped to 
form majority of the myxoprincomide variants or the growing chain is extended by the 
upstream module 9 to generate the larger myxoprincomides.   
The role of the loading module in terms of structural diversity was not touched on in this 
work.  None of the myxoprincomides presented contained an acyl moiety attached to the 
N-terminus of the compounds due to the putatively inactive C domain in module 1.  By 
exchanging this inactive C domain with one that has the full set of conserved motifs (e.g. 
C domains from module 4 and module 8 which incorporate L-serine), it might be 
possible to observe N-terminal acylated myxoprincomide variants.  It is also possible 
that N-acylated myxoprincomides are produced at the early stage of growth and are 
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cleaved off later on.  A production kinetics study of the overproducer strain and the 
knockout mutant could shed light into this possibility.   
Obtaining sufficient purified myxoprincomides is advantageous for both structural 
elucidation and bioactivity assays.  The possibility of obtaining enough amounts can be 
achieved by increasing the volume of the VY/2 fed batch cultivation.  Whereas it cannot 
be guaranteed that all myxoprincomides can be successfully isolated, getting a handful 
pure is already a step in the right direction.  For example, it is feasible, using the 
isolation protocol employed, to isolate myxoprincomide-c651 and myxoprincomide-c562 
(data not shown).  Unfortunately, the yield was too low for either NMR analysis or 
bioactivity assays when both compounds were purified.  The idea of putting more effort 
into isolating the myxoprincomide variants comes from the observation that 
myxoprincomide-c708 imparted a weak activity against Mucor hiemalis as opposed to 
myxoprincomide-c506 which had no observed activity at all.  Therefore, it cannot be 
completely ruled out that the other myxoprincomide variants exhibit antimicrobial 
activitiy. 
Mxp1622 and the Group I myxoprincomides fit well under the diversity-oriented 
paradigm of secondary metabolite biosynthesis wherein a lone hybrid synthetase is 
capable of generating a suite of structural variants.[14] The one pathway – multiple 
products is common to known M. xanthus compounds, where each compound class has 
at least 2 identified members.[1] Chemical diversity from one pathway could be viewed 
as the organism’s efficient strategy for generating a bioactive compound library.[14]  
Alternatively, it could be influenced by the need for enzymatic productivity leading to 
substrate promiscuity and unconventional biosynthetic steps (i.e. shunt product release 
or retromodular stuttering).  
The structural diversity of the myxoprincomides is further expanded by the Group II 
myxoprincomides produced by Mxp897.   It is presumed that the Mxp897 and Mxp1622 are 
mutually exclusive based on the distinct production of Group I and Group II 
myxoprincomides within the M. xanthus species.  Whether the diversification of the 
multimodular assembly lines occurred by vertical inheritance or horizontal gene transfer 
is unknown and is beyond the scope of this work.  However, since there are now a 
handful of M. xanthus genome sequences available in house, the tracking of the genetic 
evolution of the Mxp megasynthase within the species is feasible.   
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6.3 Althiomycin 
The broad spectrum antibiotic althiomycin is produced by the myxobacterial strain M. 
xanthus DK897.  Herein, it was shown that the structural backbone of althiomycin is a 
product of a NRPS-PKS hybrid assembly line composed of AlmA and AlmB.  The 
formation of the mature althiomycin involved three tailoring reactions: a methylation by 
AlmC, formation of an oxime group by AlmD, and heterocyclization to form the 
methoxypyrrolinone ring. possibly by AlmF.   
Targeted gene inactivation with promoter insertion and subsequent genetic 
complementation via insertion of the native gene in the attb phage attachment site 
insinuates that AlmC and AlmD act on the structural backbone either during or post 
assembly. As the peptide intermediate was not detected in the LC-MS profile of the 
crude extracts after targeted inactivation of either AlmC or AlmD, two possible scenarios 
were proposed.  If the tailoring reactions occur during assembly, it is likely that the 
downstream domains do not recognize the intermediate without the modifications 
thereby halting the assembly process. On the other hand, should the tailoring reactions 
occur post assembly, it is possible that the transporter AlmE does not recognize the 
peptide intermediate and is therefore not secreted out of the cell.  
AlmD warrants further investigation as enzymatic oxime formation has not been 
mechanistically elucidated.  Only the cytochrome P450 NocL of the nocardicin 
biosynthetic pathway has been ascribed to form oxime functional groups.[15, 16] But AlmD 
distinguishes itself from NocL, as AlmD is not a cytochrome P450 and most likely 
installs the rarely observed oxime moiety via a different mechanism.   
The formation of the methoxypyrrolinone ring by AlmF is still speculative.  It is clear 
that loss of the AlmF functionality led to a significant decrease in althiomycin 
production.  However, the exact role that AlmF plays in the formation of the 
methoxypyrrolinone ring or in althiomycin biosynthesis altogether is yet to be 
established.  
AlmE showed significant homology to transporters of the major facilitator superfamily.  
Members of these secondary carriers make use of ion gradients for energy and counts 
drug efflux as one of its functions.[17] Specifically, AlmE showed similarity with 
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bicyclomycin resistance protein which, in E. coli, confers resistance to sulfathiazole.[18] 
The common thiazole element between sulfathiazole and althiomycin is most likely 
necessary for molecular recognition for the drug efflux of these potent antibiotics.   
Inactivation of almE in the native producer DK897 was unsuccessful, but heterologous 
expression of almE in althiomycin-sensitive M. xanthus DK1622 established AlmE’s role.   
Using purified althiomycin and dehydrated althiomycin as test substances, the loss of 
inhibition zones in the almE-harboring DK1622 mutant lawns provided sufficient 
evidence in AlmE’s involvement in self resistance. Inactivation of almE in DK897 would 
have led to a polar effect on the downstream biosynthetic gene cluster as alm appears to 
be a single operon.  Assuming there was no polar effect and expression of the 
althiomycin biosynthetic genes were to proceed, then it could be speculated that the loss 
of AlmE activity could result in a build up of althiomycin in the cytosol and is 
potentially lethal to the organism.    
More than a year after the alm biosynthetic pathway from DK897 was published, an 
althiomycin pathway homolog was also reported from the enteric bacteria Serratia 
marascens Db10 (gene cluster termed alb).[19] The gene organization of alb matches that of 
the DK897 alm gene cluster.  The gene products of alb1-5 showed significant identity and 
similarity with almEDCAB.  Results of deletion experiments on the genes encoding the 
assembly line (alb4 and alb5) and the tailoring enzymes (alb2 and alb3) parallels the result 
that were already established for DK897.   The heterologous expression of alb1 in a 
related althiomycin sensitive strain conferred resistance to the recombinant strain similar 
to what was observed when almE was heterologously expressed in DK1622.  While the 
almE gene could not be inactivated in DK897, a deletion mutant was successfully 
constructed in Db10 which was unable to produce althiomycin owing to the low level of 
transcription of the other alb genes.  However, the authors do raise the possibility of 
second site mutations that could lead to the loss of althiomycin production.   
The main difference between alm and alb lies in the gene products of almF and alb6.  
Whereas almF is translationally coupled to almB and encodes a protein with similarity to 
proline iminopeptidases, there is a 146 bp gap betwewen alb5 and alb6 and alb6 is 
predicted to have a thioesterase II which is hypothesized to have a proofreading 
function.  Inactivation of both genes in the respective species did not completely abolish 
althiomycin biosynthesis but significantly reduced althiomycin production.  Initially, 
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AlmF was hypothesized to be involved in the methoxypyrrolinone ring.  Supposing that 
the AlmB TE domain is capable of ring formation by itself, an alternative function for 
AlmF would be the regeneration of PCP domains during biosynthesis if the PCP is 
tethering an incorrect intermediate (e.g. an R configuration at C4 of the thiazoline ring 
instead of an S configuration).  If AlmF does have a proline iminopeptidase-like activity 
(exclusive cleaving of L-proline residues from peptides), then AlmF could recognize the 
thiazoline ring with an R configuration at C4 based on its similarity to the heterocyclic 
structure of proline and consequently hydrolyze it from the thioester.  An AlmF 
enzymatic assay using althiomycin and epialthiomycin (althiomycin with an R 
configuration at C4 of the thiazoline ring)[20] or their corresponding intermediates could 
shed light if proofreading of the thiazoline group is indeed the function of AlmF.   
Extrapolating from the secondary metabolome survey of M. xanthus strains, althiomycin 
appear to be an uncommon antibiotic produced by this species.[1] It is possible that the 
strain DK897 acquired the alm gene cluster by horizontal gene transfer as a consequence 
of the microbial predatory nature of myxobacteria.[21] 
 
6.4 Final word 
Genetically tractable and relatively easy to cultivate, Myxococcus xanthus has now 
presented itself, not just as an excellent model for social behavior in myxobacteria but as 
a representative strain for the actualization of bacterial secondary metabolite 
biosynthetic potential.  With continuous efforts, it is possible to obtain the full secondary 
metabolome by applying and extending the techniques presented in this work.   
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7 Author’s Contribution to Chapters 3 to 5 
 
Chapter 3:  
The author carried out the mutagenesis , strain cultivation, sample work up, HPLC-MS 
data and statistical analyses.  Further the author performed the optimization of 
myxoprincomide-c506 production inclusive of selection of best producer, genetic 
manipulation, and improvement of cultivation conditions.  The author performed the 
sequence analysis on the presented biosynthetic gene clusters and designed and carried 
out gene inactivation experiments of possibly related genes.  The author was involved in 
the purification of myxoprincomide-c506 and  performed the feeding experiments.   
Chapter 4: 
The author conceptualized and carried out the optimization of cultivation conditions to 
improve access to the newly identified myxoprincomides.  The author purified 
myxoprincomide-c534 and myxoprincomide-708 and performed the structural 
elucidation from tandem MS and NMR data.  The author combined feeding of isotope-
labeled substrates and tandem MS experiments for the structure elucidation of the less 
abundant myxoprincomides.  The author performed the genome scan for related genes 
and carried out the inactivation experiments.   
Chapter 5:  
The author performed the genome scanning for the althiomycin biosynthetic gene cluster 
in the strain M. xanthus DK897 and the corresponding gene inactivation experiments.  
The author carried out the heterologous expression of almE in M. xanthus DK1622 and 
performed the althiomycin sensitivity assay.   
